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 Abstract
Despite continued improvements in early detection and therapeutic strategies, 
chemotherapy resistance and relapse remain key obstacles for successful breast 
cancer therapy. Survivin, a key member of the inhibitor of apoptosis family, is over-
expressed in a variety of human cancers though its role within tumour initiating cells 
(T-ICs) remains elusive. Here we demonstrate that survivin is a key contributor to 
drug-resistance in T-ICs in a doxorubicin (Dox)-resistant breast cancer cell model 
(MCF-7/Adr). Through down-regulation of the survivin gene via in vitro siRNA 
transfection, MCF-7/Adr demonstrated an increased Dox sensitivity (4-fold decrease 
in IC50). Furthermore, the combined treatment of survivin siRNA and Dox resulted in
a significant reduction in tumourigenic capacity (from 11.4% to 3.8%) and T-IC 
frequency (from 20.6% to 9.2%) as determined by the mammosphere assay and T-IC 
surface marker analysis, respectively (Chapter 3).  
To translate this T-IC targeted anticancer strategy into an effective therapeutic, a 
novel T-IC targeted system was developed by fusing a breast T-IC surface marker 
EpCAM targeted aptamer with survivin siRNA (EpCAM aptamer-survivin siRNA 
chimera). Through optimized chemical modifications, an optimal chimera (Chimera 
#10), having an 8.3 h half-life in 50% human serum and producing strong dose-
dependent in vitro survivin gene silencing efficacy, was developed for further studies
(Chapter 4). 
To facilitating in vivo imaging and accurate quantification of the chimera without 
compromising Dicer processing efficiency, Fluorescein isothiocyanate (FITC) and 
Biotin was conjugated to Chimera 10 at optimized positions. Since Chimera 10 did 
not show sufficient serum retention in MCF-7/Adr tumour-bearing mice, it was 
further engineered by conjugating a terminal 20 kDa PEG. The resulted PEGylated 
chimera displayed significant improvements in pharmacokinetic parameters with 5 h 
and 6 h elimination half-life and mean residence time, respectively. In addition, an 
enhanced tumour accumulation was also observed (Chapter 6).
After confirming the near 80% survivin gene-silencing efficacy of the PEGylated 
chimera in MCF-7/Adr tumours, a 7-day treatment of chemo-resistant xenograft 
breast tumours was carried out by combining PEGylated chimera and Dox 
 
 
 administrations. The chimera-mediated in vivo survivin silencing resulted in a
significant increase in Dox sensitivity of MCF-7/Adr tumours as evidenced by the 2-
fold decrease in proliferation (via Ki-67 assay) and the 10-fold increase in apoptosis 
(via TUNEL assay) of the tumours that underwent combined treatment, compared 
with those treated with Dox-alone (Chapter 7). In addition, the in vivo limited dilution 
assay illustrated a strong inhibition effect of the combined chimera and Dox treatment 
on the T-ICs of the tested MCF-7/Adr tumours, with a 5-fold lower tumour forming 
frequency and a much longer latency than those tumours treated with Dox-alone. This 
T-IC targeting effect was further confirmed by a universal reduction in the expression 
of stemness proteins, a 2.5-fold and 4.6-fold greater reduction in self-renewal
capacity in the primary and secondary mammosphere assays, as well as an 
approximately 5-fold reduction in the T-IC population in tumours (via cell surface 
marker analysis) after the combinatorial chimera and Dox treatment (Chapter 7).
Consequently, the combined treatment of chimera and Dox resulted in a markedly 
improved treatment outcome as evidenced by the greatly extended overall survival of 
MCF-7/Adr tumour-bearing mice (Chapter 7).
The ability of this EpCAM aptamer-survivin siRNA chimera to be internalized into
T-ICs of the xenograft MCF-7/Adr tumours and reverse their drug resistance to Dox 
was demonstrated directly using purified breast T-ICs that had been sorted using 
Fluorescence-activated cell sorting (FACS) from MCF-7/Adr tumours treated with 
the chimera and Dox. Promisingly, the intravenously administered chimera was 
detected in approximately 89% of breast T-ICs and knocked down ~78% survivin 
gene, which in turn led to a marked increase in the sensitivity of these purified T-ICs 
to Dox-induced apoptosis (Chapter 8). 
Finally, it was demonstrated that the aptamer-siRNA chimera did not elicit either an 
in vitro or in vivo innate immune response, indicating that the suppression of tumour 
growth by the chimera/Dox co-treatment is not immune-mediated and the chimera is 
probably safe for future clinical application (Chapter 9).  
In conclusion, in this project, firstly, the pivotal role of survivin played in the drug 
resistance of breast T-ICs in a Dox-resistant breast cancer model was established.
Secondly, we developed a breast T-IC targeted and aptamer-based siRNA in vivo
delivery system. With chemical modifications, this aptamer-mediated siRNA 
 
 
 delivery system possessed a high therapeutic index, such that combined treatment 
with low dose of Dox could inhibit stemness, eliminate T-ICs, sustain tumour 
suppression and prolong survival in mice bearing chemo-resistant MCF-7/Adr
tumours. Thirdly, since EpCAM and survivin gene are also highly expressed in some 
other types of cancers, the anticancer effect of this chimera may be utilised beyond 
the breast cancer as demonstrated here. Lastly, this work provides a rationale for T-
IC targeted siRNA delivery. Theoretically, T-ICs can be effectively targeted by 
siRNA in any cancer as long as there is a critical gene and a reliable surface marker.   
Significance
This study uncovered a crucial role of survivin in chemo-resistance in breast 
tumour initiating cells.  Targeting tumour initiating cells with an optimized aptamer-
mediated siRNA delivery system successfully knocked down the high level survivin 
expression in these cells both in vitro and in vivo.  Importantly, this approach 
reversed chemo-resistance, transforming a classical chemotherapy drug to one able to 
act on tumourigenic cells in addition to the bulk tumour cells, which has far reaching 
implications for future development of efficacious anti-cancer therapies.
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Chapter 1 Introduction
In accordance with the purposes and experimental designs of this study, the 
corresponding background information is introduced from two aspects, which are 
organized into two sections. In the first section the significance of tumour initiating 
cell (T-IC) targeted therapies and targeting strategies are presented, while the 
obstacles faced by current siRNA in vivo delivery systems and the potential solutions 
are addressed in section two. The key techniques and principles involved in this 
project such as T-IC relevant marker analysis, mammosphere assay, in vivo
tumourigenic assay, the role of survivin gene in the chemo-resistance of tumours, 
aptamer-mediated siRNA delivery and current chemical modification strategies are 
discussed in detail. At the end of this Chapter, the research aims and the hypotheses 
on which this project was based and conducted are illustrated. 
Section one
Tumour Initiating Cell Targeted Anticancer Therapy
1.1 A brief view of anticancer chemotherapy
Firstly initiated in 1946 when Nitrogen mustard was used for cancer therapy 
(Nabarro 1951), by the early 1990s, anti-cancer chemotherapeutic drug development 
had been transformed from a low-budget, government-supported research effort to a 
high-stakes, multi-billion dollar industry (Chabner and Roberts 2005). This trend 
continued for the following 20 years. In 2009, it was reported that anticancer 
chemotherapeutic drugs accounted for 5% of the total market share of the 
pharmaceutical industry with 50 billion US dollars (Sosa 2009).  In sharp contrast to 
the rapid development of anticancer drugs, it was expected that cancer will surpass 
heart disease to become the number one cause of death worldwide (WHO 2008, 
2014). Even in developed countries like the US, cancer mortality rates had not
changed significantly during the 30 years spanning from 1975 to 2007 (WHO 2008). 
The classical cancer theory was partly responsible for this situation. 
1.2 Classical cancer theory
For decades, anti-cancer therapy has been guided by the stochastic (clonal 
evolution) theory (Dick 2003). It holds that cancer derives from normal somatic cells 
which undergo at least five genetic mutations (Alberts B 2010) before they possess 
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 all of the ten cancer hallmarks, such as enhanced proliferation, reduced capacity to 
undergo apoptosis and  inhibition of differentiation (Hanahan and Weinberg 2011). 
However, this classical theory is far from being satisfactory. Since differentiated 
somatic cells have a limited life span, it would be theoretically impossible for any 
given cell to acquire all the necessary mutations (Bagley 2009). A more reasonable 
explanation contends that it is likely that the initial mutational hit to the cell confers 
the capacity of unrestrained proliferation, which provides it with a sufficiently long 
lifespan to acquire the remaining mutations (Tomasetti et al. 2013). Following this 
logic, it would be reasonable to assume that all cancer cells in a tumour would be 
homogeneous and in principle, each viable tumour cell is equally capable of forming 
a new tumour. However, this hypothesis is paradoxical to a well-known phenomenon 
- usually more than 10,000 cancer cells are required to reproducibly initiate tumours 
in immunocompromised mice (Friedman et al. 2009). Recent developments in the T-
IC (also known as cancer stem cell) theory suggest that the classical theory of cancer 
initiation and progression may be overly simplistic.  
1.3 T-IC theory
The T-IC theory is based on experimental evidence that the status of different 
cancer cells in a tumour are not equal, similar to that of normal tissues, with some 
rare undifferentiated T-ICs at the top of the hierarchy responsible for maintaining the 
whole population of cells in a tumour (Ito et al. 2012). As shown in Figure 1-1, these 
cells share several key properties with normal stem cells (Antoniou et al. 2013).
Firstly, self-renewal, T-ICs are built to last a lifetime and possess the ability to renew
themselves indefinitely with an undifferentiated state; secondly, multipotent 
differentiation capacity via asymmetric division, which, apart from self-renewal, is 
responsible for giving rise to differentiated daughter cells which make up the bulk of 
the tumour and are characterized by rapid propagation and limited or no proliferative 
potential in the case of progenitor and bulk cancer cells, respectively. Understanding 
this phenomenon is important for cancer therapy, as it means that the contribution of 
these daughter cells to the long-term sustenance of the tumour is negligible (Clevers 
2011). In a tumour, only T-ICs have the ability to initiate tumours as they are solely 
capable of self-renewal and unlimited replication; thirdly, T-ICs are resistant to 
electromagnetic and chemical insults, which is mainly because of their infrequent 
replication, heightened activation of DNA repair mechanisms (resulting in a lower 
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 rate of apoptosis compared to normal cancer cells), active drug efflux system 
(through ATP binding cassette (ABC) transporter) and increased defences against 
reactive oxygen species (Lou and Dean 2007, Tirino et al. 2013)
Figure 1-1. Self-renewal and asymmetry division of T-ICs (modified from 
(Bruce et al. 2008))
The T-IC theory is not an entirely new concept, having previously been discussed 
and investigated for decades (Nguyen LV. 2012). The major reason for it becoming 
one of the hottest topics in current cancer research (Medema 2013) lies in the 
explanation that it provides for the poorly understood phenomena raised from both 
the clinic and laboratory. From the perspective of the T-IC theory, since T-ICs, the 
prime suspects of tumour recurrence and metastasis, confer resistance to traditional 
electromagnetic and chemical insults by various strategies, it is easy to understand 
why cancer is almost impossible to be cured with current anti-cancer treatments 
(which mainly target the bulk cancer cells), even when the initial response to 
radiation or chemotherapy is encouragingly robust. As well, in the laboratory, the 
rarity of T-ICs in a tumour dictates that a large number of cancer cells are needed to 
initiate tumours in animal models. Another reason the T-IC theory has generated 
such enthusiasm is because of the hopeful and whole new anti-cancer strategy it 
promises - aiming not at reducing tumour bulk, but rather at targeting the beating 
heart of the tumour, the T-ICs (Vinagolu K. Rajasekhar 2014).
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 1.4 Controversies regarding the T-IC theory
As in any other rapidly developing field of science, the current theory of T-IC is 
undergoing evolution (Nguyen LV. 2012). Therefore, critical and cautious thinking is 
required before applying the T-IC theory into clinical applications. This is especially 
true when considering that our understanding of T-ICs is not complete and generally 
based on the understanding of normal stem cells. This is why, on many occasions,
the T-IC theory is also known as the T-IC hypothesis (Venere et al. 2013). In recent 
years, the debates and controversies regarding the T-IC theory mainly focus on the 
origin and frequency of T-ICs, as well as their phenotypic and functional properties. 
1.4.1 The frequency of T-ICs 
According to the classical T-IC theory, only exceedingly rare T-ICs in tumours 
have the ability to initiate tumours; for example, a frequency of less than 0.0001% 
has been reported in acute myelocytic leukaemia (AML) (Dominique Bonnet 1997, 
Elsa Quintana 2009, Schatton et al. 2008). However, some research findings
suggested that the proportion of stem cell-like cancer cells in a tumour could be as 
high as one in four (Kelly Priscilla N. et al. 2007, Krivtsov et al. 2006, Quintana E. et 
al. 2008, Yilmaz et al. 2006), which challenged one of the basic principles of T-IC 
theory - the hierarchy structure among tumours. 
These controversial results may have resulted from the research models for T-IC 
assessment.  Currently, only one single “gold standard” method, the in vivo limited 
dilution assay (in vivo tumour-initiating assay), exists to define human T-ICs, which 
involves xenotransplantation of sorted cancer cells (based on specific cell surface 
markers) into immunocompromised mice (Tsuyada and Wang 2013). However, this 
gold standard has its own limitations. One of the key problems in this model is the 
cross-species barrier. Obviously, the mouse tissues to which human cancer cells are 
transplanted provide a dramatically different microenvironment to the original 
environment from where they arise. In recent years, although this limitation has been 
mitigated by various methods such as providing human growth factors (Feuring-
Buske et al. 2003) and human stromal elements (Karnoub et al. 2007), or by 
orthotopic transplantation rather than transplantation under the skin or kidney 
capsules (Kennedy et al. 2007), it is still accepted that the cross-species barrier can 
affect the assessment of the T-IC frequency quantitatively, although not qualitatively 
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 (Clevers 2011). We have only to turn to some recent reports to see cases in which 
different experiment conditions could contribute to the controversial T-IC frequency. 
For example, although both of the next groups reported high T-IC frequency (1 in 4)
in tumours, Kelly et al. have transplanted mouse tumour cells into fully histo-
compatible mice recipients (Kelly N. et al 2007), which obviously did not meet the 
“gold standard” and therefore could not speak for human T-ICs. In Quintana’s 
experiment (Quintana E., et al. 2008), human melanoma cells were transplanted into 
immunocompromised mice. However, they used non-obese diabetic, severe 
combined immunocompromised (NOD/SCID) Il2rg-/- mice rather than the more 
commonly used NOD/SCID mice. As discussed, “The cross-species barrier probably 
affects the outcome quantitatively”, it is reasonable to assume that the difference 
regarding the frequency of T-ICs in different studies can be attributed to the different 
animal models and different cancer cell models used. Since it is impossible to test 
cancer cells in the human body, this debate will most likely remain unsolved in the 
near future. 
The different results in T-IC frequency may also result from the heterogeneous 
feature of tumours. As has been reported, even strictly defined normal tissue stem 
cells showed different differentiation and self-renewal capacities in accordance with 
different sites or stages of development (Schulenburg et al. 2010, Van K. 2012).
Considering the even higher heterogeneity present among tumours, it is not 
surprising to see a certain degree of difference in the T-IC frequency, even for the 
same types of tumours. 
Recently, based on observations that there may be a large proportion of T-ICs in 
tumours, some researchers claimed that T-IC targeted therapy could be meaningless 
(Clevers 2011). Obviously, there are flaws with this argument. Firstly, according to 
the analyses above, the data on T-IC frequency itself is debatable. Secondly, the 
frequency of T-ICs within a tumour is irrelevant to the concept whether a tumour 
adheres to the T-IC theory. Lastly, even if it is true that T-ICs make up a large 
proportion in some types of tumour, from another perspective, it only indicates that 
controlling T-ICs should be more urgent - although it also means that controlling T-
ICs could be more difficult than previously expected. 
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 1.4.2 The Origin of T-ICs
T-ICs are commonly considered to arise from normal stem cells. This is because 
the majority of cancers develop in epithelia that undergo substantial cell turnover, 
and in these tissues, only stem cells remain in the body and proliferate for long 
enough to accumulate the number of mutations required to develop into cancer 
(Pardal et al. 2003). However, recent studies suggest that the state of T-ICs is quite 
plastic, such that they can arise from a progenitor or even normal cancer cell that has 
acquired the capacity for sustained self-renewal through mutation, epigenetic change, 
or both (Gupta et al. 2011, Nguyen et al. 2012, Zomer et al. 2013). This is different 
from the traditional T-IC theory, which contends that it is impossible for 
differentiated cells to transform into T-ICs.
This odd observation is not entirely surprising, especially considering our current 
understanding of the T-IC theory (unidirectional differentiation) is still limited and 
generally based on results derived from the imperfect research models. Even today, it 
is still unclear when and how a differentiated cancer cell loses the molecular 
machinery required for T-IC-like functions (a critical mechanism to explain the 
unidirectional differentiation feature of T-ICs). In fact, this phenomenon is not 
exclusively observed in tumours. Accumulating evidence showed that under certain 
conditions, differentiated epithelia tissues including skin, mammary gland and 
intestine could display regenerative activities (Herzog EL 2003, Horwitz EM 2003) -
the main property of stem cells. Recently, a similar phenomenon was also observed 
in memory T and B lymphocytes cells (Van Keymeulen and Blanpain 2012).
Given the potential plasticity of T-ICs, some researchers contended that “only if 
the T-IC phenotype is a stable trait, will it be advantageous to selectively target T-
ICs as a cancer treatment” (Clevers 2011). Certainly, the plasticity of the T-IC state 
should be given serious consideration. However, from the perspective of treatment, it 
is more important to verify if T-ICs exist and whether they are the root of tumour 
recurrence and metastasis. In contrast, it is not that important as to where they come 
from. If there is anything to be learned, it is that both T-ICs and normal cancer cells 
should be targeted to cure cancer (Korkaya and Wicha 2013).
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 1.4.3 Are T-IC markers reliable? 
So far, there is no absolutely specific marker for T-IC identification. All of the 
currently used markers can be detected not only on T-ICs but also, more or less, on 
normal stem cells or normal cancer cells or even normal tissues (Medema 2013),
leading some researchers to ask “whether T-IC markers used today are bona fide T-
IC markers or not” (Clevers 2011). It is easy to realize that the unspoken words 
behind this query are “T-IC markers should be expressed only on T-ICs” and “there 
should be a T-IC marker expressed on many types of T-ICs”. In reality, since current 
understanding suggests T-ICs probably originate from either normal stem cells or 
normal cancer cells, it is conceivable that T-ICs would share some degree of similar 
surface marker expression pattern with the cells they come from. Moreover, 
considering the high heterogeneity even in a single tumour, it is unreasonable to 
assume a certain marker could be observed on many types of T-ICs. Different T-ICs
may have different T-IC markers. However, this is not a problem for T-IC targeted 
therapy, as in terms of cancer therapy, once a marker can be confirmed to be overly 
expressed on T-ICs, even if it is only expressed on one type of T-IC, or even if it is 
also expressed in other tissues, it is still worth exploiting.  
Compared with the specificity of T-IC markers, the stability of T-IC markers poses 
an even bigger obstacle for T-IC relevant diagnosis and treatment. Previously, it has 
been reported that the cell populations (defined by surface marker/marker 
combination) meeting the gold standard of T-IC assessment (in vivo limited dilution 
assay) have not proved to be singular or even stable (Wilson et al. 2013). For 
instance, in earlier studies, it was found that only the CD34+CD38í subset of AML 
cells showed T-IC properties in NOD/SCID mice. However, subsequent experiments 
detected that CD34+CD38+ AML cells also demonstrated similar T-IC activity 
(Goardon et al. 2011, Taussig et al. 2008, Taussig et al. 2010). In other cases, similar 
phenomena of coexisting or unstable T-IC markers have also been observed in 
human solid tumours (Dirks 2010, Quintana E. et al. 2010, Shmelkov 2008, Stewart 
et al. 2011) and human acute lymphoid leukaemia (ALL) (Kong 2008). The 
instability of T-IC markers may result from a well-established theory that the 
malignant tumour cells with aberrant gene expression regulation mechanisms may 
dramatically affect the developmental control or the typical stability of the 
expression of cell surface markers. This is especially true when experiments were 
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 conducted in vitro (Domcke et al. 2013).  Additionally, as discussed previously, 
tumours are highly heterogeneous. It is not surprising to see the expression of 
different T-IC markers in different types of tumours or tumours in different stages or 
obtained from different patients. Taken together, the existing instability of T-IC 
markers could weigh heavily against the effectiveness of their application. As a 
result, this factor has to be taken into account when employing cell surface markers 
for T-IC associated analyses or treatments. 
1.5 Analytical methods for tumour initiating cell research
1.5.1 Three commonly used methods for T-IC assessment
Since the primary characteristics of T-ICs (maintaining prolonged quiescence, 
ability to self-renew and plasticity to differentiate into multiple cell types) are similar 
to normal adult stem cells, various methods developed originally for the analysis and 
characterization of adult stem cells have been used to evaluate T-ICs. As discussed 
earlier, the in vivo limited dilution assay is by far the gold standard for T-IC analysis. 
This approach involves demonstrating the tumour initiating capacity of cells that are 
directly isolated from tumours to produce new tumours in immunocompromised
mice. It was firstly conducted to enumerate T-ICs in various types of ALL 
(Kamelreid et al. 1989), AML (Lapidot et al. 1994) and chronic myeloid leukaemia 
(CML) (Sirard et al. 1996). Later, its application was extended to many types of solid 
human tumours including breast cancer (Al-Hajj et al. 2003), colon cancer (O'Brien 
et al. 2007, Ricci-Vitiani et al. 2007), ovarian cancer (Stewart et al. 2011), lung 
cancer (Eramo et al. 2008) and head and neck cancer (Prince et al. 2007). However, 
the in vivo limited dilution assay is not only expensive but also time-consuming, with 
a standard test taking as long as six months or longer. Therefore, a reliable in vitro
assay model is necessary to efficiently and cost-effectively test characteristics 
associated with T-ICs. In 1992, Reynolds and colleagues developed an in vitro
technique termed the neurosphere assay to quantify activity of neural stem cells 
(Reynolds B. A. and Weiss 1992), which provides the basis for the most popular in 
vitro T-IC assay – mammosphere assay (Iglesias et al. 2013). Recently, this assay has 
been commonly employed in various T-IC associated studies and in some cases, used 
as a surrogate for the in vivo limited dilution assay. The mammosphere assay 
involves dissociation into a single cell suspension of T-IC containing tissues and 
8 
 
 subsequent culture on non-adherent substrata in the presence of serum-free media 
supporting growth of stem cells until they form organized floating cell spheres. Since 
progenitor cells are able to proliferate several times, the formation of primary 
mammospheres is considered a measure of stem cell/progenitor cell activity, and thus 
cannot be used to assess the frequency of T-IC. To assess T-IC frequency, primary 
mammospheres can be harvested, dissociated into single cells, and passaged again to 
create a ‘second’ generation mammosphere or even tertiary mammosphere (Shaw et 
al. 2012). Another method for T-IC assessment is based on the specific phenotypic 
and transcriptional marker profiles of T-ICs (Shigdar et al. 2013). In practice, this 
method is very straightforward and convenient and therefore more clinically 
meaningful. In recent years, with the increasing number of T-IC related cell surface 
markers reported in various types of cancers, this method holds great potential in not 
only clinical diagnosis and cancer research but also in developing T-IC targeted anti-
tumour therapies. 
1.5.2 Limitations associated with current T-IC assessment methods
Although cell surface marker analysis represents a direct and low-cost T-IC 
assessment method, its reliability relies on a prerequisite that the employed T-IC 
surface markers can show sufficient specificity, generality and stability. However, 
considering the phenotypic and genomic heterogeneity shown in tumours even with a 
similar histological appearance and grade, the surface protein expression pattern 
among T-ICs could be unstable. Actually, this instability in surface marker 
expression has been reported repeatedly as discussed above. As a result, in the past 
decade, although various surface marker combinations (rather than a single marker) 
have been successfully used to detect T-ICs in various types of tumours, to 
standardize this method in clinical or scientific research is still a considerable 
challenge (Uwe Karsten 2013).
Compared with surface marker analysis, the mammosphere assay is comparatively 
more reliable. However, caution has to be taken considering it is after all conducted 
in an artificial and less physiological environment. The typical test period for in vitro
mammosphere assay is several weeks, during which the tested cells are likely to 
undergo abnormal differentiation and transform into a clinically irrelevant state 
(Valent et al. 2012). In addition, it is likely that the artificial in vitro cell culture 
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 conditions will unavoidably cause selected or even no growth of cells under study.
Consequently, it is widely accepted that the mammosphere assay, although less 
expensive and time-consuming, is less useful for deducing clinically meaningful 
predictions (Iglesias et al. 2013). For solid evidence of the presence of T-ICs, in vivo
limited dilution assay is irreplaceable.  
As for the in vivo limited dilution assay, although immunocompromised mice have 
been regarded as the most reliable recipients to detect and quantify various sources of 
T-ICs, to what extent the results collected from this assay can accurately reflect the 
T-IC properties (self-renewal and multipotent differentiation) of cancer cells in a 
patient is unclear. The possible reasons and solutions for the deficits of the in vivo
limited dilution assay have been actively explored. Firstly, the relatively shorter 
lifespan of mice poses the question of how faithfully those results collected from 
mouse models reflect the clinical outcomes. Applying secondary recipients or other 
types of long lifespan animal models represent potential solutions for this problem. 
Secondly, the altered setting of transplanted tumour cells, including the species 
difference and the changed microenvironment could weigh heavily against the 
reliability of this assay both phenotypically and genetically (Filatova et al. 2013). In 
this respect, the development in genetically modified mouse models will probably 
provide a solution to at least partly solve this problem. These models include the 
production of mice transplanted with human haematopoietic or local tissue 
components (humanized mice) to create human-like microenvironments or 
production of transgenic mice that will express species-specific human cytokines 
(Akkina et al. 2011, Lan et al. 2006, Strowig et al. 2011, Takagi et al. 2012, 
Wunderlich et al. 2010). Thirdly, the absence of immune-surveillance in the mouse 
model used for in vivo tumourigenic assays compromises its capacity in mimicking 
the normal in vivo environment. Correspondingly, through injection of specific 
immune effector cells, the mimicry of natural immune surveillance mechanisms 
could be partly achieved (Nam et al. 2008).
1.6 Three strategies to target T-ICs
Under the T-IC theory, the malignant cell populations are organized as cellular 
hierarchies in which T-ICs are distinguished from the bulk cancer cells and 
responsible for maintaining the whole tumour by self-renewal and indefinite 
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 proliferation (Antoniou et al. 2013). This theory is of considerable clinical 
importance since it underlies a novel anti-cancer strategy aimed at overcoming many 
of the limitations of current treatments by targeting T-ICs. For T-IC targeted therapy, 
two aspects need to be emphasized. Firstly, T-ICs are characterized by enhanced 
drug-resistance, which could be derived either directly from their previous 
generations or through accumulation of the constant genomic and epigenetic 
mutations (Kreso and Dick 2014). Secondly, the microenvironment (niches) of the 
tumour plays a pivotal role in the behaviour of T-ICs. As previously reported, the 
surrounding microenvironment is even responsible for the plasticity of T-IC 
(Blanpain and Fuchs 2014). In fact, current T-IC targeted therapies mainly target 
these two factors through targeting relevant pathways or molecules including various 
receptors, oncogenic derivatives, adhesion molecules, antibody-accessible surface 
components, signalling intermediates, survival pathway elements, chromatin 
modifiers and metabolic targets (Jin et al. 2006, Laugesen and Helin 2014, Lorico 
and Rappa 2011, Pannuti et al. 2010, Sun et al. 2014, Tachezy et al. 2014, Zeilstra et 
al. 2014). Generally, these studies can be classified according to the employed 
therapeutic strategies as detailed below. 
1.6.1 “Destemming” T-ICs
Although the strategy of “destemming” T-ICs (Hill and Perris 2007) includes two 
aspects, either promoting T-IC differentiation into non-T-ICs or inhibiting their self-
renewal property, the ultimate aim is the same - “exhausting dormant T-ICs” (Figure 
1-2). With mounting evidence suggesting that there are similarities between normal 
stem cells and T-ICs in terms of their self-renewal and differentiation signalling 
pathways (Holland et al. 2013, Kawasaki et al. 2011, Zhu et al. 2011), several critical 
signalling pathways involved in self-renewal and differentiation of normal stem cells 
have been studied intensively.
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 Figure 1-2. The outcomes of inhibiting self-renewal and inducing differentiation 
are the same. During asymmetry division, fewer T-ICs and more normal cancer 
cells are generated.
1.6.1.1 Inhibiting self-renewal
By far the most exploited signalling pathways associated with the self-renewal of 
T-,&V DUH WKH :QWȕ-catenin signalling, Hedgehog signalling (HHG) and Notch 
signalling (Hassan et al. 2013, Holland et al. 2013). Both in vitro and in vivo
experiments have been conducted to test the feasibility of targeting these pathways to 
cure cancer. Among them, the Notch signalling pathway emerged as a promising 
target, partly because it has the ability to regulate T-IC fate in various types of 
cancers, including both solid tumours and leukaemia (Pannuti et al. 2010). Indeed, 
different Notch inhibitors such as Ȗ-secretase inhibitors and monoclonal antibodies 
have been evaluated in the past years and promising results were recorded (Fan 2006, 
Pannuti et al. 2010, Saito et al. 2014).
1.6.1.2 Inducing differentiation
As for promoting the differentiation of T-ICs, bone morphogenic protein (BMP) 
and Oncostatin M (OSM) are among the mostly studied signalling pathways. 
Encouraging results have been obtained from some recent work. For example, 
through the promotion of BMP signalling in colorectal T-ICs by BMP4 (a natural 
ligand of MBP receptor), Lombardo et al observed not only increased terminal 
differentiation and apoptosis but also enhanced chemo-sensitivity of T-ICs 
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 (Lombardo et al. 2011). The sensitization of T-ICs to chemotherapeutic drugs was 
also demonstrated in other studies through the activation of OSM signalling in breast 
cancers (West et al. 2014, Yamashita et al. 2011). All of these results indicate that 
the combinatorial treatment of signal transduction and conventional chemotherapy 
may aid in eradicating T-ICs. 
What should be taken into account is that since these signalling pathways are 
shared by T-ICs and normal stem cells, any modification to them will inevitably 
disturb normal stem cells and cause potential toxicity. Furthermore, these pathways 
auto-regulate and interact with many other pathways, and therefore, strategies have 
to be designed to evaluate the full effects of intervention with any single pathway 
(Ebben et al. 2010).
1.6.1.3 A promising tool for T-ICs “destemming” – oligonucleotide
A new method to promote the differentiation of T-ICs has been developed recently. 
Through a kinome-wide RNA interference screen, Wurdak and colleagues identified 
Transformation/transcription domain-associated protein (TRRAP) as a critical 
protein for regulating the differentiation of T-ICs derived from multiple glioblastoma 
multiforme patients. When TRRAP was silenced through small interfering RNA 
(siRNA), substantial differentiation of T-ICs was achieved (Wurdak et al. 2010). 
Current methods to adjust signalling pathways depend mainly on inhibiting or 
activating the critical receptors of the corresponding signalling pathways through 
endogenous ligands or cytokines. The experiment conducted by Wurdak shed lights 
on the RNA interference (RNAi) mediated T-IC destemming (Wurdak et al. 2010). 
Obviously, blocking the critical receptors through RNAi and through endogenous 
ligands or cytokines could achieve similar outcome.
1.6.2 Targeting the T-IC niche
The concept of the T-IC niche is derived from the understanding of the normal 
stem cell niche, in which normal stem cells have discrete locations in tissues and are 
regulated by its surrounding environment (Filatova et al. 2013). Similarly, cancer 
cells in tumours are in a complicated ecosystem that includes tumour cells, various 
endothelial, hematopoietic, stromal fibroblast and other types of cells. As a 
component of this system, the tumour cells are heavily influenced and supported by 
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 their microenvironment. For example, such surrounding components can cause 
metabolic changes such as a hypoxic environment and nutrient fluctuation, which in 
turn not only initiate survival pressure to tumour cells to push them towards a more 
malignant state, but also contribute greatly to the heterogeneity observed in various 
types of tumours. That is to say, the overall fitness of a tumour is modulated by their 
microenvironment. Moreover, it has been reported that the drug responses of T-ICs 
were usually different between in vitro and in vivo, providing evidence that the niche 
in which a T-IC is located may pivotally determine its response to a given treatment 
(Junttila and de Sauvage 2013). In another instance, when the cell phenotype was 
studied, it was discovered that the interaction between T-ICs and their niche may 
even contribute to the epithelial to mesenchymal transition (EMT) of T-ICs 
(Oskarsson et al. 2014). Since the acquired EMT could lead to an abnormal or 
accelerated dissemination and metastasis formation, it confers T-ICs with a more 
aggressive property. Other researchers have also shown that the niche of T-ICs 
directly affected their mobilization and sensitivity to chemotherapies (Kaminska et al. 
2013). The implication of all these is that the niche of T-ICs represents a potential 
target for T-IC targeted therapy.  
To date, the most explicitly described cell types involved in the T-IC niche include 
fibroblasts, endosteum cells in the bone marrow, perivascular and vascular cells, and 
tissue macrophages (Konopleva and Jordan 2011). Moreover, several recent studies 
suggested that certain adhesion receptors, cytokine receptors, membrane-bound, 
soluble cytokine ligands and various chemotactic factors may also play important 
roles in the interaction between T-ICs and their niches (Filatova et al. 2013). These 
results provide us with an opportunity to develop a T-IC niche targeted anti-tumour 
therapy. Accordingly, various targets have been exploited in this area. One of the 
most promising targets is CXCR4, which is expressed on many kinds of cancer cells 
and works as a receptor for stromal cell-derived factor 1 (SDF1; also termed 
CXCL12). As a niche-derived chemo attractant for CXCR4+ cells, SDF1 enhances 
their entry into the bone marrow (Domanska et al. 2013). Recently, several clinically 
effective drugs have been developed to inhibit the interaction of CXCR4 and SDF1, 
aiming at mobilizing T-ICs and sensitizing them to traditional therapies (Damon and 
Damon 2009, Kessans et al. 2010).
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 However, although it has attracted great interests, targeting T-IC niche does not 
come without problems. Firstly, it is still unclear how the particular cells in the T-IC 
niche contribute to the behaviour of T-ICs and how their effects on T-ICs are 
mediated at a molecular level. Secondly, further studies should be conducted to 
investigate whether, and to what extent, T-ICs contribute to important features of 
their microenvironment through autocrine or paracrine mechanisms, or by creating 
clonal niche components. Lastly, similar to the strategy of targeting signalling 
pathways, T-ICs share similar niches with normal stem cells, and therefore potential 
side effects associated with this method have to be considered and circumvented 
(Reya and Clevers 2005).
1.6.3 Targeting T-ICs via specific cell surface markers 
To successfully act on T-IC related genes or pathways and achieve T-IC 
destemming, or affect their microenvironment as discussed above, a very critical step 
is to recognize and effectively target T-ICs. This is very important given that the 
reported T-IC related pathways and genes are usually present in normal stem cells or 
even normal cells. To date, various T-IC markers including epithelial cell adhesion 
molecule (EpCAM), CD133 and CD44 have been reported on different types of
tumours, which have been detailed in several recent reviews (Munz M, 2009,
Medema 2013, Uwe Karsten 2013). Despite controversies regarding the stability and 
specificity of T-IC markers, they do provide an opportunity to develop a “T-IC 
marker-specific antibody introduced targeted therapy”. However, to develop a 
successful T-IC targeted therapy via specific surface markers, several hurdles have to 
be overcome (Figure 1-3).
1.6.3.1 Four obstacles for successful T-IC targeted therapies
Firstly, as Clevers suggested “The markers that have been used so far to define T-
ICs constitute unlikely candidates for antibody therapy given that they are usually 
broadly expressed in healthy tissue” (Clevers 2011). An ideal antibody mediated 
therapy is expected to deliver drugs to T-ICs specifically. Secondly, T-ICs highly 
express ABC transporters (also expressed on normal stem cells and the blood-brain 
barrier), and therefore therapeutic methods must be able to not only specifically 
target T-ICs, but also escape from the efflux activity of ABC transporters and finally 
pass through the cell membrane of T-ICs. Thirdly, T-ICs have heightened activation 
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 of DNA repair mechanisms, which results in a lower rate of apoptosis compared with 
normal cancer cells. Last but not least, T-ICs are dormant cells, which makes them 
difficult to be inhibited or killed by traditional anti-cancer therapies, which target
cells undergoing rapid proliferation. 
According to the analyses mentioned above, traditional anti-cancer drugs, although
they appear to control bulk cancer cells well, are inefficient in affecting T-ICs (Gil J 
2008). To develop an effective antibody mediated T-IC targeted therapy, a 
comprehensive strategy is required.
Figure 1-3. Obstacles for T-IC targeted therapies and corresponding solutions
1.6.3.2 Four steps to achieve successful T-IC targeted therapy
The first step is to design a strategy that is able to concentrate drugs in tumours 
following systemic delivery. This is essential to avoid extensive side effects. 
Otherwise, once drugs are introduced to normal stem cells or healthy tissues that 
express the same pathways or protein targets with T-ICs, side effects will ensue. This 
mission could be fulfilled through exploiting a widely utilized phenomenon in cancer 
research - the permeability and retention effect (EPR effect) (Maeda H 2000). 
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 According to the EPR effect, if particles have a size between 10 nm and 200 nm 
(more than 50 kDa in the case of macromolecules), they will show accumulation in 
tumours with a much higher concentration (5 - 7 fold) than in other tissues after 
systemic delivery (Cortez-Retamozo et al. 2004, Jinhao Gao 2012).
Since ABC transporters can only extrude micro-molecules, the second hurdle, ABC 
transporters, does not appear to be a problem for the delivery of nanoparticles. 
However, it is worth noting that they can rapidly extrude traditional 
chemotherapeutic drugs from the cytoplasm, even when they have been delivered 
into cells by loading into nanoparticles. The rapidly growing RNAi technology 
presents a promising way to overcome the obstacles caused by both ABC 
transporters and anti-apoptosis mechanisms via silencing of the underlying genes 
(Geng et al. 2013, Haenisch et al. 2014).
To the best of our knowledge, in terms of anti-apoptosis pathways, there seems to 
be no reported qualitative differences between bulk cancer cells and T-ICs (He Y. C. 
et al. 2014, Jagani and Khosravi-Far 2008, Signore et al. 2013). The difference in 
drug resistance degree may relate to quantitative differences in the expression of 
some critical anti-apoptotic molecules. By far, the most employed pro-apoptotic 
strategies include targeting death receptors (Tam et al. 2012), targeting IAP family 
protein (Brouxhon et al. 2013) and targeting Bcl-2 family proteins (Deng J. and Letai 
2013). Among them, both IAP family and Bcl-2 family showed promise for nucleic 
acid-based therapy.  IAP family comprises eight human homologues and have been 
implicated to play an important role in the regulation of apoptosis in different types 
of cancer cells (Fulda 2013). Among them, survivin and XIAP have received more 
attention in recent years. More than 30 survivin- and XIAP-based anti-cancer 
preparations have taken their ways to clinical trials (ClinicalTrials.gov 2014a, b). As 
a cytoprotective molecule, survivin protein participates in at least three homeostatic 
networks: the control of mitosis, the regulation of apoptosis and the cellular stress
response (Altieri 2010). As for its anti-apoptotic effect, survivin acts through 
interacting with other protein partners, especially XIAP rather than directly inhibiting 
caspase pathway (Altieri 2010).  The survivin-XIAP complex suppresses apoptosis 
through promoting increased XIAP stability against degradation, activating multiple 
signalling pathways and synergistically inhibiting caspase-3 and -9 (Altieri 2010). In 
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 addition, survivin can also inhibit apoptosis through affecting a very important pro-
apoptosis molecule in apoptosis pathway, SMAC, either sequestering it away from 
XIAP or preventing its release from mitochondria (Dario C. 2013). 
From the perspective of T-IC targeted therapy, survivin is quite unique. Firstly, 
different from other IAP family members and Bcl-2 family members, survivin 
specifically over-expresses in human cancers and not expresses in most adult tissues, 
which makes it an attractive target for anticancer therapy (Altieri DC. 2010);
Secondly, Survivin has very close relationship with stem cells as evident by the fact 
that it is highly expressed in foetal tissues and absent from differentiated terminal 
cells (Végran F, 2011). Furthermore, different with other IAPs, survivin can perturb 
:QWȕ-catenin signalling pathway directly thURXJKLQWHUDFWLQJZLWKȕ-catenin (Torres 
et al. 2007). A recent global gene expression analysis conducted in human embryonic 
stem cells (hES) has shown that genetic ablation of survivin induced apoptosis in 
hES cells both in vitro and in vivo (Amber N. Mull 2014, Larman et al. 2011). As a 
result, together with Hiwi, hTERT genes, survivin has been proposed to be an 
important stem cell-associated gene and the co-expression of all of these three genes 
has been shown to result in a significantly increased risk of tumour-related death in 
soft-tissue sarcoma patients (Taubert et al. 2010). Admittedly, there are still concerns 
about the safety of survivin-targeted genetic therapy, especially considering the low 
but detectable level of survivin in some normal tissues and the essential role it plays 
in normal stem cells. In reality, these seem to be not a problem. As reported, the 
survivin addiction mechanism specifically shown on tumours and the existence of 
qualitative differences of survivin only appear in transformed cells while not in 
normal tissues (O'Connor et al. 2002). 
The final barrier is the slow cell division rate of T-ICs. As noted, both inhibiting 
self-renewal and promoting differentiation can exhaust dormant T-ICs and improve 
their chemo-sensitivity. These could be achieved through employing endogenous 
ligands or cytokines or RNAi technology. 
Once all of these barriers are eradicated, the traditional chemotherapeutic drugs can 
be followed. However, at this stage, they do not have to be attached to T-IC marker 
specific antibodies. It will be more beneficial to target the whole tumour, including 
both T-ICs and non-T-ICs. This is imperative as increasing evidence suggests T-ICs 
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 are quite plastic, and non-T-ICs can revert to T-ICs under certain conditions (Gupta 
et al. 2011, Nguyen et al. 2012).
Such a strategy may appear too complex to be executed. However, it is worth 
pursuing as experience from the past 60 years shows that it is almost impossible to 
cure such an intricate disease like cancer with a single treatment. From the viewpoint 
of anti-cancer therapy, even if this comprehensive strategy is partially effective, it 
still has a great potential.
1.7 Conclusion
Admittedly, current T-IC theory is far from being perfect and is still undergoing 
further development. However, T-IC targeted therapy does provide us with a new 
and promising opportunity to treat tumour cells that are resistant to current therapies 
and responsible for recurrence and treatment failure. In actuality, the concept of T-IC 
targeted therapy is feasible as evident by many of the successful T-IC related studies 
reported in recent years. With better understanding of the fundamental biology of T-
ICs, with improved technologies and apparatus such as gene expression profiling and 
next generation sequencing and high content screen, we are closer to achieving the 
goal of eradicating T-ICs. 
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 Section two
siRNA and in vivo siRNA delivery
1.8 RNA interference 
RNA interference (RNAi) is a conserved pathway present in most eukaryotes 
where double-stranded RNA triggers a series of biochemical events and results in 
sequence-specific suppression of gene expression (Liu Q. and Paroo 2010). The 
phenomenon of RNA introduced silencing was first reported in 1990 with attempts to 
improve aesthetic characteristics of petunia (Napoli.C 1990). There was no 
indication that it would initiate such an explosion of interest in various research 
fields until 1998 when research conducted by Fire and Mello in Caenorhabditis 
elegans proved for the first time that double-stranded RNA (dsRNA) could result in 
sequence-specific gene silencing (Fire et al. 1998). In the subsequent two years, 
dsRNA introduced gene silencing was confirmed in various species such as plant, 
yeast and Drosophila (Elbashir S.M. 2001). However, similar attempts in mammalian 
cells failed initially. With hindsight, this unexpected result could be attributed to a 
common mistake made in scientific research - applying experiences derived from one 
species to another directly. The earlier research revealed that a length of more than 
150 bp is necessary for dsRNA to induce effective RNAi responses in Drosophila
and other species (Elbashir S.M. 2001, Kamath et al. 2001, Parrish et al. 2000, Wei 
et al. 2000). However, as known today, this is not the case for mammalian cells in 
which the strongest RNAi response was recorded with 25-30 bp duplexes and the 
potency decreased with length (duplexes longer than 45 bp are usually assumed to be 
inactive) (Kim D. H. et al. 2005). Considering the length of duplexes used to 
measure RNAi in mammalian cells by early researchers were all based on knowledge 
obtained from other eukaryotes with the length of the duplex being as long as 100 bp 
or even 1662 bp (Ui-Tei 2000), it is not surprising that frustrating results were 
recorded in early days.  
In 2001, only three years after the first RNAi paper was published, the key 
mechanisms underlying RNAi were elucidated (Bernstein et al. 2001). It has been 
revealed that although the endogenous mechanisms to direct RNAi in mammalian 
and other eukaryotes are different, the mechanisms behind exogenous dsRNA 
induced gene silencing are similar between them. There are three steps involved in 
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 this process (Figure 1-4). In the first step, long dsRNAs are recognized and cleaved 
to 21-23 bp dsRNAs with 2-nt 3’overhangs at each end by Dicer enzyme (a member 
of RNase III). Then, the guide strand, which has a complementary sequence to the 
targeted mRNA, is loaded onto the RNA-induced silencing complex (RISC) (Kelly 
Priscilla N. et al.). Finally, the guide strand introduces RISC to the target mRNA and 
results in cleavage and subsequent degradation of the mRNA. 
Figure 1-4 Mechanism of dsRNA induced gene silencing
Based on the knowledge that the products of Dicer are 21-23 bp dsRNAs, Elbashir 
and colleagues designed an experiment using Drosophila embryos to test if these 
short dsRNAs can be loaded on RISC and mediate RNAi directly, bypassing the 
process of Dicer (Elbashir S.M. 2001). With subsequent success in Drosophila, they 
repeated the experiment in mammalian cells (Elbashir et al. 2001). Similar results 
were achieved and for the first time, the short dsRNAs induced RNAi was confirmed 
in mammalian cells. Today, it is not difficult to understand why this experiment is 
depicted as a “significant breakthrough” or “most important achievement” (Liu Q 
and Paroo 2010), as it provided the foundation for numerous siRNA-based 
applications, including powerful loss-of-function tools and a new class of potential 
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 therapeutics. Since then, these 21-23 bp dsRNAs, termed small interfering RNA 
(siRNA), started to attract more and more attention in various research fields.       
1.9 Advantages of siRNAs
1.9.1 siRNAs vs small molecule drugs
Compared with conventional small molecule drugs which interact with their targets 
(usually receptors) based on molecular conformation (Shoichet and Kobilka 2012),
siRNAs enjoy higher specificity by base complementary matching. Even more 
importantly, in principle, any genetic abnormality associated disease could be 
specifically targeted by siRNAs. Given that the majority of diseases such as cancer, 
viral infections, and various metabolic disorders involve some forms of genetic 
abnormality, siRNAs have a much broader range of disease applications than small 
molecule drugs (Vaishnaw et al. 2010), which makes it extremely attractive. 
1.9.2 siRNAs vs antisense oligonucleotides
“Specifically recognizing and cleaving targeted genes” is not a new concept. Back 
in 1978, 23 years before siRNA was discovered, Zamecnik and colleagues 
introduced the concept of “antisense oligonucleotides (AON)” through a famous 
experiment - “a 13-nucleotide-long DNA that was complementary to a target 
sequence in Rous sarcoma virus mRNA inhibited viral replication and protein 
translation in vitro” (Zamecnik and Stephenson 1978). 
Then, as a Nobel prize-winning discovery, what advantages does siRNAs possess 
compared with AONs? Probably the most important advantage for siRNAs is their 
high efficiency. This had been revealed in the very early stages of siRNA research. 
In the first paper detailing siRNA induced gene knockdown in mammalian cells, 
Elbashir and colleagues reported the extraordinary power of siRNAs - “siRNAs are 
effective at concentrations that are several orders of magnitude below the 
concentrations applied in conventional antisense or ribozyme gene-targeting 
experiments” (Elbashir S.M. 2001). The power of siRNAs partly lies in their capacity 
to engage with the endogenous RNAi machinery. In contrast to AONs, there are a 
couple of endogenous proteins such as RISC and Dicer to facilitate the binding of 
siRNAs to their target mRNAs, which decreases the number of non-productive 
interactions that an oligonucleotide may undergo (Bennett 2010, Kubowicz et al. 
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 2013). Furthermore, unlike siRNAs, which meet their targeted mRNAs in the 
cytoplasm, the targets of classic AON are pre-mRNAs (Ming 2011), which exist in 
nuclei of cells.  In other words, extra effort is required to translocate AON from the 
cytoplasm to the nucleus. 
1.10 siRNA in vivo delivery
Nowadays, it has become a common practice to inhibit gene expression in in vitro
experiments using various commercially available siRNA transfection reagents. In 
contrast, in vivo RNAi remains a very challenging task (Hobel and Aigner 2013). If 
considered simply from a pharmaceutical perspective, viral vectors may possess 
several desirable properties for in vivo RNAi.  For example, the gene knockdown 
effect it creates can last a long time (Lambeth and Smith 2013). Unfortunately, the 
widespread safety concerns associated with viral vectors limits their application 
(Martin S.E., Caplen, N.J. 2007). As a result, only non-viral siRNA delivery systems 
are discussed here. 
The first siRNA-related clinical trial was conducted in 2004, in which a naked 
siRNA termed Bevasiranib was delivered successfully by topical intravitreal 
injection (Lares et al. 2010). Although, as has been pointed out that “RNAi does not 
have to cure cancer to be of value” (LaMattina 2014), considering the high expenses 
involved in siRNA therapies, they will be clinically economical by targeting diseases 
where the cost of therapy would be justified by the beneficial medical effects (Zhou J. 
et al. 2013).
1.10.1 Obstacles for successful in vivo siRNA delivery
For successful siRNA in vivo delivery, a series of obstacles have to be overcome 
(Figure 1-5). Firstly, after systemic administration, siRNAs must avoid rapid 
degradation by nucleases in the bloodstream (Martin D. T. et al. 2014); secondly, 
siRNAs need to avoid fast clearance via vessel diffusion, renal filtration and 
reticuloendothelial system (Lee S. J. et al. 2013); thirdly, they should accumulate in 
targeted tissues with a high enough concentration for a sufficient period of time; 
fourthly, the delivery systems have to show effective tissue penetration (Martin D. T. 
et al. 2014); fifthly, they have to cross the cell membrane through endocytosis; 
sixthly, they must escape from endosomes before being delivered to lysosomes, 
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 where they will be degraded (Harris DA 2011); and lastly, they have to show no or 
acceptable immunogenicity or other types of unwanted toxicity. In fact, it has long 
been realized that the induction of the innate immune response is a major undesirable 
side effect of oligonucleotide-related therapy because of the toxicities associated 
with excessive cytokine release (Diner et al. 2013, Xue et al. 2014).
Figure 1-5 Obstacles for successful siRNA in vivo delivery
1.10.2 Strategies for successful siRNA in vivo delivery
In the last 10 years, many efforts have been made in this area. Due to limitations on 
space, only the most important achievements are discussed. 
1.10.2.1 Increasing in vivo stability of siRNAs via chemical modification 
Nuclease degradation is the first challenge after systemic administration. As 
reported, naked siRNAs are naturally rapidly degraded in the bloodstream after 
recognition by plasmatic nucleases containing a double-stranded RNA binding 
domain (Ambardekar et al. 2013). As a result, direct chemical modification to siRNA 
and/or encapsulation of siRNA using various delivery systems such as lipids or 
polymers have been employed to increase the in vivo stability of siRNAs. In this 
section we focus on chemical modifications and the delivery systems will be 
discussed later.
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 Chemical modifications can be introduced in the base, sugar or backbone of 
oligonucleotides, yet the sugar, especially the 2’-OH position, has been intensively 
exploited (Bramsen and Kjems 2013). For instance, both of the only two approved 
nucleic acid-based drugs - Fomivirsen (AON) and Macugen (aptamer) are modified 
in this position, with a 2’-fluoro substitute being employed (Arvin A 2007, Frenkel et 
al. 2007). In addition, other modifications associated with 2’-OH including locked 
nucleic acid (Alexis et al.), 2’-O-methyl and 2’-O-methoxyethyl have also been used 
in various studies (Bramsen and Kjems 2013, Lares et al. 2010).
Of note, almost all of the currently applied chemical modifications are based on 
previous strategies developed for AON in vivo delivery (Prakash 2011).  However, 
siRNAs are different from AONs in that they take advantage of the endogenous 
RNAi mechanism. As a result, while modifications can increase the in vivo stability 
of siRNAs, they can equally interrupt the interaction between siRNAs and their
corresponding endogenous enzymes, leading to reduced gene knockdown efficiency 
of siRNAs. This is especially true when modifications are introduced to the Dicer 
recognition position of siRNAs (8 bp from 5’ end of the guide strand) (Scott D. Rose 
2013). Annoyingly, given the efficacy of siRNA mediated gene silencing is highly 
sequence specific, there is still no universal rule to determine the optimum chemical 
modification pattern (Reynolds A. et al. 2004). For example, in contrast to results 
obtained from several earlier studies which found that large numbers of 2’-O-Me 
modifications could decrease siRNA activity (Czauderna et al. 2003), Allerson’s 
team reported an up to 500-fold increase in siRNA potency when fully modifying 
siRNAs with the same 2’-O-Me modification (Allerson et al. 2005). Therefore, it is 
still imperative to experimentally ascertain the influence of specific modification 
pattern on stability and gene silencing capacity in individual siRNA.
1.10.2.2 Improving pharmacokinetics by nanoparticles and PEGylation 
The second challenge is comparatively easier to resolve. It is well known that the 
pore size of normal capillary endothelium and glomeruli is 5 nm and 10 nm,
respectively (Sarin H. 2010, Ruggiero A et al. 2010). This means that as long as the 
size of a siRNA delivery system is larger than 10 nm, which could be achieved by 
encapsulating siRNAs into delivery systems such as liposomes or polymers, the 
quick clearance via vessel diffusion and renal filtration can be bypassed and 
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 consequently achieve a longer in vivo circulation time (Kievit and Zhang 2011).
Accordingly, in recently years, various carriers with a size between 50 nm and 100 
nm have been developed for in vivo siRNA delivery. However, the mostly used 
siRNA delivery systems such as the cationic liposomes and polymers, like some 
other exogenous macromolecules, are often recognized and removed by the 
reticuloendothelial system (Alexis et al. 2008), especially those in the liver, spleen 
and kidneys. Care must be taken to avoid opsonisation when designing drug delivery 
vehicles. Efforts have been made to solve this problem. Apart from introducing 
neutral materials such as cholesterol and 1, 2-Dioleoyl-sn-Glycero-3-
Phosphoethanolamine (DOPE) into formulations, covalently attaching polyethylene 
glycol (PEG) (Jokerst et al. 2011, Ryan et al. 2006) has become a common practice 
in this area (Matthew C. Parrot 2012, Yang W. et al. 2012). In fact, in addition to 
masking siRNA delivery systems from the host’s immune system, PEG can 
contribute to siRNA in vivo delivery in many other ways. For instance, improving 
drug solubility, preventing particle aggregation in the presence of serum, as well as 
adjusting the hydrodynamic size of nanoparticles (Jokerst et al. 2011).
However, although the beneficial effect of PEGylation on siRNA delivery is well 
acknowledged, PEG conjugation also causes problems. Firstly, PEGylation usually 
results in poorer loading of siRNAs into particles and results in the premature release 
of siRNAs (Jokerst et al. 2011). Post-PEG-coating might to some extent mitigate 
against this problem (Lin Q. Y. et al. 2014). Secondly, PEGylation may lead to the 
accelerated blood clearance of particles owing to PEG mediated immune response. It 
was observed that anti-PEG lgM could be induced after repeated injection of 
PEGylated particles, which in turn compromises the long circulation characteristic of 
PEGylation (Ichihara et al. 2013).
1.10.2.3 Passive targeting and active targeting  
The third challenge is how to deliver siRNAs to the desired tissues or cells. In this 
respect, both passive and active targeting can be exploited. The passive targeting is 
based on the previously discussed EPR effect (Fang et al. 2011). As reported, tumour 
vessels are best characterized by high permeability and a lack of an intact lymphatic 
system, which allow the preferential accumulation of particles with a size between 10 
nm and 200 nm in tumours (lung and liver share a similar distribution pattern) rather
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 than other tissues (Bartlett and Davis 2006, Bogdanov 2008, Fang et al. 2011). 
Actually, this is partly why nanoparticles less than 200 nm (Acharya and Sahoo 
2011, Lipovsky et al. 2012) have been so popular for the delivery of siRNAs and 
why almost all of the effective siRNA delivery systems seen in recent years have 
targeted diseases associated with tumours or tissues displaying the EPR effect (liver 
and lung for instance) (Rink et al. 2013, Babu et al. 2013, Whitehead et al. 2009).
Nonetheless, the EPR effect does not come without limitation. Firstly, it only 
allows particles to move through abnormal, inflammatory endothelium that possesses 
large fenestrations but does not result in specific cell targeting. Secondly, since lung 
and liver can also take advantage of this mechanism, when one tissue is targeted for 
siRNA delivery, toxic side effects may appear in other tissues. Additionally, tumours 
are highly heterogeneous, with even the same type of tumours possessing different 
degrees of vasculature, angiogenesis, maturity and microenvironment (Chaplain et al. 
2012), which makes it difficult to assess the effect of the EPR on individual cases. 
Therefore, apart from passive targeting, active targeting is usually required for 
targeted siRNA delivery. 
Active targeting requires attaching the siRNA delivery carriers with ligands or 
antibodies that not only bind to specific cell surface markers but also result in 
endocytosis. Endocytosis is very important for siRNA in vivo delivery. As 
macromolecules with negative charge and a size around 13 kDa, siRNAs cannot 
cross the cell membrane through free diffusion like small molecules (Yan Li 2013).
Endocytosis offers the only opportunity for them to reach the cytoplasm, where they
can meet their targeted mRNAs. In recent years, several endocytosis-inducible 
ligands or antibodies including folic acid, transferrin, scFv, anti-CD20 and several 
aptamers have been employed (Chen et al. 2010, Fernandez and Rice 2009, Gabizon 
et al. 2006, Lares et al. 2010, Ku et al. 2014, Peer and Lieberman 2011, Zhou Y. et al. 
2014).
1.10.2.4 Optimized particle size facilitates tissue penetration 
Although systemic bio-distribution and intracellular trafficking are of primary 
interest to in vivo delivery of siRNA, intra-organ distribution is another critical factor 
to consider (Bae Y. H. and Park 2011b, Lee S. H. et al. 2013). To be internalized into 
individual cells, after crossing the vascular endothelium, the siRNA delivery vehicle 
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 has to penetrate into and distribute throughout the target tissues. The extracellular 
matrix (ECM) is another obstacle. The ECM is composed of gels of polysaccharides 
and fibrous proteins, and acts as a structural support for the animal cells. The tight 
structure of the ECM (around 20 - 42 nm) (Lin Q. Y. et al. 2014) hinders the 
diffusion of larger nanoparticles, especially in poorly permeable tissues such as 
tumours (Huo et al. 2013). Given drug carriers move into tissue compartments by 
random Brownian motion and convection, the rate of diffusional extravasation at a 
certain concentration gradient across tumour vascular fenestrae would be affected 
mainly by the particle size (Huo et al. 2013). For example, when tumour penetration 
capacity was tested for two particles (with a size of 25 nm and 60 nm respectively), 
although the 25 nm particle was found to clear faster from the plasma compared to 
the 60 nm particle, its tumoural clearance was delayed and subsequent studies 
revealed that the 25 nm particle diffused further from the blood vessels following 
extravasation while the 60 nm particle remained mainly in the perivascular regions 
(Lee H. et al. 2010). In another study, although a 90 nm stealth liposome achieved a 
relatively higher concentration in the tumour, it did not appear to penetrate deeply 
into the tumour tissue even two days after delivery (Yuan et al. 1994). Other 
experiments demonstrated that only nanoparticles smaller than 30 nm could penetrate 
poorly permeable tumours (Cabral et al. 2011, Tang et al. 2013, Kano 2013) and 
similar results were obtained from research on human glioblastoma and melanoma 
(Lin Q. et al. 2014). Indeed, even the stable nucleic acid lipid particles (SNALP), the 
currently most sophisticated siRNA delivery system with a particle size around 70-
150 nm, showed poor penetration capacity in tumours. In contrast, a recently 
developed SNALP with a size of 30 nm achieved deeper tissue penetration (Lin Q. et 
al. 2014). Altogether, a size between 10 nm and 30 nm seems to be essential for 
effective delivery of siRNA to poorly permeable tissues. In this respect, the aptamer 
introduced siRNA delivery system (aptamer-siRNA chimera) with a size around 15 
nm appears to be promising (Li X. et al. 2013). Apart from particle size, the surface 
property also needs to be taken into account. For example, Stylianopoulos et al. 
demonstrated that the charge of the nanoparticles could influence particle diffusion 
and by introducing neutral materials to the nanoparticles, an enhanced diffusion was 
observed (Stylianopoulos et al. 2013).
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 However, reducing particle size is usually at the cost of compromising in vivo
circulation time. To solve this problem, some endogenous lipoproteins such as HDL 
and LDL (previously widely employed for systemic delivery of imaging agents and 
chemotherapeutics) can be exploited. With the controlled ultra-small size (< 30 nm) 
and suitable blood circulation time (13.5 and 15 h half-life for native HDL and LDL, 
respectively), they hold great potential to achieve excellent tissue penetration yet 
keep prolonged in vivo circulation time (Putnam 2014).
1.10.2.5 Strategies for endosome escape
Because negatively charged siRNAs with molecular weights around 13 kDa are 
unable to cross the cell membrane, current delivery systems achieve cellular 
internalization through endocytic pathways such as macropinocytosis, clathrin-
mediated endocytosis or caveolae-/lipid raft-mediated endocytosis (Juliano et al. 
2013). Under the theory of endocytosis, once siRNA delivery systems are delivered 
to the endosomes, escaping from the endosome becomes imperative. Otherwise, 
siRNAs will be delivered to the lysosome within 5-10 minutes and degraded 
eventually (Pittella et al. 2011). Existing techniques achieve this goal through 
employing the chemical and physical properties of the delivery carriers. 
Unfortunately, although endosome escape is commonly thought to be very critical 
for successful siRNA delivery, little improvement has been made in the last decade. 
For example, three of the most popular strategies for endosome escape, pH 
responsiveness, lipid diffusion and the proton-sponge effect had been trialled with 
AON delivery 10 years before RNAi was discovered (Xu and Anchordoquy 2011). 
In recent years, probably the most prominent improvement in this area is the 
invention of SNALPs, which are surrounded by a lipid bilayer containing a mixture 
of cationic and fusogenic lipids, coated with PEG (Peer and Shimaoka 2009). Since 
PEGylation is known to limit the cellular uptake as well as the endosome escape, in 
many cases, PEG is conjugated to SNALPs via a pH sensitive linker (Dong et al. 
2013). Once particles are delivered to acidic endosomal vesicles, PEG chains are 
released, thereby bypassing the negative effects of PEGylation. In May 2010, a 
SNALP mediated Ebola virus targeted siRNA treatment made headlines, as the 
preparation presented effective endosome escape capacity with promising therapeutic 
potential (Geisbert TW 2010). However, under current technologies, the endosome 
escape rate is still far from being satisfactory. As reported, even with the most 
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 sophisticated siRNA delivery system, SNALPs, the endosome escape rate is only ~5 
% (Lin Q. Y. et al. 2014). Considering siRNAs can be reused in the endogenous 
RNAi mechanism, the requirement for endosome escape might not as high as AON.
However, to reduce the in vivo siRNA dose, it is still imperative to increase the 
endosome escape rate. Some endogenous materials, such as the endogenous 
cholesterol transporter (HDL, LDL) and their artificial counterparts (reconstituted 
HDL (rHDL) and HDL-mimicking peptide-phospholipid scaffold (HPPS)) may 
provide us with opportunities to solve this problem and represent attractive siRNA 
delivery vehicles (Anil.S 2014). As reported, these materials are not only highly 
biocompatible and effective in loading siRNAs but also, more importantly, are able 
to deliver siRNAs directly into the cytoplasm via the lipid raft/caveolae pathway
(through SR-BI receptor) and therefore bypass the detrimental endosomal trapping 
(Lim et al. 2013). Apart from delivering siRNAs to the cardiovascular system, 
recently, their application has been extended to cancer therapies as many kinds of 
cancer cells, particularly ovarian, colon, lung, prostate and breast cancers, similar to 
cardiovascular system, highly express the SR-BI receptor (Lin Q. Y. et al. 2014).
Another factor that makes these materials fascinating lies in, as discussed before, 
their prolonged in vivo circulation time (around 15 hours in half-life) and near 30 nm  
particle size (Tsunemi et al. 2014), which endow them with excellent tissues 
penetration efficacy and the capacity to deliver siRNAs to the targeted cells in certain 
tissues. Overall, HDL and LDL based siRNA delivery systems possess many 
attractive features and thus offer a new opportunity for effective siRNA in vivo
delivery. 
1.10.2.6 Improving biocompatibility and reducing toxicity
Nowadays, it has become a common practice to abrogate the oligonucleotide 
mediated innate immune responses by either chemically modifying the siRNA 
backbone or by avoiding some known immunogenic nucleotide sequences (Engels 
2013). However, more and more evidence shows that the toxicity associated with the 
delivery systems themselves presents an even bigger problem. To protect siRNAs 
from enzymatic degradation, facilitate particles’ intracellular uptake and endosomal 
escape, cationic lipid- or polymer-based delivery systems have been extensively
employed in the past decade. However, these materials generally possess higher 
electric charge density that readily induces nonspecific interactions with negatively 
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 charged cellular components, which not only results in their rapid elimination after 
delivery, but also drives undesirable side effects (Nuhn et al. 2014). To overcome 
this problem, various lipoproteins have been explored and displayed desirable 
properties. As endogenous carriers, these materials are able to not only escape from 
being recognized as foreign entities by the human immune system but also avoid 
being absorbed by the reticuloendothelial system. Apart from lipoproteins, in recent 
years, several other human compatible materials were also tested. For example, Leaf 
Huang’s group developed a liposome-protamine-hyaluronic acid nanoparticle by 
introducing hyaluronic acid, a biogenic component in the ECM, into a liposome-
protamine-DNA (LPD) nanoparticle. As a result, hyaluronic acid conferred this 
delivery system with multivalent charges to enhance the particle condensation while 
eliminating the previously observed immunostimulatory effects (Chono et al. 2008).
In another study, Yang et al. developed a stable lipid-polymer hybrid nanoparticle by 
integrating BHEM-Chol into the formulation of cationic lipids and polymers. Such 
hybrid nanoparticles exhibited excellent stability in serum and showed significant 
improvement in biocompatibility compared with the pure liposome and polymer 
components (Yang X. Z. et al. 2011). Similar reduction of toxicity has also been
achieved by using other hybrid nanoparticles consist of poly glutamate (Hadinoto et 
al. 2013).
Considering the toxicity associated with the positively charged delivery systems, 
some researchers endeavoured to develop neutral or even anionic siRNA delivery 
systems. Landen’s group developed a neutral liposome that showed capacity to 
deliver various siRNAs. Promisingly, this system’s utility for EphA2 gene therapy 
has been scheduled for a Phase I clinical trial (Landen et al. 2005). Koldehoff’s 
group went one-step further by developing an anionic liposome for siRNA delivery 
(Koldehoff et al. 2007). Unfortunately, the anionic systems often have poor siRNA 
encapsulation capability owing to the electrostatic repulsion between negatively 
charged delivery systems and siRNAs. To solve this problem, a new liposome 
formulation was developed by using physiologically occurring anionic lipids, in 
which the anionic liposomes integrate with siRNA through stable calcium ion 
bridges (Kapoor and Burgess 2012). This improved siRNA-anionic liposomes 
presented excellent intracellular uptake, efficient endosomal escape and silencing 
efficiency with low toxicity. In addition, by creating an artificially negative 
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 hydrophilic and flexible ring, PEGylation can also be used to hide and limit the 
detrimental effects of positively charged lipids and polymers (Yang W. et al. 2012).
1.11 Optimistic basic research vs pessimistic market expectation 
When the wave of optimism for RNAi-based therapeutics was peaking around 
2004, it was widely considered siRNA-based drugs would soon become clinically 
available. However, the progress of in vivo siRNA delivery has been slow and 
questions were raised as to whether RNAi therapy could ever be broadly applicable
to a wide variety of diseases. An article published in 2011 entitled “Is RNAi dead?” 
reflected such concerns - “despite more and more promising results achieved from 
basic research, the industry remains cautious about the therapeutic potential of 
RNAi-based drugs”(Krieg 2011). For example, although Merck bought the company 
“SiRNA Therapeutics” for US$1.1 billion, it was quoted in 2009 as remaining 
sceptical regarding the development of siRNA-based drugs (Hunter 2011); 
meanwhile, Roche, Novartis and Pfizer decided to dramatically reduce or eliminate 
their RNAi research programmes (Kole et al. 2012). In the area of clinical trials, 
several promising drugs have been suspended in the last two years, including the first 
clinically studied siRNA-based drug - Bevasiranib, which had entered into phase III 
clinical trials before it was interrupted (Health 2012).  The year 2010 saw the lowest 
point for RNAi related industrial efforts. In this year, there were only two big 
pharmaceutical companies remaining directly involved in RNAi research (Krieg 
2011). Yet the most impressive news came from Alnylam in 2014, who bought the 
company of Sirna technology from Merck with $165M, while Merck paid $1.1 
billion for it back in 2006 (Bouchie 2014).
1.12 The limitations underlying current siRNA in vivo delivery
Several strategies used to facilitate siRNA in vivo delivery make it difficult to 
translate many of the current researched siRNA in vivo delivery systems into the 
clinic. Firstly, it is worth noting that many delivery systems that are touted as “self-
assembling” (e.g., liposome, polymer) are often very difficult to control on a 
commercial scale (Xu and Anchordoquy 2011). In practice, many of these self-
assembling systems require diluted conditions to achieve reasonably uniform particle 
characteristics. Therefore, many early studies have used too large a volume for 
injections into animal models, e.g. injection of 1 mL drug into a mouse having a 
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 blood volume of approximately 2 mL, which is clinically unattainable (Lewis and 
Wolff 2007, Sebestyen et al. 2006). 
Secondly, to develop a successful siRNA-based product, the components of the 
delivery system should be feasible for large-scale manufacturing at both research-
and industrial-scales. From this perspective, many of the approaches utilized in 
recent studies are not practical for clinical translation. For example, the cost of 
manufacturing a relatively simple liposome product is considerable.  If one combines 
the additional cost of the siRNAs, the targeting ligands, molecules to enhance 
delivery (e.g., PEG) and the process of conjugation and purification at the GMP 
level, many of the delivery systems that appear promising in the laboratory are
worthwhile academic exercises rather than viable technologies that will lead to 
commercial development.
Lastly, the most popular protein-based ligands (e.g., antibodies, transferrin, RGD 
peptide) used to mediate active targeting also contributed to the pessimistic market 
expectation. Using antibodies as an example, although they have been confirmed to 
be highly effective, the use of proteins as targeting ligands compromises one of the 
primary advantages of employing synthetic delivery systems (e.g., oligonucleotides, 
lipids or polymers) - the lack of a specific immune response (Keefe et al. 2010, 
Maurer et al. 2001). What’s more, it is also well known that these protein-based 
ligands are very difficult to handle during conjugation, purification and storage on a 
commercial scale with existing technologies (Cortez-Retamozo et al. 2004).
1.13 Aptamer-mediated siRNA in vivo delivery – a promising strategy
Aptamer-mediated siRNA delivery system, a completely RNA-based formulation 
first introduced by Giangrande’s group in 2006, seems to have the capacity to 
overcome many of the obstacles faced by other siRNA in vivo delivery systems 
(McNamara J. et al. 2006).
1.13.1 Aptamers vs traditional antibodies
Aptamers are non-naturally occurring single-stranded RNA/DNA generated via an 
in vitro selection process referred to as SELEX (systematic evolution of ligands by 
exponential enrichment) (Shigdar et al. 2011a). Similar to that observed with 
antibodies, aptamers can bind to their targets (e.g., small molecules, peptides, 
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 proteins) with high affinity and specificity, suggesting their potential utility as 
therapeutic antagonists, agonists, diagnostic agents and drug delivery carriers 
(Taghdisi et al. 2010). 
The fact that aptamers are selected and produced in vitro endows them with many 
advantages compared to traditional antibodies in terms of commercial application. 
Firstly, it allows selection under non-physiological conditions and toward targets 
ranging from small molecules to whole cells or even an organ in a live animal; 
secondly, they are smaller and less complex than antibodies (5 - 25 kDa vs. 150 kDa) 
and have not been shown to be immunogenic; thirdly, in vitro synthesis/production 
ensures minimal batch-to-batch variation; fourthly, the whole procedure can be
automated and thus is easier, quicker and cheaper than antibody production. Even 
more importantly, similar to other types of oligonucleotides, aptamers can be easily 
chemically modified, helping to circumvent the main concerns regarding the 
applicability of aptamers - sensitive to nuclease attack (Moore et al. 2011). In 2004, a 
PEGylated aptamer, called Macugen, was approved in the US (Chapman and Beckey
2006), which makes it the only currently available oligonucleotide-based drug in the 
clinic (another approved oligonucleotide, Fomivirsen, an AON drug, was 
discontinued in 2004) (Jones 2011).
1.13.2 Applications of aptamers
Generally, the potential clinical application of aptamers includes two aspects. 
Firstly, neutralizing receptors or blocking ligand-induced activations after specific 
binding to receptors, which is exactly the mechanism of Macugen (specifically binds 
and blocks VEGF receptors) (Starita et al. 2007). The second application of aptamers 
exploits their high binding specificity for targeted moieties on specific cells or 
tissues. By conjugating aptamers with therapeutic drugs or imaging reagents, active 
targeting can be achieved. Furthermore, if an aptamer can undergo cellular 
internalization following specific binding, it has the potential to be used as a carrier 
to delivery siRNAs (Cerchia and De Franciscis 2010). 
To date, several endocytosis-inducible aptamers have been used to deliver siRNAs 
through different approaches (Figure 1-6) (Chu et al. 2006, Dassie et al. 2009,
Wullner et al. 2008). In a recent study, promising anti-cancer results were achieved 
using an aptamer-siRNA chimera. With a concentration of only 4 nM, the in vitro
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 cancer cell inhibition rate reached 85%. Additionally, by attaching a 20 kDa PEG to 
this chimera, a significant extension of its half-life was achieved - from less than 35 
minutes to more than 30 hours (Dassie et al. 2009). Consequently, in preclinical
studies, approximately 70% of all the tumours treated of 1 nmol/mouse chimera 
showed complete regression by the end of the experiment. 
Figure 1-6 Schematic of Aptamer-siRNA chimera structure. A: non-covalent 
conjugation of siRNA and aptamers via streptavidin connector; B: covalently attached 
aptamer–siRNA chimeras. (Modified from (Zhou, J., 2010))
1.13.3 Challenges and opportunities for aptamer mediated siRNA delivery
As with any new technology, there are perplexing problems associated with 
aptamer mediated siRNA delivery. Firstly, how do they escape from the endosome 
and reach the cytoplasm? With the current understanding of endocytosis, this is an 
almost impossible mission for aptamer-siRNA chimeras to achieve. These negatively 
charged macromolecules cannot diffuse into the cytoplasm like small molecules, and 
neither can they take advantage of built-in endosome escape mechanisms of any 
kind. The detailed endosome escape mechanism of aptamer-siRNA chimera remains
to be elucidated though given the successful delivery of siRNA for gene knockdown, 
they do escape from the endosome (Liu H. Y. and Gao 2013). Another problem is 
based on the fact that compared with lipid- and polymer-based delivery systems, the 
gene-silencing capacity of aptamer-siRNA chimera is somehow sequence specific, 
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 which means the experiences obtained from developing a certain chimera, including 
structure and modification patterns, may or may not be applicable to others. Even so, 
the aptamer-mediated siRNA in vivo delivery system still has great potential. Firstly, 
it has high gene-silencing efficiency and elicits no or negligible immune response, 
both of which are big problems for other delivery methods (Huang and Liu 2011); 
secondly, the chemically synthesized structure offers the best hope for regulatory 
approval (potentially avoiding regulation as a “biologic drug”) and commercial 
development (Xu and Anchordoquy 2011); thirdly, the simple structure not only 
ensures lower cost but also facilitates quality control; lastly, through chemical 
modification, the stable chemical properties could significantly facilitate the whole 
production processes including purification, conjugation and storage.  
1.14 Conclusion
Admittedly, siRNA-based therapy is still facing challenges in industrial 
development. However, the bright side is that siRNA in vivo delivery is still one of 
the most promising and rapidly advancing frontiers in biomedicine and drug 
development today. Encouraging news also came from clinical trials. The recent 
release of promising clinical data by Alnylam has resulted in a significant increase in 
its market capitalisation from US $290M to US $6B in only three years (Alnylam 
2014). Although “RNAissance” (Marshall 2014) might be overly optimistic, in all 
likelihood, the first approved siRNA therapeutics may soon become available. 
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 Section three
1.15 Aims of research
An aptamer mediated in vivo siRNA delivery system was first reported in 2006 and 
combines two important advancements in the biomedical research field in recent 
years (i.e. siRNA and aptamer). Compared with other in vivo siRNA delivery 
systems, this aptamer mediated siRNA delivery system possesses a simple structure, 
highly efficient targeting activity, outstanding immune compatibility and an ease of 
chemical modification, making it a new RNAi strategy with great potential for the 
treatment of various traditionally incurable diseases. In this project, we endeavour to 
take this promising technical advancement to the next step – developing a T-IC 
targeted in vivo siRNA delivery system. 
The specific aims of this project are:
i. To discover a critical gene for the chemo-resistance of T-ICs in a drug-
resistant breast cancer model.
ii. To develop a chemically modified aptamer-siRNA chimera structure 
displaying enhanced stability, efficient gene silencing capacity, low 
immunogenicity and optimal pharmacokinetic parameters suitable for 
future clinical applications. 
iii. To study the in vivo gene-silencing capacity of the developed aptamer-
siRNA chimera in T-ICs in the drug-resistant breast cancer model. 
iv. To study the synergistic anticancer efficacy of combinatorial treatment 
using the T-IC targeting aptamer-siRNA chimera and traditional 
chemotherapy.
1.16 Hypotheses
i. A drug resistant breast cancer cell line enriches for T-ICs.
ii. There exists at least one drug-resistant gene contributing to the chemo-
resistance of the enriched T-ICs and it is amenable to RNAi-based therapy 
in the drug-resistant breast cancer model.
iii. Conjugating siRNA to the EpCAM aptamer will not compromise its 
targeting efficacy and cellular internalization. 
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 iv. The 2’-fluoro-pyrimidine and 2'-O-methoxyethyl modifications may 
confer the aptamer-siRNA chimera with sufficient serum stability.
v. An aptamer-siRNA chimera with a 27-mer siRNA portion and an 
asymmetric structure will ensure the processing of the chimera by Dicer
from a specific position and result in a previously confirmed 21-mer
siRNA.
vi. Since coating with Polyethylene glycol (PEG) has the potential to extend 
circulation time of macromolecules and take advantage of enhanced 
permeability and retention (EPR) effect, conjugation of a PEG to the 
chimera will confer favourable pharmacokinetic and bio-distribution 
properties. 
vii. The carefully engineered PEGylated chimera with a size of around 15 nm
should display sufficient tumour penetration capacity and achieve 
efficient gene silencing efficacy in tumours. 
viii. Since the aptamer portion of the chimera is designed to target a well-
established breast T-IC surface marker (EpCAM), the chimera will show 
effective accumulation in T-ICs of the drug-resistant breast tumour after 
systemic administration.
ix. Silencing a critical gene associated with chemo-resistance of T-ICs will 
sensitize T-ICs to chemotherapy in the tumour model. 
x. Combined treatment using the aptamer-siRNA chimera and traditional 
chemotherapeutic agent improves the treatment outcome of mice bearing 
drug-resistant tumours.
xi. One distinguishing feature of this project is to use a chemically modified 
pure RNA structure, which lacks immunogenicity, thus, a better safety 
profile is expected. 
The studies carried out in this thesis are outlined in Figure 1-7.
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 Figure 1-7 Research outline and the corresponding chapters shown in thesis
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 Chapter 2
Material and methods
2.1 Ethics Statement
All animal protocols used in this research have been approved by the Deakin 
University Animal Welfare committee. Human breast cancer tissues were obtained 
from consenting patients through Geelong Hospital with relevant institutional review 
board approval. 
2.2 Materials and equipment
2.2.1 Chemicals and reagents 
1% acid alcohol (Amber Scientific, Cat No: 100305)
10 × PCR loading buffer (Takara, Cat No: A260)
10% Neutral buffered formalin (Sigma, Cat No: HT5014-ICS) 
2-Mercaptoethanol (Merck, Cat No: 8.05740.0250)
3M sodium acetate (pH 5.2) (Invitrogen, Cat No: 46-0236)
4% Metaphor Agarose gel (Lonza, Cat No: 50535) 
40 μm cell Strainers (BD Falcon, Cat No: 352340) 
8- chamber coverglass slides (Lab-Tek, Cat No: 155409) 
Acetic acid (Merck, Cat No: 1.00063.2500)
Acrylamide (Bio-Rad, Cat No: 161-0156)
Agar (Merck, Cat No: 1.01614.1000)
Agarose powder (Bio-Rad, Cat No: 161-3105)
Ammonium Persulphate (Bio-Rad, Cat No: 161-0700)
ApopTag Red In Situ Apoptosis Detection Kit (Millipore, Cat No: SK-4105) 
ATP (Invitrogen, Cat No: 46-0223)
B27 (Gibco, Cat No: 10889-038)
Bisbenzimide Hoechst 33342 (Sigma, Cat No: 14533) 
Bovine serum albumin (BSA, Sigma, Cat No: A4503)
Bromophenol Blue (Bio-Rad, Cat No: 161-0404)
CaCl2 (Merck, Cat No: 172570)
Chloroform (Sigma, Cat No: 366927)
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 Collagenase II (Sigma, Cat No: C6885) 
Costar Ultralow attachment surface 6-well plates (Corning, Cat No: 3471) 
DAB peroxidase substrate solution (Vector Laboratories, Cat No: SK-4105) 
DAPI (Sigma, Cat No: D9642)
DAS 2.0 software (Mathematical Pharmacology Professional Committee of China). 
DEPC-treated water (Santa Cruz, Cat No: sc-204391A)
Dimethyl Sulfoxide (DMSO, Merck, Cat No: 1.02952.1000)
DMEM medium (Invitrogen, Cat No: 12800-017)
DMEM/F-12 media (Invitrogen, Cat No: 12500-096) 
DNase I (Epicentre, Cat No: PSZ-10226)
Doxorubicin (Sigma, Cat No: 44583)
DPX (Sigma, Cat No: 317616)
Eosin (Amber Scientific, Cat No: 110543)
Epidermal growth factor (EGF, Sapphire Bioscience, Cat No: 701-02360) 
Ethanol (Merck, Cat No: 1434543)
Ethylenediaminetetraacetic acid (EDTA, Scharlau, Cat No: AC0965)
Ex Taq DNA Polymerase (Katara, Cat No: RR001A), 
Fast SYBR Green Master Mix (Invitrogen, Cat No: 4385612)
Fibroblast growth factor (FGF, Sapphire Bioscience, Cat No: 701-23300)
Ficoll-Paque plus (GE Healthcare, Cat No: 17-1440-02) 
Foetal bovine serum (FBS, Invitro Technologies, Cat No: A50111-5039)
GelStar (Lonza, Cat No: 50535)
GeneAmp Fast PCR Master Mix (Applied biosystems, Cat No: 4359187)
GeneRacer RNA adaptor (Invitrogen, Cat No: 46-0243) 
Geneticin (G-418 sulfate, Gibco, Cat No: 11811-031)
Giesma (Sigma, GS500)
Glucose (Sigma, Cat No: 50-99-7)
Glutamax (Life Technologies, Cat No: 35050-061) 
Glycerol (Ajax Finechem, Cat No: 0810081)
Glycine (MP Biomedical, Cat No: 808831)
Goat serum (Abcam, Cat No: ab7481)
Ham’s F12 medium (Invitrogen, Australia, Cat No: 11765-054) 
HCL (Merck, Cat No: K37835117 737)
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 Hematoxylin (Amber Scientific, Cat No: 111207)
HEPES (Applichem, Cat No: A3724, 0100)
HhaI enzyme (Katara, Cat No: 1056A) 
High Capacity cDNA Reverse Transcription kit (Applied Biosystems, Cat No: 4368814) 
Histolene (Grale Scientific, Cat No: Z60809)
Human transferrin conjugate Alexa Fluor 488 (Life technologies, Cat No: T13342) 
Hydrogen peroxide (Selby-Biolab, Cat No: FOC171)
Insulin (Sigma, Cat No: 19278) 
Isopropyl alcohol (Fluka, Cat No: 59304)
Kanamycin (Sigma, Cat No: K4378)
KCl (Sigma, Cat No: P9541)
KH2PO4 ( Sigma, Cat No:  P0662)
Ligase buffer (Invitrogen, Cat No: 46-0226)
Lipofectamine 2000 (Life Technologies, Cat No: 11668-030)
Low melt agarose powder (Bio-Rad, Cat No: 161-3113) 
LysoTraker Green (Life technologies, Cat No: L-7526) 
Matrigel™ Basement Membrane Matrix (BD Biosciences, Cat No: 354234) 
Methanol (Merck, Cat No: 6.10158.2511)
MgCl2 (Ajax Finechem, Cat No: A296)
MgSO (Merck, Cat No: 1.05886.0500)
Mouse IFN-ڷ*LEFR&DW1R30&
Mouse IFN-Į(/,6$NLW3%/,QWHUIHURQ6RXUFH&DW1R-1) 
Mouse TNF-Į ELISA kit (BD, Cat No: 560478) 
Thiazolyl Blue Tetrazolium Bromide (MTT) (Sigma, Cat No: M5655)
Mussel glycogen (Roche, Cat No: 10901393001)
MxPro software (Agilent Technologies). 
N-[1-(2,3-Dioleoyloxy)propyl]-N,N,Ntrimethylammonium methylsulfate (DOTAP)
(Roche, Cat No: 1811177) 
Na2HPO4 (Riedel-de Haen, Cat No: 30435 )
NaCl (Merck, Cat No: K37303004)
NaHCO3 (Sigma, Cat No: 30435)
One Shot® TOP10 chemically competent E.coli (Life technologies, Cat No: C4040-10) 
OptEIA (Human TNF ELISA Set) ELISA sets (BD Biosciences, Cat No: 555212 and
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 558874)
Opti-MEM reduced serum medium (Gibco, Cat No: 31985)
Penicillin /Streptomycin (InvitrogenTM, Australia, Cat No: 15070-063) 
Phenol:Chloroform (Invitrogen, Cat No: 46-0374)
Phosphate saline buffer (PBS, Medicago, Cat No: 09-7400-100) 
Pierce High Sensitivity Streptavidin HRP conjugate (Thermo Scientific, Cat No: 21140) 
Platinum Taq DNA Polymerase High Fidelity kit (Invitrogen, Cat No: 11304-011) 
Poly I:C (InvivoGen, Cat No: PIC-34-08) 
Propidium iodide (Sigma, Cat No: P4864)
Protease inhibitor cocktails (Roche, Cat No: 11697498001). 
Proteinase K (Merck, Cat No: VL700168) 
QIAprep spin miniprep kit (Qiagen, Cat No: 27106) 
Quanta Blu fluorogenic Peroxidase substrate system (Thermo scientific, Cat No: 15169) 
Recombinant dicer enzyme kit (Genlantis, Cat No: T510002) 
RNaseOut (Invitrogen, Cat No: 51535) 
RPMI 1640 plus l-glutamine medium (Invitrogen Life Technologies, Cat No: 11875) 
S.N.A.P. column (Invitrogen, Cat No: 46-0261) 
S.O.C medium (Invitrogen, Cat No: 15544-034)
S.O.M medium  (Invitrogen, Cat No: 15544-034)
Salmon sperm DNA (Sigma, Cat No: D1626) 
Scott’s tap water substitute (Amber Scientific, Cat No: 111226)
Skim milk powder (Diploma, Cat No 28510001)
Sodium dodecyl sulfate (SDS, Medicago, Cat No: 09-2026-1000)
Stripping buffer (Thermo Scientifics, Cat No: 21059)
Super Signal West Dura substrate (Thermo Sciences, Cat No: 34075)
SuperBlock Blocking buffer (Thermo Scientific, Cat No: 37537) 
T4 RNA ligase (Invitrogen, Cat No: 46-2141) 
TdT enzyme (Millipore, Cat No: 90418)
TEMED (Invitrogen, Cat No: 15524-010)
Tetramethyl benzidine substrate (Sigma-Aldrich, Cat No: T0440) 
TOPO TA Cloning vector pCR 4-TOPO vector (Invitrogen, Cat No: K4575-02) 
Transfer RNA (Sigma, Cat No: R8508)
Tris Base (Sigma, Cat No: T6066)
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 Triton X-100 (Merck, Cat No: 1.08603.2500)
Trizol (Invitrogen, Cat No: 15596-026) 
Trypan Blue (Sigma, Cat No: T8154)
Trypsin-EDTA (Gibco, Australia, Cat No: 15400-054) 
Tryptone (Sigma, Cat No: T7293)
Tween 20 (MP Biomedicals, Cat No: Tween201)
VECTASHIELD® Mounting medium (Vector Laboratories, Cat No: H-1000) 
Yeast extract (Fluka, Cat No: 92144)
2.2.2 Equipment, services and consumables
0.22 mm syringe driven filter (Millipore, Cat No: SLGP033RS)
15 mL centrifuge tube (Corning, Cat No: 430791) 
5 ml polystyrene round bottom tube with strainer (BD Falcon, Cat No: 352235)
ABX Micros ESV60 haematology analysing system (Horiba Medical).
Australian Genome Research Facility (AGRF) 
BD FACSDiva software (v6.0) 
BD ultrafine insulin syringe (BD, Cat No: 326769)
CellBank Australia
Cellstar 24 well plates (Greiner Bio One, Cat No: 662160)
Cellstar 6-well plate (Greiner Bio One, Cat No: 657160)
Cellstar 96-well plates (Greiner Bio One, Cat No: 657185)
Cellstar Cell culture dish (Greiner Bio One, Cat No: 664160)
CLD MIAN WORKBWENCH software 7.0.3 (Qiagen).
Electrical homogenizer (Glas-Col, S/N CTM0500082) 
FACS Canto II flow cytometer (Becton Dickinson) 
FACSAria II flow cytometer (BD Biosciences)  
Flowjo 7.6.1 (Tree star)
Fluostar OPTIMA plate reader (BMG Labtech)
FluoView FV10i confocal microscope (Olympus , Japan)
FrameStrip 8 Clear Tubes & Caps (Integrated Sciences, Cat No: 4ti-0751)
HERA cell 150i CO2 incubator (Thermo Scientific)
Heparin coated Microtainer, (BD, Cat No: 015576N)
Hitachi CT15RE Bench-top Refrigerated Centrifuge (Japan, Cat No: 90560701)
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 Image-Pro software (Media Cybernetics)
ImageQuant LAS-4000 Chemiluminescence & Fluorescence Imaging System
(Fujitsu Life Sciences)
LAS-4000 Imaging software (GE Healthcare Life Sciences). 
Living Image Software V2.50 (Xenogen) Electrical homogenizer (Glas-Col) 
Microtome (Leica, Cat No: RM 2125RT)
Milli-Q® Advantage A10 Water System (Millipore)
Mini Trans-Blot Electrophoretic Transfer Cell (Bio-Rad, 170-3931)
NC membrane (Whatman, Cat No: 10401196)
Olympus SC20 camera (B & B Microscopes, USA)
Orbital Shaking Incubator (Ratex, Cat No: OM15)
Paraffin embedding machine (Leica, Cat No: TP 1020)
PCR thermal cycler (Takara, Dice mini) 
Petri Dish (Global Science, Cat No: 031604-000110)
pH metre (HANNA, Cat No: pH211) 
Poly-l-lysine coated glass slides (Sigma, Cat No: S9027-1PAK)
PowerPac 300 Basic Power Supply (Bio-Rad, 164-5050).
PVDF membrane (Thermo Scientific, Cat No: 77010)
qRT-PCR machine (Agilent Technologies, Stratagene Mx 3000P)
Semi-Micro Analytical Balances (A&D, Cat No: GR-200)
Spectrophotometers and Fluorospectrometers (Thermo Scientific, NanoDrop 2000c)
TaKaRa PCR Thermal Cycler Dice™ mini (Cat No: TP100)
T75 flask (CELLSTAR, Cat No: 658170).
TECNIPLAST SealsafeTM Individually Ventilated Cages (UK)
The limiting dilution formula on the website of Walter and Eliza Hall Institute of 
Medical Research (http://bioinf.wehi.edu.au/software/elda/index.html).
UV Trans-illuminator (Scientifix, M-20) 
VICTOR TM X5 Plate Reader (PerkinElmer Life and Analytical Sciences). 
Xenogen IVIS Lumina II imaging system (Caliper life sciences) 
Zetasizer Nano ZS Particle Characterisation System from Malver Instruments
(Malvern, UK).
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 2.2.3 Cells used in this study 
The MCF-7 (human breast adenocarcinoma, ATCC® HTB22™) cell line, T47D 
(human ductal breast epithelial tumour, ATCC® HTB133™) cell line, U-118MG 
(human glioblastoma, ATCC ® HTB-15™) cell line, HT-29 (human colorectal 
adenocarcinoma, ATCC® HTB38™) cell line, MDA-MB-231 (human breast 
adenocarcinoma, ATCC®HTB-26™) cell line, KATOIII (human gastric carcinoma, 
ATCC® HTB103™) cell line and HEK-293T (human embryonic kidney, ATCC ® 
CRL-11268™) cell line were purchased from American Type Culture Collection 
(ATCC, Manassas, VA). MCF-7/Adr cells were induced from MCF-7 cells exposed 
to 300 nM Dox for 20 passages and maintained in 300 nM Dox every other passage. 
All the above cells were cultured in DMEM (Invitrogen, Australia) medium 
supplemented with 10% foetal bovine serum (FBS, Hyclone, Canada), penicillin (50 
U/mL, Invitrogen, Australia), and streptomycin (50 μg/mL, Invitrogen, Australia) 
and 1× Glutamax (Life Technologies) in a humidified atmosphere containing 5% 
CO2 at 37 °C. Mouse LA-4 and IMGE5 cell lines were generous gifts from Dr 
Michael Gantier (Monash University, Australia). LA-4 was maintained at 5% CO2
and 37 °C in Ham’s F12 medium (Invitrogen, Australia) supplemented with 15% 
FBS and 1× Glutamax; IMGE5 was maintained at 5% CO2 and 33 °C in DMEM 
medium supplemented with 10% FBS, 1× Glutamax and 1 unit/mL mouse IFN-ڷ
(Gibco). Primary breast cancer cells and single tumour cells were dissociated from 
clinical samples (Table 2-1) or tumours using Collagenase II (Sigma) and cultured in 
DMEM supplemented with 15% FBS and 1× Glutamax at 5% CO2 and 37 °C. For 
subculturing cells from monolayer, cell culture medium was removed and cells were 
rinsed gently with sterilised phosphate saline buffer (PBS) twice, followed by 
detachment with 0.05% trypsin-EDTA (Invitrogen, Australia) at 37 °C until cells 
were rounded up and detached from the surface of flasks. Then, complete medium 
was used to inactivate the trypsin. Cells were centrifuged and collected at room 
temperature, followed by resuspension with appropriate buffer or medium.
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 Table 2-1 Summary of clinic-pathological features of primary breast tumours 
used in this project. 
Immunohistochemistry
ID Age Tumour pathology Grade ER PR HER2 Ki-67
#1 46 IDC 3 Negative Negative Negative > 15%
#2 52 Adenocarcinoma 2 Negative Negative Negative < 15%
#3 76 IDC 2 Negative Negative Negative < 15%
#4 45 IDC 2 Negative Negative Positive > 15%
IDC, Invasive ductal carcinoma; ER, estrogen receptor; PR, progesterone receptor; HER2, 
human growth factor receptor 2.
2.2.4 Animals used in this study
All animals were purchased from The Animal Resources Centre (Perth, Australia).
Six to eight week old NOD-SCID female mice were used for U118MG and MCF-
7/Adr xenograft establishment. The mice were housed in the TECNIPLAST 
SealsafeTM Individually Ventilated Cages, which were placed in a temperature-
controlled room (25 ± 1 °C) with a 12-h light-dark cycle. Mice were fed ad libitum
with a standard diet. Beddings, cages and water were autoclaved at 121 °C for 30 
min while the fodder was sterilised by ultraviolet irradiation before use. 
Male Sprague-Dawley rats (200 to 250 g) were housed in a temperature-controlled 
room (25 ± 1 °C) with a 12-h light-dark cycle. Rats were fed ad libitum with a 
standard diet and were fasted overnight before treatments administration.
Eight weeks old female BALB/c mice were used for immune response analysis. 
The mice were housed in a temperature-controlled room (25 ± 1 °C) with a 12-h
light-dark cycle and fed ad libitum with a standard diet.
2.2.5 Aptamers and aptamer-siRNA chimeras used in this study
Aptamers were synthesised by IBA GmbH followed by HPLC purification. 2’-F
represents 2’-fluoropyrimidine modified nucleotides while “m” indicates 2’-O-
methyl modification.
EpCAM targeting aptamer: 5’- A (2’-F-C) G (2’-F-U) A(2’-F-U) (2’-F-C) (2’-F-C) 
(2’-F-C) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-C) G (2’-F-C) G (2’-F-U) -
fluorophore-3’ (fluorescence: FITC). Negative control aptamer: 5’- A mC G mU A 
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 mU mC mC mC mU mU mU mU mC G mC G mU - fluorophore-3’ (fluorescence: 
FITC). The negative control aptamer is an aptamer of the same sequence as EpCAM 
targeting aptamer but with a different side-chain modification that could affect the 3-
dimensional structure of aptamer (Chushak & Stone 2009). As a result, it is not able 
to bind to EpCAM and does not specifically target the cancer cells with high 
expression of EpCAM.
Chimeras were synthesised by Thermo Scientific or IBA GmbH or BioSpring 
followed by HPCL purification. 2’-F represents 2’-fluoropyrimidine modified 
nucleotides while “m” indicates 2’-O-methyl modification.
Longer strand 1 (obtained from Thermo Scientific): 5’- A (2’-F-C) G (2’-F-U) A(2’-
F-U) (2’-F-C) (2’-F-C) (2’-F-C) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-C) G (2’-
F-C) G (2’-F-U) A A A A(2’-F-U) G (2’-F-U) A G A G A (2’-F-U) G (2’-F-C) G G 
(2’-F-U) G G (2’-F-U) (2’-F-C) (2’-F-C) (2’-F-U) (2’-F-U) -3’ (WD47)
Longer strand 2 (obtained from IBA GmbH): 5’- A (2’-F-C) G (2’-F-U) A(2’-F-U) 
(2’-F-C) (2’-F-C) (2’-F-C) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-C) G (2’-F-C) 
G (2’-F-U) A A (2’-F-C) (2’-F-U) (2’-F-U) G A A(2’-F-U) G (2’-F-U) A G A G A 
(2’-F-U) G (2’-F-C) G G (2’-F-U) G G (2’-F-U) (2’-F-C) (2’-F-C) (2’-F-U) (2’-F-U) 
-3’ (WD-49)
Longer strand 3 (obtained from IBA GmbH): 5’- A (2’-F-C) G (2’-F-U) A(2’-F-U) 
(2’-F-C) (2’-F-C) (2’-F-C) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-C) G (2’-F-C) 
G (2’-F-U) (2’-F-U) (2’-F-U) C UUG A AU G (2’-F-U) A G A G A (2’-F-U) G (2’-
F-C) G G (2’-F-U) G G (2’-F-U) (2’-F-C) (2’-F-C) (2’-F-U) (2’-F-U) -3’   (WD-52)
Longer strand 4 (obtained from IBA GmbH): 5’- A (2’-F-C) G (2’-F-U) A(2’-F-U) 
(2’-F-C) (2’-F-C) (2’-F-C) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-C) G (2’-F-C) 
G (2’-F-U) AA (2’-F-C)  (2’-F-U) (2’-F-U) G A A(2’-F-U)  G (2’-F-U) A G A G A 
(2’-F-U) G (2’-F-C) G G (2’-F-U) G G (2’-F-U) (2’-F-C) (2’-F-C) (2’-F-U) (2’-F-U) 
-3’   (WD-49)
Longer strand 5 (obtained from BioSpring): 5’- A (2’-F-C) G (2’-F-U) A(2’-F-U) 
(2’-F-C) (2’-F-C) (2’-F-C) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-C) G (2’-F-C) 
G (2’-F-U) A A (2’-F-C) (2’-F-U) (2’-F-U) G A A(2’-F-U) G (2’-F-U) A G A G A A 
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 G A G G (2’-F-U) G G (2’-F-U) (2’-F-C) (2’-F-C) (2’-F-U) (2’-F-U) -3’ (WD-65 
negative)
Longer strand 6 (obtained from IBA GmbH): 5’- A (2’-F-C) G (2’-F-U) A(2’-F-U) 
(2’-F-C) (2’-F-C) (2’-F-C) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-C) G (2’-F-C) 
G (2’-F-U) mA mA  C  U U G A A U  G mU A mG A mG A mU G mCG mG U mG 
G mU CmC mUmU -3’   (WD-45)
Longer strand 7 (obtained from IBA GmbH): 5’- A (2’-F-C) G (2’-F-U) A(2’-F-U) 
(2’-F-C) (2’-F-C) (2’-F-C) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-C) G (2’-F-C) 
G (2’-F-U) X X  C  U U G A A U  G mU A mG A mG A mU G mC G mG U mG G 
mU CmC mUmU -3’ (XX: HEGL)  (WD-34Ep27 Guide-MC)
Longer strand 8 (obtained from IBA GmbH): 5’- A (2’-F-C) G (2’-F-U) A(2’-F-U)
(2’-F-C) (2’-F-C) (2’-F-C) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-U) (2’-F-C) G (2’-F-C) 
G (2’-F-U) X X C  U U G A A U  G mU A mG A mG A A G A G mG U mG G mU 
CmC mUmU -3’ (XX: HEGL)  (WD-34Ep27 Guide-control)
Shorter strand 1 (obtained from Thermo Scientific): 5’- Dy647- G G A C C A C C G 
C A U C U C U A C A U U  -3’  (23siRNA)
Shorter strand 2 (obtained from IBA GmbH): 5’- Dy647 - G G A C C A C C G C A 
U C U C U A C A U U C A dA dG -3’  (WD-53)
Shorter strand 3 (obtained from IBA GmbH): 5’- Dy647 - G mG A mC C mA C mC 
G mC A mU C mU C mU A C A U U C A A G -3’ (WD-44B)
Shorter strand 4 (obtained from IBA GmbH): 5’ - G G A C C A C C G C A U C U C 
U A mC mA mU mU mC mA mA mG - Cy5 -3’ (Ep23-P-O-Me, WD42) 
Shorter strand 5 (obtained from IBA GmbH): 5’ - G G A C C A C C G C A U C U C 
U A C A U U C A dA dG – Cy5 -3’ (WD-32Ep27-passenger)
Shorter strand 6 (obtained from BioSpring): 5’ – Cy5- G G A C C A C C G C A U C 
U C U A C A U U C A dA dG-PEG (20 KDa) -3’ (PEG terminally linked to aptamer 
via C6-Amino) (WD-66)
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 Shorter strand 7 (obtained from BioSpring): 5’ – PEG (20 KDa)- FITC - G G A C C 
A C C G C A U C U C U A C A U U C A dA dG-Biotin -3’ (PEG terminally linked 
to aptamer via C6-Amino) (WD-64)
2.2.6 Survivin RNAi-resistant survivin plasmid, 429 bp 
For plasmid rescue, a pEX-3 (pGCMV/MCS/Neo), mammalian expression vector 
driven by a CMV promoter with a human survivin cDNA insert cloned at EcoRI and 
BamHI sites which contains eight silent mutations (RNAi-resistant) in the region 
corresponding to survivin siRNA guide strand was obtained from GenePharma. No
epitope tag was introduced.
ATGGGTGCCCCGACGTTGCCCCCTGCCTGGCAGCCCTTTCTCAAAGATCATCGTATT
TCCACTTTCAAGAACTGGCCCTTCTTGGAGGGCTGCGCCTGCACCCCGGAGCGGATG
GCCGAGGCTGGCTTCATCCACTGCCCCACTGAGAACGAGCCAGACTTGGCCCAGTGT
TTCTTCTGCTTCAAGGAGCTGGAAGGCTGGGAGCCAGATGACGACCCCATAGAGGAA
CATAAAAAGCATTCGTCCGGTTGCGCTTTCCTTTCTGTCAAGAAGCAGTTTGAAGAA
TTAACCCTTGGTGAATTTTTGAAACTGGACAGAGAAAGAGCCAAGAACAAAATTGCA
AAGGAAACCAACAATAAGAAGAAAGAATTTGAGGAAACTGCGGAGAAAGTGCGCCGT
GCCATCGAGCAGCTGGCTGCCATGGATTGA (bold sequence: siRNA 
complementary sequence)
Translation:
MGAPTLPPAWQPFLKDHRISTFKNWPFLEGCACTPERMAEAGFIHCPTENEP
DLAQCFFCFKELEGWEPDDDPIEEHKKHSSGCAFLSVKKQFEELTLGEFLKL
DRERAKNKIAKETNNKKKEFEETAEKVRRAIEQLAAMD
The RNAi-resistant survivin expression construct was generated by introducing 
mutations to the survivin cDNA sequence matching siRNA guide strand binding 
section 5’- AAG GAC CAC CGC ATC TCT ACA -3’, corresponding to nucleotide 
positions 166 - 184 of human survivin cDNA to 5’- AAA GAT CAT CGT ATT TCC 
ACT -3’.  This generated a sequence that encodes the same amino acids but 
abolished the RNAi.
                  
2.2.7 siRNA sequences 
siRNAs were synthesized by Thermo Scientific. The guide strands of survivin 
siRNA and MDR1 siRNA are 5’-UGUAGAGAUGCGGUGGUCCTT-3’ and 5’-
GAAGCACTGGGATGTCCGGT-3’, respectively.
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 2.2.8 Antibodies 
Mouse anti-human Survivin antibody (Santa Cruz, Cat No: SC-17779), 
Mouse anti-human MDR1 antibody (Santa Cruz, Cat No: SC-55510)
Mouse anti-human BCL-2 antibody (Abcam, Cat No: AB117115)
Mouse anti-human Nanog antibody (AbD Serotec, Cat No: MCA 5658)
Mouse anti-human SOX2 antibody (AbD Serotec, Cat No: MCA 5659T)
Mouse anti-human Notch1 antibody (AbD Serotec, MCA 4804Z),
Mouse anti-human CD338 antibody (AbD Serotec, Cat No: OBT 1177)
Mouse anti-human Nestin antibody (AbD Serotec, Cat No: OBT 1610)
Mouse anti-human BIM1 antibody (AbD Serotec, Cat No: MCA 3993Z) 
Mouse anti-human OCT4 antibody (AbD Serotec, Cat No: MCA 5683) 
Mouse anti-KXPDQȕ-actin antibody (Sigma, Cat No: A5441) 
Goat anti-mouse secondary antibody (Thermo Fisher, Cat No: 31430) 
Goat anti-mouse anti-fluorescein HRP secondary antibody (Abcam, Cat No: 
AB6656) 
Goat anti-mouse lgG pre-coated wells (Sapphire Bioscience, Cat No: 600-11050)
Goat anti-rabbit HRP-conjugated Ab (Pierce, Cat No: 31460) 
PE conjugated mouse anti-human CD24 antibody (BD Biosciences, Cat No: 555428)
Percp.cy5.5 conjugated mouse anti-human CD44 antibody (BD Biosciences, Cat No:
560531) 
FITC conjugated mouse anti-human EpCAM antibody (BD Biosciences, Cat No:
347197) 
V450 mouse anti-human CD44 (BD Biosciences, Cat No: 561292)
Rabbit polyclonal Abs (PBL Biomedical, Cat No: 31130-1)
Monoclonal Anti-FITC antibody (mouse IgG1 isotype) (Sigma, Cat No: F5636) 
Rhodamine conjugated anti-digoxigenin antibody (Millipore, Cat No: 90429)
Mouse anti-human Ki67 antibody (DAKO, Cat No: M7240)
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 2.3 Methods
2.3.1 Development of DOX resistant MCF-7 cell line 
MCF-7 parental cells were seeded into a T-75 flask. Drug treatment was carried out 
24 hours later when cells achieved 20% confluence. Cells were initially treated with 
full DMEM medium containing 20 nM Dox. Medium was changed every two days 
until cells grew to around 80% confluence. Cells were then collected and re-seeded 
in another T-75 flask at 20% confluence and preceded to another round of Dox 
treatment with a 2-fold concentration of Dox increase from the previous treatment 
until the cells were maintained in DMEM medium containing 300 nM Dox. During 
incubation, duplicate flasks were prepared, with one flask drug-treated and the other 
allowed growing for that passage in drug-free medium as backup. Cells from the 
drug-treated flask were then used for the next round of drug resistance induction. The 
increase in drug doses generally followed the pattern of doubling the concentration.
If the cells grew well, the drug doses were increased after every passage; otherwise, 
if cells grew too slowly and appeared to not be able to tolerate the concentration, 
another round of drug treatment with the previous Dox concentration was repeated or
cells were even grown in drug-free medium for one generation. After every two 
generations, aliquots of cells were frozen in liquid nitrogen as backup. Once cells 
were maintained in DMEM medium containing 300 nM Dox, gene expression was 
tested by qRT-PCR and/or immunoblotting assays.
MCF-7 and MCF-7/Adr cells were authenticated by CellBank Australia using short 
tandem repeat (STR) profiling, during which the ATCC obtained cell line HTB-22
was used as reference.
2.3.2 Preparation of aptamer-siRNA chimera
The longer and shorter strands of the PEGylated chimera were synthesized by 
TriLink BioTechnologies, Inc, followed by HPLC purification.  The molecular 
weight for the longer strand and shorter strand are 14,692 g/mol and 28,432 g/mol 
respectively. Both of the strands were dissolved in pH 7.4 buffer containing 300 mM 
KCl, 30 mM HEPES and 10 mM MgCl2.  For chimera folding, the two strands were 
mixed with equal molar amount and denatured at 95 °C for 5 min, following cooling 
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 down to room temperature. The creation of chimeras was confirmed using a 4% 
Metaphor agarose gel.
2.3.3 MTT assay
The response of cells to Dox was determined by the MTT (3-(4, 5-dimethylthiazol-
2-yl)-2, 5-diphenyl-2H-tetrazolium bromide) assay which measures the 
mitochondrial conversion of MTT to formazan as detected by the change of optical 
density at 570 nm (Jung et al. 2009b; Zhang, FY et al. 2009). Briefly, both MCF-7
and MCF-7/Adr cells were plated at a density of 1 × 103 FHOOVSHUZHOO LQȝ/
DMEM medium containing 10% FBS in 96-well plates and allowed to grow for 24 h. 
7KHFHOOVZHUHWKHQH[SRVHGWRDVHULHVRIFRQFHQWUDWLRQVȝJP/ ȝJP/
ȝJP/ ȝJP/ȝJP/ ȝJP/ ȝJP/ ȝJP/RIDOX for 72 h at 37 
°C under 5% CO2. Ten microlitres of MTT reagent was added into each well and 
incubated for 4 h. The reaction was terminated by removing medium prior to the 
DGGLWLRQRIȝ/ZHOOVROXELOLVDWLRQUHDJHQW'LPHWK\O6XOIR[LGH'062, Merck). 
The absorbance of the wells, including the blanks, was measured at 570 nm using a 
VICTOR X5 Plate Reader (PerkinElmer Life and Analytical Sciences). The 
inhibitory concentration 50 (IC50), defined as the dose of agents that inhibited 50% of 
cell growth, was calculated using GraphPad Prism software. All experiments were 
performed in triplicate and repeated thrice.
2.3.4 Protein extraction and immunoblotting assay
Cells from cell culture or tumours were lysed with lysis buffer (20 mM Tris HCL, 
135 mM NaCl, 1.5 mM MgCl2, 1 mM EDTA, 1% Triton X-100 and 10% Glycerol) 
containing 1 × protease inhibitor cocktails (Roche). Briefly, cells were trypsinized 
and collected into a 1.5 mL eppendorf tube. Lysis buffer was then mixed with cells at 
a ratio of 0.2 mL/1 ×106 cells. Following 10 min incubation on ice, the contents were 
subjected to centrifuge at 21,500 × g at 4 °C for 30 min. The supernatants were 
finally collected and quantification was conducted using a Nanodrop (Thermo 
Scientific NanoDrop 2000c). When total protein was extracted from tissues, fresh 
tissues were washed with PBS and minced in a Petri dish. The collected tissue pieces 
were then briefly homogenized with an electrical homogenizer (Glas-Col) with 
tissue: PBS weight ratio at 1:3. After washing with PBS, the pellets were mixed with 
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 lysis buffer and subjected to the same procedure as with extracting protein from 
FXOWXUHGFHOOV/\VDWHVȝJODQHZHUHVHSDUDWHGZLWK6'6-PAGE gel and protein 
was transferred onto a nitrocellulose membrane (Whatman) or PVDF membrane 
(Thermo Scientific). Following sufficient blocking with 5% skim milk (overnight at 
4°C), primary antibodies were incubated according to the manufacturers’ 
suggestions. Specific mouse anti-human antibodies to Survivin (Santa Cruz), MDR1 
(Santa Cruz), BCL-2 (Cell signalling), Nanog (AbD Serotec), SOX-2 (AbD Serotec), 
Notch1 (AbD Serotec), CD338 (Cell signalling), Nestin (AbD Serotec), BIM1 (AbD 
Serotec), OCT-$E'6HURWHFDQGȕ-actin (Sigma) were detected using goat anti-
mouse antibody (Sigma) and visualized using the Super Signal West Dura substrate 
(Thermo Sciences). Relative quantification was conducted using a LAS-4000 
,PDJLQJ6\VWHP*(+HDOWKFDUH/LIH6FLHQFHVZLWKȕ-actin as an internal control.
2.3.5 Total RNA Extraction and Reverse Transcription
Total RNA was extracted using Trizol (Invitrogen) according to the manufacturer’s 
instructions. Briefly, 5 - 10 × 106 cells were trypsinized and washed and then 
resuspended in ice cold PBS. Cells were then washed again and lysed with 1.0 mL 
Trizol reagent in a 1.5 mL Eppendorf tube by vortexing for 15 seconds followed by 
incubation at room temperature for 5 min. Next, 0.2 mL of chloroform was added to 
the homogenized sample and the mixture was shaken vigorously for 30 seconds and 
incubated at room temperature for 3 min. After a 15 min centrifugation at 12,000 × g
at 4 °C, the upper aqueous phase was carefully collected into a new 1.5 mL 
Eppendorf and RNA was precipitated by mixing the collected upper phase with 0.5 
mL of isopropyl alcohol at room temperature for 10 min. The RNA pellet was then 
collected by centrifugation at 4 °C at 12,000 × g for 10 min and subjected to two 
rounds of washing with 75 % alcohol. Finally, the RNA pellet was air dried for 5 –10
min and dissolved in DEPC-treated water. Following the quantification of the RNA 
with the Nanodrop, the RNA was kept at -80 °C. When total RNA was processed 
from tissues, tissues were subjected to the same mince and wash step as described for 
protein extraction and followed the same protocol as described above. Reverse 
transcription was performed using a High Capacity cDNA Reverse Transcription Kit 
(Applied Biosystems) according to the manufacturer’s instruction. Briefly, total RNA 
ZDVWKDZHGRQLFHDQGȝJ51$ZDVSXULILHGXVLQJ'1$VH,DQGWKHF'1$ZDV
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 WKHQSURGXFHGXQGHUDȝ/UHDFWLRQYROXPHXVLQJUDQGRPSULPHUVDIWHUK
incubation at 37 °C. The cDNA was kept at -20 °C. 
2.3.6 Real-Time Quantitative Reverse Transcription PCR (qRT-PCR) assay
qRT-PCR reactions were carried out on a Stratagene Mx3000P system (Agilent 
Technologies) using Fast SYBR Green Master Mix (Invitrogen). All primers used in 
this project were designed with a melting temperature of approximately 58 °C to 
meet the optimum working condition of the PCR Master Mix. The experiments were 
FRQGXFWHGDFFRUGLQJWRWKHPDQXIDFWXUHU¶VLQVWUXFWLRQ%ULHIO\ȝ/F'1$UHYHUVH
tranVFULEHGIURPȝJWRWDO51$SHUȝ/UHDFWLRQZDVPL[HGZLWKȝ/PDVWHU
PL[ȝ/HDFKSULPHUWRWDOO\ȝ/SULPHUVDQGWKHILQDOFRQFHQWUDWLRQZDVQ0
LQDȝ/UHDFWLRQDQGWKHDQQHDOH[WHQVLRQWHPSHUDWXUHZDVVHWDW&IRU
seconds and fluorescence was detected at 72 °C to minimize the disturbance of 
primer dimers. Data analysis was performed using the MxPro software (Agilent 
Technologies) with GAPDH served as an internal control. To determine the 
amplification efficiency of each primer, serial dilutions of cDNA were prepared (1-
fold, 2-fold, 4-fold to 20-fold dilution). After the PCR reaction, the amplification 
efficiency was calculated according to the following equation:
E=10(-1/slope) -1
Where E is the efficiency of the reaction and slope refers to the slope of the plot of 
CT value versus the log of the input template amount. An amplification efficiency 
between 0.8 and 1.2 was considered acceptable. The relative quantification was 
calculated using the Pfaffi method using the following equation:
Fold change= (Ep-target gene) ǻ&W- target / (Ep-GAPDH) ǻ&W- GAPDH
:KHUH(S3IDIILHIILFLHQF\HTXDOV(ǻ&WLVWKHGLIIHUHQFHRI&WEHWZHHQ
compared samples.  
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 Table 2-2 Primers used for qRT-PCR
Gene Primer sequence Amplicon (bp)
GAPDH (Human) F  5’-GAAATCCCATCACCATCTTCCAGG-3’ 120
R  5’-GAGCCCCAGCCTTCTCCATG-3’
MDR1 (Human) F  5’-ATATCAGCAGCCCACATCAT-3’ 154
R  5’-GAAGCACTGGGATGTCCGGT-3’
Survivin (Human) F  5’-GAACTGGCCCTTCTTGGAG-3’ 93
R  5’-AAGTCTGGCTCGTTCTCAGT-3’
XIAP (Human) F  5’-GACAGTATGCAAGATGAGTCAAGTCA-3’ 93
R  5’-GCAAAGCTTCTCCTCTTGCAG-3’
GAPDH (Mouse) F  5’- GGAAGCCCATCACCATCTTCCAGG -3’ 120
R  5’- GGGCCCCGGCCTTCTCCATG -3’
IFIT1 (Mouse) F  5’-CTGAGGAGTTCTGCTCTGCT-3’ 86
R  5’-ACCTGGTCACCATCAGCATT-3’
ABCG2 (Human) F  5’- CACAACCATTGCATCTTGGC- 3’ 74
R  5’ – GCTGCAAAGCCGTAAATCCA-3’
2.3.7 Mammosphere assay
The mammosphere assay was conducted according to previously reported 
protocols for the quantification of breast T-IC capacity (Shaw FL, 2012). Briefly, 
2000 viable single cells from different treatment groups were cultured in DMEM/F-
12 media (Invitrogen) supplemented with 1× B27 (Gibco), 20 ng/mL EGF (Sapphire 
Bioscience), 10 ng/mL FGF (Sapphire Bioscience) and 4 ng/mL insulin (Sigma) in 
ultralow attachment surface 6-well plates (Corning) at 5 % CO2 and 37 °C. Seven 
days later, first-generation spheres were counted and digested using trypsin for 3 min 
at 37 °C and then dispersed by pipetting with a 23-gauge needle. After checking for 
single cells, the cells were pelleted and replated under the same conditions as with 
the first generation. The sphere numbers were counted seven days later and only 
spheres with a size larger than 50 μm in diameter were counted. 
2.3.8 Survivin plasmid transfection
The plasmid was firstly amplified in E.coli. Firstly, resuspension of plasmid in TE 
buffer and the quantification was conducted using the Nanodrop. Then, one vial of 
Top10 E.coli (Life technologies) was thawed on ice and 100 ng plasmid was mixed 
gently with E.coli cells. Following an incubation on ice for 30 min, the heat-shock 
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 step was performed in a 42 °C water bath for 30 seconds followed by rapid cooling 
down on ice for 2 min. Then 259 μL pre-warmed S.O.C medium was added to E.coli
containing vial and the vial was shaken horizontally at 225 r.p.m. at 37 °C for 1h. 
Then E.coli cell streaking was conducted on agar plate containing 50 μg/mL 
Kanamycin with 10 μL cells per plate. Plates were incubated at 37 °C overnight and 
separated colonies were picked into 10 mL centrifuge tubes and incubated at 37 °C
and kept shaking at 200 r.p.m. overnight. Then plasmid DNA was extracted from 
amplified E.coli using a QIApre Miniprep kit (Qiagen). The DNA was assessed 
using Nanodrop. 
The transfection experiment was conducted in 6-well cell culture plate using 
Lipofectamine 2000 (Life Technologies). In short, one day before transfection, 6 × 
105 MCF-7/Adr cells were plated in 2 mL DMEM medium without antibiotics so that 
cells will be 90-95% confluent at the time of transfection. Eight hundred nanograms 
of plasmid DNA was gently diluted in 250 μL of Opti-MEM reduced serum medium 
for use. Lipofectamine 2000 reagent was gently mixed and 4 μL of Lipofectamine 
was diluted in 250 μL Opti-MEM medium. Following a 5 min incubation at room 
temperature, the diluted DNA and Lipofectamine 2000 were mixed gently and 
incubated for 20 min at room temperature followed by the addition of 500 uL of 
complexes to each well (containing cells and 1.5 mL full DMEM medium). The plate 
was then mixed gently by rocking back and forth and the cells were incubated in a 
humidified atmosphere containing 5% CO2 at 37 °C for 24 h prior to testing for 
survivin gene expression. The medium was changed to DMEM medium 
supplemented with 10% FBS and 1× Glutamax after 6 h of transfection incubation to 
minimize the toxicity of transfection reagent. 
2.3.9 MDR1 and Survivin siRNAs transfection
Twenty-four hours before transfection, cells were plated in 6-well cell culture 
plates at a concentration of 60,000 cells/mL in 2 mL per well DMEM medium 
without antibiotics. Twenty nanomolar and 50 nM of survivin siRNA or MDR1 
siRNA was gently diluted in 250 μL of Opti-MEM reduced serum medium for use.  
Thereafter, the steps performed were the same as described for survivin plasmid 
transfection. The gene silencing at mRNA and protein levels were examined using 
qRT-PCR and immunoblotting 24 h and 48 h later, respectively. 
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 2.3.10 Selection of stably transfected cell lines
Survivin plasmid was cloned into an expression vector carrying a Neomycin 
resistant gene. This confers the transfected cells with resistance to Geneticin. After 
plasmid transfection, the transfected cells were incubated with full medium including 
500 μg/mL Geneticin (Gibco, G-418 sulfate). The medium was changed every 
another day and the cells were constantly maintained in Geneticin. Once cells from 
the negative control parental cells died, cells that had undergone plasmid treatment 
were plated into cell culture dishes and allowed to form separate colonies. Individual 
colonies were then collected into 24 well plates and examined for gene expression 
through qRT-PCR and immunoblotting. 
2.3.11 Flow cytometry analyses and Fluorescence-activated cell sorting
For binding affinity assays, cells were cultured in T-75 flasks and harvested at 80% 
confluence with trypsin digestion and resuspended in PBS supplemented with 5 mM 
MgCl2 and enumerated. Following centrifugation at 1000 × g for 5 min, the cells 
were resuspended in blocking buffer (PBS supplemented with 5 mM MgCl2, 0.1 
PJP/W51$PJ»P/VDOPRQVSHUP'1$DQG)%6DQGGLOXWHGWR× 106
FHOOV»P/7KHEORFNLQJVWHSZDVFDUULHGRXWDW&IRUPLQ7RGHWHUPLQHWKH
equilibrium dissociation constant, the cells were incubated at 37 °C for 30 min in 100 
μL blocking buffer including a chimera concentration of 0 nM, 10 nM, 20 nM, 40 
nM, 80 nM, 160 nM and 200 nM. After thorough washing, fluorescent intensity was 
determined using a FACS Canto II flow cytometer (Becton Dickinson) and counting 
50 000 events each sample. An EpCAM negative control RNA aptamer that does not 
bind EpCAM and an EpCAM-negative cell line HEK293T were used to determine 
non-specific binding. The binding affinity was calculated after subtracting the mean 
fluorescence intensity obtained from target cells to that of negative control cells 
according to a method described by Ellington and colleagues (Li N. et al. 2009). Side 
and forward scatter as well as VWDLQLQJZLWKJ»P/SURSLGLXPLRGLGH were used 
to eliminate debris and cell doublets. Fluorescent histograms were recorded by BD 
FAC-SCantoTM II flow cytometer and analysed using BD FACSDiva software 
(v6.0).
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 For cell surface marker analysis and cell sorting, cells from cell culture or tumours 
were dissociated into single cells, washed with PBS containing 0.1% BSA and 
stained with human-specific antibodies to PE conjugated CD24 (1:50 dilution) (BD 
Biosciences), Percp.cy5.5 conjugated CD44 (1:50 dilution) (BD Biosciences) and 
FITC conjugated EpCAM (1:11 dilution) (BD Biosciences) for 30 min at 4 °C. After 
thorough washing with PBS, the population of T-ICs (defined as 
EpCAM+/CD44+/CD24-) were analysed using FACS Canto II (Becton Dickinson) or 
sorted using the FACSAria flow cytometer (BD Biosciences) for further analysis. 
Cells were routinely sorted twice, and the cells were reanalysed for purity, which 
typically was > 95%. For surface marker analysis, a minimum of 10,000 events were 
analysed for each sample from three independent experiments. 
2.3.12 Predicting RNA secondary structure
CLC MAIN WORKBENCH software (Qiagen) was used to predict the secondary 
structures of chimera structure. The most stable structure with the lowest Gibbs' free 
energy for each RNA oligo was used.
2.3.13 Chimera stability assay
Five microlitres of chimeras (5 μM) were mixed with an equal volume of 100% 
human serum and then incubated at 37°C for a series of time points including 30 
min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 14 h, 24 h and 36 h. The samples were then 
mixed with loading dye and electrophoresed using 4% Metaphor Agarose gel 
(Lonza) and stained with 1: 10,000 diluted GelStar (Lonza). The stability of treated 
chimera was compared with that of untreated chimera and the relative quantification 
was conducted using a LAS-4000 Imaging System (GE Healthcare Life Sciences). 
2.3.14 Confocal microscopy analysis for cellular uptake and subcellular 
distribution
Twenty-four hours prior to imaging, cells were seeded at a density of 75,000 cells 
per cm2 in 8- chamber slides (Lab-Tek) and incubated in conditions and mediums as 
described  in Section 2.2.3. EpCAM negative HEK293T and U118MG cell lines 
were used as negative controls. Following removal of medium, cells were incubated 
in blocking buffer (PBS supplemented with 5 mM MgCl2PJ»P/W51$
PJ»P/VDOPRQVSHUP'1$DQG)%6 at 37 °C for 15 min, and washed twice 
59 
 
 prior to incubation with 100 nM chimera for 30 min at 37 °C. Bisbenzimide Hoechst 
J»P/6LJPDZDVDGGHGWRWKHFHOOVGXULQJWKHILQDOPLQRI
incubation. The chimera solution was removed and the cells were washed thoroughly 
prior to visualization using a FluoView FV10i confocal microscope (Olympus,
Japan).
The endocytosis inhibition was carried out as previously reported (Shigdar et al. 
2011). Briefly, cells were pre-treated with potassium-depleted buffer (50 mM 
HEPES, 140 mM NaCl, 2.5 mM MgCl2, and 1 mM CaCl2) for 1 h at 37 °C (this 
buffer was also used in the chimera incubation step and all rinsing steps) followed by 
the addition of 100 nmol/L chimera for additional 30 min, with Bisbenzimide 
+RHFKVWJ»P/DGGHGWRWKHFHOOVGXULQJWKHILQDOPLQ of incubation. 
Cells were washed thoroughly and imaging was conducted using confocal 
microscopy. Human transferrin (Life technologies) was used as a positive control to 
determine the effectiveness of this treatment in inhibiting endocytosis. The 
endocytosis was restored by replacing the potassium-depleted buffer with PBS, and 
cells were imaged using confocal microscope at time points of 0 min, 5 min, 10 min, 
15 min, 20 min, 25 min and 30 min.  
To measure the co-localization of the chimera and the late endosome/lysosome, 
cells were firstly incubated with 100 nM chimera for 30 min at 37 °C, followed by 
thorough washing.   The surface chimera was quenched with 0.04% Trypan Blue. 
Cells were then incubated in full DMEM medium for another 2 h with 50 nM 
Lysotraker (Life technologies) applied in the last 30 min.  Cells were imaged after 
washing. The proportion of co-localization and free chimera was quantified using 
Image-Pro software (Media Cybernetics). 
2.3.15 In vitro Dicer digestion assay 
One microgram of chimera was digested using recombinant Dicer enzyme kit 
(Genlantis) in 10 μL for 12 h at 37 °C following the manufacturer's 
recommendations. The reaction was stopped by adding Dicer stop solution and the 
digests were then resolved on a 4% Metaphor Agarose gel (Lonza) and stained with 
1:10,000 diluted GelStar (Lonza) before visualization using the LAS-4000 Imaging 
System (GE Healthcare Life Sciences). The Dicer digestion of treated chimeras was 
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 compared with that of a 21-bp siRNA and the relative quantification was conducted 
using the LAS-4000 Imaging software (GE Healthcare Life Sciences). 
2.3.16 5’RACE PCR Assay 
The whole procedure is illustrated in Figure 4-3.
Twenty-four hours after chimera-mediated survivin gene silencing, the total RNA 
was extracted and the survivin gene silencing was confirmed through qRT-PCR 
assay. The total RNA samples showing survivin gene silencing were subjected to 
5’RACE assay. Table 2-3 shows the GeneRacer adaptor and primers used in this 
assay:
Table 2-3 GeneRacer adaptor and primers used in the 5’RACE assay
GeneRacer adaptor 5'-CGACUGGAGCACGAGGACACUGACAUGGACUG
AAGGAGUAGAAA-3'
5' RACE Primer 5'-CGACTGGAGCACGAGGACACTGA-3'
Survivin primer 5’-CGCACTTTCTCCGCAGTTTCCTCAA-3’
Nested 5’RACE Primer 5'-GGACACTGACATGGACTGAAGGAGTA-3'
Nested survivin Primer
M13 primer Forward 
M13 primer Reverse
5’-GCCAAGTCTGGCTCGTTCTCAGT-3’
5’-GTAAAACGACGGCCAG-3’
5’-CAGGAAACAGCTATGAC-3’
2.3.16.1 Ligating RNA oligo to total RNA
Total RNA was ligated to a GeneRacer RNA adaptor (Invitrogen) without prior 
treatment. Firstly, 7 μL of RNA (3.5 μg) was added to the tube containing the pre-
aliquoted RNA oligo (0.25 μg). After a gentle mixing and brief centrifugation, the 
tube was capped tightly with parafilm and incubated at 65 °C for 5 min to disrupt the 
RNA secondary structure. Then the sample was chilled on ice for 2 min and 
centrifuged briefly again. Next, 10 × ligase buffer (1 μL), 10 mM ATP (1 μL), 40 
U/μL RNaseOut (1 μL) and 5 U/μL T4 RNA ligase (1 μL) were added to the RNA 
oligo containing tube and incubated at 37 °C for 1 h. Finally, ligated RNA was 
precipitated by the addition of 90 μL DEPC treated water and 100 μL 1:1 saturated 
phenol: chloroform, followed by vortexing vigorously for 30 seconds. Following 
centrifugation at 12,500 × g for 5 min at room temperature, the top aqueous phase 
was transferred to a new tube. Then 2 μL of 10 mg/mL mussel glycogen and 10 μL 3 
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 M sodium acetate (pH 5.2) were added and mixed well prior to adding 220 μL 95% 
alcohol and vortexing briefly. The mixture was then cooled on dry ice for 10 min and 
centrifuged at 12,500 × g for 20 min at 4 °C. The supernatant was carefully removed 
the pellet was washed with 500 μL 70% alcohol and centrifuged at 4 °C for 2 min. 
Finally, the alcohol was removed and the RNA pellet was air-dried for 2 min at room 
temperature followed by resuspending in 10 μL DEPC treated water and quantified 
using Nanodrop. The integrity of RNA after ligation was verified using agarose gel 
electrophoresis. 
2.3.16.2 Amplifying 5’cDNA ends
Ligated RNA was firstly reverse transcribed to cDNA using High Capacity cDNA 
Reverse Transcription kit (Applied Biosystems) as detailed in Section 2.3.5. The end 
of 5’ cDNA was amplified using Platinum Taq DNA Polymerase High Fidelity kit 
(Invitrogen) following the manufacturer’s instruction. 5’ RACE primer and gene 
specific survival primer were added at the concentration of 600 nM and 200 nM,
respectively, in a 50 μL reaction. To increase specificity of the PCR reaction, 
touchdown PCR was applied with the following reaction conditions: 94 °C for 2 min; 
94 °C 30 sec and 72 °C 2 min for totally 5 cycles; 94 °C 30 sec and 70 °C 2 min for 
totally 5 cycles; 94 °C 30 sec, 65 °C 30 sec and 68 °C 2 min for totally 20 cycles; 68 
°C 10 min for 1 cycle and reaction was stopped at 4 °C.
Figure 2-1 Conditions for touchdown RCR 
Since a single, discrete band was not detected, nested PCR was performed using 
Platinum Taq DNA Polymerase High Fidelity kit with equal concentration (200 nM) 
of 5’ RACE nested primer and survivin nested primer. The reaction conditions used 
were as follows: 94 °C for 2 min; 94 °C 30 sec and 65 °C 30 sec and 68 °C 2 min for 
totally 30 cycles; 68 °C 10 min for 1 cycle and reaction was stopped at 4 °C.
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 Figure 2-2 Conditions for nested RCR assay
2.3.16.3 Gel-Purification of PCR products
Ten micrograms of amplified DNA was subjected to gel purification and separated 
using 1% low melt agarose gel (Bio-Rad) and the band with a correct size was 
excised using a new razor blade under UV light. The gel slice was transferred to an 
S.N.A.P. column (Invitrogen) and placed in a sterile microcentrifuge tube. After 
centrifuging at 12,500 × g at room temperature, the recovered DNA was collected 
and quantified using the Nanodrop. 
2.3.16.4 Transforming competent E.coli cells
TOPO TA Cloning vector pCR 4-TOPO vector (Invitrogen) was used to perform 
transformation. Firstly, 50 ng of freshly recovered DNA was mixed with 20 mM 
NaCl, 10 mM MgCl2 and 1 μL of vector to a total volume of 6 μL. The mixture was 
then gently mixed and incubated at room temperature for 5 min. After that the 
mixture (2 μL) was added into a vial of One Shot TOP10 competent E.coli cell 
(Invitrogen). Following gentle mixing, the mixture was incubated on ice for 15 min. 
Then heat-shock step was performed in a 42°C water bath without shaking for 30 
seconds followed by cooling down on ice. Two hundred and fifty microlitres of pre-
warmed S.O.M medium was then added to cells. After shaking cells horizontally at 
200 r.p.m. at 37 °C for 1 h, an appropriate volume of cells (usually between 10 μL to 
50 μL) were spread on pre-warmed selected LB plates containing 100 μg/mL 
Ampicillin and incubated overnight at 37 °C. 
2.3.16.5 Colony amplification 
Distinct colonies were picked using sterilized 200 μl pipette tips and seeded into 3 
mL of 2YT medium and incubated at 37°C at 200 r.p.m to grow overnight. At the 
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 same time, cells from the same colony was picked into PCR master mix and 
subjected to PCR to confirm the insertion of the expected 5’ DNA sequence. The 
PCR was conducted by using Ex Taq DNA Polymerase (Katara), 50 mM dNTP mix 
and 200 nM M13 primers. The conditions used were as follow: 94 °C for 10 min; 94 
°C 1 min, 55 °C 1 min and 72 °C 1 min for totally 25 cycles; 72 °C 10 min for 1 cycle 
and reaction was stopped at 4 °C. The amplicons were then separated by 1% agarose 
gel (Bio-Rad) for analysis. The insertion of expected DNA sequence was further 
confirmed through restriction enzyme digestion. HhaI enzyme (Katara) was used and 
the process of M13 primer products was performed in M buffer (Katara). 
2.3.16.6 Plasmid preparation and DNA sequencing
Plasmid DNA purification was conducted with the QIAprep spin miniprep kit 
(Qiagen) following the manufacturer’s instructions. The purified plasmid DNA was 
then quantified using the Nanodrop and verified by PCR using 5’ RACE nested 
primer and Survivin nested primer. The presence of a ~141 bp band upon gel 
electrophoresis indicates as the successful cloning of the insert. The recombinant 
plasmids (200 ng – 800 ng) mixed with M13 reverse primer (10 pmol) were sent to 
Australian Genome Research Facility (AGRF) for sequencing.  
2.3.17 Determination of particle size of non-PEGylated chimera and PEGylated 
chimera
$ȝ/DOLTXRWRIFKLPHUDȝ0ZDVGLOXWHGLQȝ/3%6DQGPL[HGJHQWO\
The vesicle size was measured using a Zetasizer Nano ZS Particle Characterisation 
System (Malvern, UK) following the manufacturer’s instruction.  
2.3.18 Tumour Implantation and Evaluation
Six to eight week old NOD-SCID female mice were kept under pathogen-free 
conditions at 25 ± 1 °C and a 12 h light/12 h dark cycle and allowed a 7-day 
acclimatisation period after arrival. They were fed ad libitum with a standard diet. To 
establish xenograft tumours, single MCF-7/Adr cells were harvested by 
trypsinization. The cells were then washed in PBS and resuspended in 50% Matrigel 
(Rahman et al.). Cells of 4,000,000 were injected into the 4th mammary fat pad of 
each mouse with a 1 mL syringe and 26-gauge needle. Tumour size was monitored 
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 every other day after implantation and approximate tumour burden (mm3) was 
calculated as Length × Width2/2, where length and width are the longest and shortest 
axis in millimetres. Once tumours arose, mice were randomized into treatment 
groups of 8 mice per group. Treatment was initiated when the tumour volume 
reached 60 mm3. Mice were euthanized two days after the last treatments or in the 
cases of in vivo LDA and survival assays, monitored over 6 months. The endpoints 
were defined as either diameter of the tumour reached 17 mm, consistent or rapid 
body weight loss of 20%, or other health deteriorations impacting on the welfare of 
the animal. Tumour fragments were archived in neutral buffered formalin for further 
analysis. Slides of sections were stained with haematoxylin and eosin (H&E) or 
processed for TUNEL using the ApopTag Red In Situ Apoptosis Detection Kit 
(Millipore) or Ki-67 analysis.
To establish U118MG xenograft tumours as EpCAM negative control in the in vivo
gene silencing assay and in vivo imaging assay, single U118MG cells were 
resuspended in 50% Matrigel at a concentration of 50,000,000 cells/mL and injected 
subcutaneously with 100 μL/mouse. The endpoints were defined as the same as 
MCF-7/Adr tumour bearing mice. 
2.3.19 In vivo imaging 
Non-PEGylated chimera or PEGylated chimera were injected into the tail vein of 
MCF-7/Adr or U118MG tumour (60 mm3)-bearing NOD/SCID mice (n=5) at a dose 
of 2 nmol/mouse. The live animal imaging was conducted at serial time points (10 
min, 30 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 14 h, 24 h) using a Xenogen IVIS 
Lumina II imaging system (Caliper life Sciences). A circular region of interest (ROI) 
around the tumour site of each mouse was made and the total flux in this region was 
quantified using Living Image Software V2.50 (Xenogen) with the units of 
photons/s/cm2/sr. The data were used for semi-quantification of fluorescence signal 
in tumours. 
2.3.20 RNA-ELISA 
Fifty microleters of the 10 μg/mL anti-FITC antibody (Sigma) in washing buffer 
(PBS containing 0.1 mg/ml tRNA and 1 mg/ml BSA) was added to 96-wells that had 
been pre-coated with the goat anti-mouse lgG (Sapphire Bioscience). After 1 h 
65 
 
 incubation at room temperature, anti-FITC antibody was removed followed by 
thorough washes. The treated wells were blocked with 50 μL 1× SuperBlock 
Blocking buffer (Thermo Scientific) at room temperature for 1 h, followed by 3
times washes, 3 min per time. Tissue or serum samples containing chimera (100 
μL/well) were added and incubated for 1 h at room temperature. After extensive 
washing, 50 μL of 1:5000 diluted Pierce High Sensitivity Streptavidin HRP 
conjugate (Thermo Scientific) was added to each well to bind biotin-conjugated 
chimera. After 1 h incubation at room temperature and extensive washing, the bound 
chimera was detected with a Quanta Blu fluorogenic Peroxidase substrate system 
(Thermo scientific) and measured at a wavelength of 325/420 nm using VICTOR X5 
Plate Reader (PerkinElmer Life and Analytical Sciences). 
2.3.21 Establishing standard curves of PEGylated chimera in plasma
PEGylated chimera was denatured at 95 °C for 5 min and dissolved in PBS to a 
stock concentration of 1 mg/mL. For each concentration (2500 ng/mL, 1250 ng/mL, 
625 ng/mL, 300 ng/mL, 150 ng/mL, 75 ng/mL, 37.5 ng/mL, 18.75 ng/mL, 9.375 
QJP/DQGQJP/WKHVWRFNZDVVHULDOO\GLOXWHGLQȝ/EODQNSODVPDWR
the final volume of 0.5 mL. PEGylated chimera with varying concentrations was 
added to FITC antibody-FRDWHGSODWHVDWȝ/ZHOODQGLQFXEDWHGIRUKIROORZHG
by measurement of chimera via RNA-ELISA as described in Section 2.3.20. 
Calibration curves were constructed by plotting OD value vs. chimera 
concentrations. A linear regression was used for quantification. The standard 
formulas were determined by linear regression as Y = aX + b, where Y is the OD value 
of chimera and X is the chimera concentration ((log values were applied on both X
and Y).
2.3.22 Establishing standard curves of chimera in tissues
7RHVWDEOLVKDVWDQGDUGFXUYHRIFKLPHUDLQWLVVXHVȝJRIGLIIHUHQWWLVVXHVZDV
placed in PBS in a 15 mL centrifuge tube and then homogenised with an electrical 
homogenizer (Glas-Col) with tissue: PBS weight ratio at 1:3. The tissue homogenate 
was centrifuged at 21,000 × g for 10 min at 4 °C. The supernatant was transferred to 
another tube and PEGylated chimera was processed as in Section 2.3.21. Serially 
diluted chimera prepared from different tissue homogenates were added to FITC 
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 antibody-coated plates and the OD values of each concentration of chimera was 
determined as in Section 2.3.20. Calibration curves were constructed as described in 
Section 2.3.21. 
2.3.23 Pharmacokinetics (PK) study
To investigate the PK properties of PEGylated chimera in vivo, healthy male 
Sprague-Dawley rats (200 to 250 g, n=5) were injected intravenously with chimera at 
a single dose of 100 nmol/kg (administration rate 0.4 mL/min). After injection, blood 
was serially collected from animals in heparinised tubes from the tail at time points 
of 10 min, 0.5 h, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 10 h, 12 h, 14 h and 24 h. Blood samples 
ȝ/ZHUHFROOHFWHGLQKHSDULQLVHGWXEHVDQGWKHQFHQWULIXJHGDW× g for 
10 min to separate the plasma. Finally, samples were measured using an ELISA-
based quantification method detailed in Section 2.3.20. The pharmacokinetic 
parameters were analysed using the DAS 2.0 software (Mathematical Pharmacology 
Professional Committee of China).
2.3.24 Bio-distribution assay
For bio-distribution assay, MCF-7/Adr tumour bearing NOD/SCID mice were 
randomly divided into four groups (5 mice per group, termed 0.5 h, 3 h, 6 h and 10 h 
time point groups) once tumours reached the average volume of 150 mm3. Chimera 
was delivered via tail vein injection with a dose of 2 nmol/mouse. Organs including 
stomach, eye, brain, skin, heart, liver, spleen, kidney, lung, intestine, tumour and 
excrement were collected 0.5 h, 3 h, 6 h or 10 h after chimera injection from 
corresponding groups. Tissues were then lightly washed in cold physiological saline 
to remove any excess blood, blot-dried using filter paper and weighed on aluminium 
foil. Tissues were then thoroughly homogenized in PBS (tissue: PBS weight ratio 
1:3) and homogenate was prepared as in Section 2.3.21. After centrifugation at 
10,000 × g at 4 °C for 10 min, the supernatants were collected and the chimera 
concentration was quantified by ELISA.  All the results are presented as means ± 
SEM. The pharmacokinetic parameters were analysed using the DAS 2.0 software 
(Mathematical Pharmacology Professional Committee of China). 
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 2.3.25 In vivo gene silencing assay and anti-tumour efficacy of the combined 
chimera and Dox treatment
When the xenograft MCF-7/Adr tumour reached 60 mm3, tumour bearing mice 
were randomized into six groups and received tail vein injection on days 1, 3, 5 and 
7. Specifically, Dox group was treated with PBS on day 1 and 5 mg/kg Dox on day 
3, 5, 7. Chimera and negative control chimera groups were treated with 2 
nmol/mouse on day 1, 3, 5 and PBS on day 7, while chimera + Dox and negative 
control chimera +Dox groups were treated with chimera or negative chimera on day 
1, followed combined chimera (or negative control chimera) and Dox on day 3 and 5, 
with a last injection of Dox on day 7. Two days after the treatment, total RNA and 
protein were processed from homogenized tumours and subjected to qRT-PCR and 
immunoblotting. Tumour growth was monitored by measuring tumour diameter 
every other day with a digital calliper and animal weights were monitored at the 
same time.
2.3.26 Haematoxylin and eosin (HE) staining 
Fresh tissues from mice were washed in PBS briefly and then fixed in 10% neutral-
buffered formalin for 48 h prior to dehydration and paraffin embedding. The paraffin 
embedding was conducted with a paraffin embedder (Leica). Sections at a desired 
thickness of approximately 5 μm were prepared from blocks of formalin-fixed 
paraffin-embedded tissues. Sections were cut and removed with clean tweezers from 
the microtome, and placed in a water bath at ~40 °C. Sections were then transferred 
to poly-L-lysine coated glass slides which have a permanent positively charged 
surface that facilitates the adherence of the tissue sections to the glass slide. Slides 
were then allowed to dry overnight at 37 °C. 
Slides loaded into slide holders were deparaffinized with Histolene twice for 5 
mins each to remove the paraffin. Rehydration of sections was then accomplished by 
immersing through 100% alcohol for 3 mins, 95% and 75% alcohol for 2 mins with a 
final wash in distilled water for 1 min. Then slides were stained in Harris 
haematoxylin solution for 5 min and followed thorough wash in running distilled 
water until the water was clear. After that, the slides were decoloured in 1% acid 
alcohol for 30 seconds followed by 1 min washing in running distilled water and 1 
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 min bluing in Scott’s tap water substitute. The slides were then washed thoroughly in 
running tap water for 5 min and counterstained in Eosin for 5 min. After Eosin stain, 
slides were dehydrated by immersing through 2 changes of 95% alcohol for 3 min 
each, 2 changes 100% alcohol for 3 minutes each and then cleared in 2 changes of 
Histolene for 5 min each. Slides were then mounted with DPX mounting medium 
and examined under a light microscope equipped with an Olympus SC20 camera 
(Victoria, Australia).  
2.3.27 Immunohistochemistry (Ki-67 assay)
Following the same deparaffinization and rehydration steps as in Section 2.3.26, 
the sections were immersed in pH 9.0 Tris-EDTA antigen retrieval buffer containing 
10 mM Tris base, 1 mM EDTA and 0.05% Tween 20 and heated at 95-100 °C in 
microwave for 30 min (3 cycles, 10 min each). Once the solution was cooled down, 
sections were taken out and washed in PBST (PBS containing 0.1% Tween 20) for 2 
changes for 2 min each. The sections were then blocked with 0.3% hydrogen 
peroxide for 30 min followed by 2 times washing in PBST buffer, 2 min each time. 
The sections were then blocked in 10% goat serum for 30 min followed by PBST 
wash, 2 changes and 2 min each. The washing buffer was removed and sections were 
incubated with 1:100 mouse anti-human Ki-67 antibody (DAKO M7240) for 1 h at 
room temperature. After thoroughly washing with PBST, sections were incubated 
with 1:400 diluted goat anti-mouse HRP-labelled secondary antibody for 30 min at 
room temperature. Sections were washed and treated with DAB peroxidase substrate 
solution (Vector Laboratories, Burlingame, CA) for 5-10 min at room temperature
for colour development, followed by a single wash under running tap water for 1 
min. Counterstaining of tissue sections was performed by immersion in haematoxylin 
solution for 5 min followed by washing under running tap water for 3-5 min. Slides 
were then differentiated in 1% acid alcohol for 30 sec and washed under running 
water for 1 min prior to bluing with Scott’s solution for 1 min. Slides were washed 
under running water for 5 min and then dehydrated with 95% and 100% alcohol 
serially. Finally, slides were cleared using two changes of Histolene for 5 min each 
and then mounted using DPX medium. Stained sections were examined under a light 
microscope equipped with an Olympus SC20 camera (Victoria, Australia).  
69 
 
 2.3.28 TUNEL assay 
The processes of tissue fixation, dehydration, embedding and deparaffinization 
were same as described in Section 2.3.26. After deparaffinization, sections were 
washed in one change of PBS for 5 min and protein digestion was conducted with 
freshly diluted proteinase K (20 μg/ml in PBS) for 15 min at room temperature plus 
5 min treatment with 0.5% Triton X100. The sections were then washed in 2 changes 
of PBS for 2 min each wash. After gently taping off excess liquid and carefully 
blotting or aspirating the section, equilibration buffer was applied directly on the 
specimen and incubated for 1 min at room temperature. Then, the sections were 
incubated with 55 μL/5 cm2 of working strength TdT enzyme at 37 °C for 1 h. One 
hour later, the reaction was stopped and washed with stop/wash buffer at room 
temperature for 10 min. After thoroughly washing in PBS, the sections were then 
incubated with rhodamine-conjugated anti-digoxigenin antibody (1:50) at room 
temperature in a darkened humidified chamber for 30 min. After another round of 
thorough wash with PBS, the sections were counterstained with mounting medium 
(Vectashield, Vector Laboratories, Burlingame, CA) containing 0.5-1 μg/ml DAPI 
before visualization under a Fluoview FV10i laser scanning confocal microscope 
(Olympus, NSW, Australia).
When applying TUNEL assay on cell culture, cell suspension were prepared and 
washed with PBS and then fixed in 1% paraformaldehyde in PBS for 10 min at room 
temperature followed thorough wash with PBS. Post-fix was performed in precooled 
ethanol: acetic acid 2:1 for 5 min at -20°C in a Coplin jar. Cells were then 
resuspended in PBS medium with concentration of 2 × 106 cells/mL and dried on a 
microscopy slide. The subsequent treatments were conducted as described above. 
2.3.29 Tumour dissociation   
All operations were performed using sterile techniques. Tumour tissues (including 
xenograft MCF-7/Adr tumours and clinical breast cancer biopsies) were washed 
thoroughly with Hank’s buffer (containing 1% penicillin/strep) to remove blood and 
any extraneous material. Tumour tissues were placed in a Petri dish and minced into 
approximately 2 - 4 mm3 pieces with a scalpel. The chopped tissues were collected in 
a 50 mL centrifuge tube in Hank’s buffer and rinsed 3 times. The small pieces of 
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 tissues were then resuspended in 50 U/mL collagenase II (Sigma) medium with the 
ratio of 6 mL/gram tumour at 37 °C for overnight, the tubes were kept rotating in 
orbit mixer incubator at 60 r.p.m. The collagenase solution was prepared in DMEM 
medium including 1% penicillin/strep and 20% FBS. After the incubation, samples 
were pipetted 10 times and filtered through 40 μm cell strainers. Cells were then 
collected through centrifugation at 1000 × g for 5 min. The pellets were resuspended 
and washed in PBS twice (centrifuge at 500 × g) to remove the debris. The cell 
viability was determined by Trypan blue staining. In the case of tumour dissociation
prepared for cell sorting, tumours were minced and incubated in 100 U/mL 
collagenase II medium with the ratio of 6 mL/gram tumour at 37°C for 3 h and 
followed the same procedure as described above. The full strength Hank's Buffered 
Salt Solution includes 0.137 M NaCl, 5.4 mM KCl, 0.25 mM Na2HPO4, 1 mg/mL 
glucose, 0.44 mM KH2PO4, 1.3 mM CaCl2, 1.0 mM MgSO4 and 4.2 mM NaHCO3.
2.3.30 In vivo limited dilution assay (LDA)
MCF-7/Adr tumour (60 mm3) bearing mice were randomly assigned to six groups
(n=8) and underwent treatments same as in Section 2.3.25. Two days after the last 
treatment, tumours from the same treatment groups were pooled and single cell
suspensions were prepared and secondary xeno-transplantation was carried out. 
Specifically, viable cells taken from each group were inoculated into three sub-
groups of mice using cell doses of 1 × 106, 2 × 106 and 4 × 106 /mouse, 8 mice per 
sub-group. The growth of tumour was evaluated daily during a 6-month period. The 
endpoint was defined the same as in Section 2.3.18. The estimated T-IC frequency 
was calculated using the limiting dilution software package on the website of Walter 
and Eliza Hall Institute of Medical Research 
(http://bioinf.wehi.edu.au/software/elda/index.html). 
2.3.31 Survival assay
MCF-7/Adr tumour (30 mm3) bearing mice were grouped and treated the same as 
that for the in vivo gene expression assay. The mice were evaluated daily for disease-
free survival and disease-related events. The endpoints are detailed in Section 2.3.18. 
The survival curves was analysed using a log-rank test with a 95% confidence 
interval.  
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 2.3.32 Innate immune response assay
For in vivo assay, eight weeks old BALB/c mice were randomly divided into four 
groups (n=6, 3 female and 3 male). Mice in chimera and negative chimera groups 
were intravenously injected with 2 nmol of either chimera or negative chimera. 200 
ng/mouse Poly I:C (InvivoGen) and equal volume of PBS were applied as positive 
and negative controls. Four hours and 24 hours after injection, 200 μL bloods were 
collected from each mouse. The blood was allowed to coagulate at 25 °C for 30 min 
before centrifuging at 17,000 × g for 10 min to collect serum. Levels of the mouse 
IFN-ĮDQG71)-ĮLQWKHVHUXPZHUHGHWHUPLQHGXVLQJPRXVH,)1-Į3%/
Biomedical Laboratories) and mouse TNF-Į(Rahman et al.) ELISA kits according to 
the manufacturer’s instruction. For IFIT1 expression assay, total RNA was processed 
from mouse livers and lungs 24 hours after treatments, and IFIT1 expression was 
determined by qRT-PCR with GAPDH as internal control. 
For in vitro human peripheral blood mononuclear cells (PBMCs) assay, PBMCs 
were prepared from fresh blood donated by healthy adult, firstly, the full blood was 
collected in heparin-treated tubes, and submitted to Ficoll-Paque plus (17-1440-02; 
GE Healthcare) gradient purification following the manufacturer’s guidelines. 
Isolated cells were plated in a 96-well plate at 2 × 105 cells/well in RPMI 1640 plus l
×glutamine medium (11875; Invitrogen Life Technologies) complemented with 1 × 
antibiotic/antimycotic (15204064; Invitrogen Life Technologies) and 10% FBS 
(referred to as complete RPMI 1640), and incubated for 4 h at 37°C in a 5% CO2
atmosphere before treating with 750 nM chimera duplexed or not with DOTAP, or 
with a known immunostimulatory single stranded RNA control (B-406-AS). The 
cells were incubated overnight and supernatants were assayed for human INF-ĮDQG
TNF-Į +XPDQ ,)1-Į LQ FXOWXUH VXSHUQDWDQWV ZDV TXDQWLILHG E\ VDQGZLFK (/,6$
XVLQJ PRXVH PRQRFORQDO  ȝJPO -1; PBL Biomedical) and rabbit 
SRO\FORQDO $EV  ȝJPO -1; PBL Biomedical). A goat anti-rabbit HRP-
conjugDWHGDQWLERG\ȝJPO3LHUFHZDVXVHGIRUGHWHFWLRQ+XPDQ71)-
ĮZDVPHDVXUHG XVLQJ WKH2SW(,$(/,6$ VHWV  DQG  UHVSHFWLYHO\
BD Biosciences). In both IFN and TNF-Į(/,6$V WHWUDPHWK\OEHQ]LGLQH VXEVWUDWH
(T0440; Sigma-Aldrich) was used for quantification of the cytokines on the Fluostar 
OPTIMA (BMG Labtech) plate reader.
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 2.3.33 Complete blood count assay
To evaluate the general toxicity of chimera, blood was collected when the mice for 
therapeutic experiments were sacrificed. Whole blood cells counts were analysed by 
an ABX Micros ESV60 haematology analysing system (Horiba Medical). Blood 
smears were obtained for each animal to obtain a relative white cell count adapted 
from the Fonio method for platelet counting (Adams, E 1948; Oliveira et al. 2003), 
with minor modifications. Slides were stained with Giesma and an area of the blood 
smear was chosen where the red cells abutted each other but did not overlap, with 
consecutive fields chosen to eliminate bias. The total number of white cells per 1500 
red cells were counted (n=3 for each slide) and compared for each group. 
2.4 Data analysis
All statistical analyses were performed using GraphPad Prism 3.03. An unpaired t
test was used for comparisons between two experimental groups, and ANOVA was 
used for comparisons of more than two groups. Survival data were analyzed with the 
Mantel–Cox log-rank test. Unless otherwise indicated, all results were averaged from 
biological triplicates and values are reported as means ± SEM. A P value of less than 
0.05 was considered statistically significant. 
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 Chapter 3
Survivin Gene Plays a Critical Role in the Chemo-resistance of T-
ICs in a Doxorubicin-resistant Breast Cancer Model
Due to an increased understanding of breast cancer in the past several decades, 
effective endocrine therapeutic reagents including various selective estrogen-receptor 
(ER) response modulators and aromatase inhibitors have been developed (Gao et al. 
2014). However, for ER negative breast cancer patients or ER positive patients 
whose tumours have progressed on hormone therapy, doxorubicin (Dox) is still one 
of the most common treatment choices (R.Seffrin 2014). As a result, Dox resistance 
represents a major hurdle for successful breast cancer treatment.   
Cancer cells in the tumour are in a dynamic state, caused by genetic instability and 
epigenetic diversity of the cancer cells (Burrell et al. 2013). This genetic instability 
and epigenetic diversity is driven to adapt to the tumour microenvironment for 
survival by selection. Such a selection, in the case of prolonged exposure to 
chemotherapeutic reagents such as Dox, could eventually enrich a small population 
of highly invasive, drug-resistant cells termed tumour initiating cells (T-ICs, also 
known as cancer stem cells) (Calcagno et al. 2010, Zhou Bin-Bing S. et al. 2009).
Although the origin and frequency of T-ICs are still under debate (Rahman et al. 
2011), it is generally acknowledged that T-ICs are the most invasive and refractory 
cells in the tumour (Kreso and Dick 2014, Zhou Bin-Bing S. et al. 2009). The lack of 
specific targeting strategies against this population of cells in current cancer 
treatment regimens is at least partly responsible for the short survival period 
experienced by many cancer patients (Zhou Bin-Bing S. et al. 2009).
In this chapter, a Dox-resistant MCF-7 sub cell line, MCF-7/Adr, was established. 
It was confirmed in in vitro work that compared with the parental MCF-7 cell line, 
MCF-7/Adr showed enhanced drug resistance and tumour initiating capacity. 
Additionally, it was discovered that the over-expression of the survivin gene - a key 
member of the inhibitor of apoptosis (IAP) family (Li Z. et al. 2013), contributed 
considerably to the drug resistance of the MCF-7/Adr cells. Through down-
regulation of survivin by siRNA transfection, an increased sensitivity of MCF-7/Adr 
to Dox was observed. More interestingly, the treatment of Dox following survivin 
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 down-regulation showed significant reduction of T-IC proportion and tumourigenic 
capacity, suggesting a critical role survivin played in the chemo-resistance of breast 
T-ICs. These findings provide us with an opportunity to show the possibility of 
overcoming Dox resistance by silencing a dysregulated gene in breast T-ICs.  
3.1 Induction of Dox-resistant MCF-7/Adr cell line through chronic Dox 
exposure
For T-IC targeted siRNA delivery, apart from effectively delivery of siRNA to T-
ICs, another important requirement is to identify and target a critical gene for their
survival.  Recently, increasing evidence demonstrated that the over-expression of 
several pro-survival genes including survivin, MDR1, X-linked inhibitor of apoptosis 
protein (XIAP) and Bcl-2 (Li Z. et al. 2013, Thiel et al. 2012, Vaillant et al. 2013, 
Wind and Holen 2011) were closely associated with the chemo-resistance and poor 
prognosis in breast cancer patients. At the same time, increased T-IC proportion has 
been reported in drug-resistant breast cancer (Gopalan et al. 2013), which suggests 
there might be a close relationship between the over-expression of these genes and 
the increased tumourigenicity. To confirm this hypothesis, a Dox resistant sub-line of 
human breast adenocarcinoma cell MCF-7 was induced by chronic exposure of 
MCF-7 cells to a clinically relevant Dox dose (300 nM) (McDermott et al. 2014).
After 20 passages of induction, the resultant MCF-7/Adr cells displayed a 5-fold 
increase in resistance to Dox as determined by MTT cell viability assay (Figure 3-1
A).  
Since the MCF-7/Adr cell model used in this study was induced by a clinically 
relevant Dox dose, with a Dox resistance comparable to the 2 - 5 folds increase in 
Dox resistance as observed in clinical Dox resistant patients (McDermott et al. 
2014), this model, would be more faithfully reflect the conditions cancer patients 
experience during chemotherapy than some previously used Dox-resistant breast 
cancer models with 100 times to 1000 times Dox resistance (Han M. et al. 2012, 
Wang F. et al. 2000). The notion of the clinical relevance of this MCF-7/Adr sub cell 
line was further suggested by its mesenchymal-like morphology (Figure 3-1 B), 
which was similar to that previously reported for drug-resistant primary breast cancer 
cells derived from biopsies (Creighton et al. 2009).
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Figure 3-1 MCF-7/Adr cell line shows five times Doxorubicin resistance 
compared with parental MCF-7 cells
A, IC50 (72h) of MCF-7 and MCF-7/Adr cells against Doxorubicin, determined by MTT 
assay. Data are means ± SEM, n=3. **, P<0.01.  (IC50: the half maximal inhibitory 
concentration). B, representative phase-contrast images of MCF-7 and MCF-7/Adr cells 
grown in monolayer culture.
3.2 Confirmation of the reliability of breast T-IC related surface marker on 
MCF-7/Adr model 
To further study the involvement of T-ICs in chemo-resistance of MCF-7/Adr, a 
combination of cell surface markers, EpCAM+/CD44+/CD24-, previously shown by 
others as a robust marker combination for identifying and isolating T-ICs in breast 
cancers (Sheridan et al. 2006) was utilized. Since tumour cells are highly 
heterogeneous, the reliability of using this marker combination in identifying breast 
T-ICs in MCF-7/Adr cells was assessed in advance. Firstly, two groups of cells, 
EpCAM+/CD44+/CD24- and EpCAM-/CD44-/CD24-, were sorted through 
fluorescence-activated cell sorting (FACS) based on the expression of EpCAM,
CD44 and CD24. Then, the capacity of multipotent differentiation and self-renewal 
of these two groups of cells were studied by cell surface marker analysis and 
mammosphere assay. The results of the multipotent differentiation capacity analysis 
were illustrated in Figure 3-2, after three passages in 10% serum containing DMEM 
76 
 
 medium (a condition promoting differentiation of T-ICs), there was no discernible
differentiation observed in the EpCAM-/CD44-/CD24- MCF-7/Adr cell population. 
As shown, the cell surface marker expression pattern did not display noticeable 
difference following three passages in serum-containing medium as evidenced by the 
fact that more than 94% cells still displayed EpCAM-, CD44- and CD24- (99.7% 
EpCAM negative, 96.7% CD24 negative and 94.7% CD44 negative), demonstrating 
the terminal differentiation status of this population of cells.  In contrast, under the 
same condition (three passages in serum-containing medium), 
EpCAM+/CD44+/CD24- MCF-7/Adr cell population showed dramatic differentiation. 
The resultant cells presented similar surface marker expression pattern with that of 
the unsorted parental MCF-7/Adr cells rather than the original 
EpCAM+/CD44+/CD24- MCF-7/Adr cells from which they were differentiated (98% 
CD24 negative, 95% CD44 positive and 25% EpCAM positive).  To confirm the
self-renewal capacity, cells were subjected to mammosphere assay. As shown in 
Figure 3-3C, it was EpCAM+/CD44+/CD24- but not EpCAM-/CD44-/CD24- MCF-
7/Adr cells that showed a significantly higher mammosphere formation capacity 
compared with parental MCF-7 cells as evident by 2.5-fold and 7-fold increase in the 
primary sphere assay and secondary sphere assay, respectively. These results 
suggested that the combination of markers, EpCAM+/CD44+/CD24- , was a reliable 
tool to identify and isolate T-IC proportion in the MCF-7/Adr model. 
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 Figure 3-2 Sub-population of EpCAM+/CD44+/CD24- MCF-7/Adr cells shows 
multipotent differentiation capacity
Representative flow cytometry profile illustrating the differentiation property of 
EpCAM+/CD44+/CD24- and EpCAM-/CD44-/CD24- cells. Dissociated MCF-7 single cells 
were incubated with fluorescence conjugated anti-EpCAM, CD44 and CD24 antibodies 
followed cell sorted via FACS. EpCAM+/CD44+/CD24- and EpCAM-/CD44-/CD24- MCF-
7/Adr cells were then collected and differentiated in DMEM medium containing 10% serum. 
After three passages, cell surface marker profile was re-assessed using flow cytometry. 
3.3 MCF-7/Adr cells show increased tumourigenic capacity  
After confirming the validity of the cell surface marker combination 
EpCAM+/CD44+/CD24- in identifying T-ICs in the MCF-7/Adr cell model, the 
expression of this T-IC surface marker combination was analysed in MCF-7/Adr and 
its parental MCF-7 cell lines through flow cytometry. Surprisingly, different to the 
parental MCF-7 cells, MCF-7/Adr cells showed a more than 20-fold increase in the 
EpCAM+/CD44+/CD24- cell population (0.86% and 21.2% in MCF-7 and MCF-
7/Adr cells, respectively), suggesting enriched T-ICs in MCF-7/Adr cells (Figure 3-
3A) after prolonged Dox exposure. To further confirm the enrichment of T-ICs in the 
chemo-resistant MCF-7/Adr cells, mammosphere assay was performed. As shown in 
Figure 3-3B and C, after two generations of incubation of cells in serum-free stem 
cell medium, MCF-7/Adr cells showed significantly enhanced mammosphere 
formation capacity than that of the parental MCF-7 cells, as evidenced by the 
approximately 2-fold and 5-fold higher sphere forming frequency observed in MCF-
7/Adr cells in the primary and secondary sphere assays, respectively. When the 
expression of several drug efflux, anti-apoptosis, and stemness involved genes were 
determined by immunoblotting or quantitative real time-PCR (qRT-PCR) analysis 
(XIAP expression was tested through qRT-PCR), a universal increase in the 
expression of these genes was observed.  Of note, the Pfaffi efficiency of qRT-RCR
primers used in this study were all between 0.8 -1.2 as shown in Figure 3-4. 
Noticeably, the expression of survivin and MDR1 genes, two previously reported 
breast cancer chemo-resistance-related genes, also showed significant increase 
(Figure3-3D). These findings suggest a significant enrichment of T-ICs in the Dox-
resistance breast cancer model.
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Figure 3-3 MCF-7/Adr cells show increased tumourigenic capacity 
A, a representative flow cytometry profile illustrating the proportion of tumourigenic 
EpCAM+/CD44+/CD24- cells in MCF-7 and MCF-7/Adr cells.  B, representative phase-
contrast images of secondary mammospheres originated from 2000 cell/well of MCF-7 and 
MCF-7/Adr cells grown in ultralow attachment 6-well plates. D, self-renewal capacity of 
cells or cell populations as illustrated, cells were trypsinized into single cells and reformed 
spheres seven days later for two passages. D, indicated gene expression in MCF-7/Adr and 
parental MCF-FHOOVDVGHWHUPLQHGZLWK,PPXQREORWWLQJDVVD\ȕ-actin was used as a 
loading control) or qRT-PCR (GAPDH as internal control, in the case of XIAP).  Data are 
means ± SEM, n=3. *, P<0.01, **, P<0.001.
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 Figure 3-4 Primers used in qRT-RCR assay show acceptable Pfaffi efficiency
cDNA was prepared to a series of dilution, corresponding primers were added and PCR was 
performed with standard program. After the PCR reaction, the amplification efficiency was 
calculated according to the equation of E=10(-1/slope) -1, where E is the efficiency of the 
reaction and slope refers to the slope of the plot of CT value versus the log of the input 
template amount. An amplification efficiency between 0.8 and 1.2 was considered 
acceptable.
3.4 Silencing MDR1 gene in vitro is ineffective in reducing Dox resistance of T-
ICs of MCF-7/Adr 
Since the increased expression of survivin and MDR1 genes has been reported to 
contribute to the drug resistance and poor prognosis of breast cancer (Jha et al. 2012, 
Liu F. et al. 2010), and since increased drug resistance and poor prognosis have been 
regarded as a relevant concept to the increased tumourigenicity (Moitra et al. 2011, 
Singh and Settleman 2010), the effects of survivin and MDR1 over-expression on the 
enhanced drug resistance and increased T-IC population of MCF-7/Adr cells were 
investigated. 
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Figure 3-5 Silencing MDR1 gene sensitizes MCF-7/Adr cells to Doxorubicin but 
does not affect T-ICs
A, immunoblotting analysis of MDR1 protein levels in MCF-7/Adr after 48 hours treatment 
ZLWKLQGLFDWHGUHDJHQWVȕ-actin was used as a loading control. B, the MDR1 mRNA levels 
after illustrated treatments were determined by qRT-PCR and the expression were 
normalized with GAPDH mRNA levels. C, IC50 (72h) of MCF-7/Adr against Dox after 
illustrated treatments as determined by MTT assay. D, self-renewal capacity of cells after 
different treatment as determined by mammosphere assay; cells were trypsinized into single 
cells and reformed spheres 7 days later for two passages. Cells were normally maintained in 
300nM Dox in untreated group. E, EpCAM+/CD44+/CD24- proportion of MCF-7/Adr after 
illustrated treatments. Data are means ± SEM, n=3. *, P< 0.05; **, P<0.001, compared with 
untreated or Dox-alone group.
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 The effects of the over-expression of MDR1 gene were tested through down-
regulation of the MDR1 expression using a previously reported siRNA sequence 
(Yoo et al. 2010). As shown in Figure 3-5A and B, compared with untreated group, 
MDR1 siRNA treatment resulted in ~ 80% gene silencing at both protein and mRNA 
levels. Similar with previously reported (Liu F. et al. 2010, Yang X. et al. 1999),
knocking down of the MDR1 gene partly reduced drug resistance of MCF-7/Adr 
cells to Dox, with the change of the IC50 (72h) from 3.72 μg/mL to 1.66 μg/mL 
(Figure 3-5C), while the corresponding value for the parental MCF-7 cell is 0.71 
μg/mL (Figure 3-1A). However, this reduction in IC50 seemed contributed mainly 
from the sensitization of the bulk cancer cells to Dox rather than that of the T-ICs. As 
illustrated in Figure 3-5D, no difference in mammosphere formation efficacy was 
detected between MCF-7/Adr cells that underwent combined MDR1 siRNA and Dox 
treatment or Dox-alone treatment. In addition, compared with Dox-alone treatment, 
after two days treatment with combined Dox and MDR1 siRNA, no discernible 
change in the proportion of EpCAM+/CD44+/CD24- cells was observed (Figure 3-4E).  
Therefore, these results suggest that although the knockdown of MDR1 is capable of 
partly sensitizing bulk MCF-7/Adr cells to Dox, it is not able to affect the drug 
response of the MCF-7/Adr T-ICs and thus is not a critical gene for the survival of T-
ICs in this model. 
3.5 Silencing survivin gene in vitro effectively reduces Dox resistance of MCF-
7/Adr T-ICs
Next, the relationship between survivin gene over-expression and the escalated 
tumourigenicity of MCF-7/Adr cells was studied. Using FACS, the putative tumour-
initiating EpCAM+/CD44+/CD24- cells were isolated and it was found that it was the 
EpCAM+/CD44+/CD24- but not the non-tumourigenic EpCAM-/CD44-/CD24- MCF-
7/Adr cells that expressed approximately 23-fold greater survivin compared to the
parental MCF-7 cells (Figure 3-6).  This led to the hypothesis that the over-
expression of survivin in T-ICs was responsible for the acquired chemo-resistance 
and tumourigenicity in MCF-7/Adr cells.  To test this hypothesis, the effect of 
silencing survivin by siRNA on reverting chemo-resistance of MCF-7/Adr cells to 
Dox was investigated. A 21-mer siRNA reported by Wang and colleagues (Wang F. 
W. et al. 2010) was chosen. This survivin siRNA was transfected into MCF-7/Adr 
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 cells using Lipofectamine 2000 (Life Technologies) and it effectively knocked down 
survivin by 85% and 87% at protein and mRNA levels, respectively (Figure 3-7).  
Figure 3-6. The EpCAM+/CD44+/CD24- MCF-7/Adr cells express ~ 23-fold 
greater survivin gene than the parental MCF-7 cells.
Survivin mRNA levels were determined by qRT-PCR analysis in parental MCF-7 cells as 
well as in EpCAM+/CD44+/CD24- and EpCAM-/CD44-/CD24- MCF-7/Adr cells prepared by 
FACS.  Data are means ± SEM, n=3. **, P<0.001.  
Figure 3-7. A siRNA resistant survivin plasmid effectively rescues survivin 
expression after siRNA mediated survivin silencing in MCF-7/Adr cells. 
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 Immunoblotting analysis (A) and qRT-PCR (B) were carried out 48h or 24h after the 
treatment with PBS, 10 nM of negative control siRNA, survivin siRNA, survivin siRNA plus 
RNAi-resistant survivin replacement construct (rescue) or mock rescue (vector-only). As the 
forward primer for survivin corresponds to the 5’-UTR region, and thus the transcripts from 
the rescue plasmid were not amplified in qRT-PCR. Data are means ± SEM, n=3. **, 
P<0.001, compared with saline treatment.  
In sharp contrast to MDR1 silencing, down-regulation of survivin gene markedly 
augmented Dox sensitivity of MCF-7/Adr cells to a similar level with that of the 
parental MCF-7 cells (the IC50 reduced from 3.72 μg/mL to 0.86 μg/mL) (Figure 3-
8A).  Furthermore, a significant decrease of T-IC population was observed upon 
combinatorial survivin silencing and Dox treatment as determined by mammosphere 
assay (Figure 3-8B) and surface marker analysis (Figure 3-9). As shown, the 
increased chemo-sensitivity was accompanied by a significant reduction in the 
mammosphere formation capacity in the MCF-7/Adr cells (1.4-fold and 2.8-fold 
reduction in mammosphere forming efficacy in primary and secondary sphere
analyses, respectively, vs Dox-only) and around 2-fold reduction in the abundance of 
EpCAM+/CD44+/CD24- population (vs Dox-only). Thus, survivin gene is likely to be 
involved in the chemo-sensitivity of MCF-7/Adr T-ICs.    
Figure 3-8. Silencing survivin reverses Dox-resistance and results in reduced 
self-renewal capacity of MCF-7/Adr cells.
A, Cell viability of MCF-7/Adr cells treated with 10 nM of indicated siRNA or controls and 
various concentration of doxorubicin as indicated for 3 days. IC50 (72h) of MCF-7/Adr 
against Dox was determined by MTT assay. B, self-renewal capacity of cells after different 
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 treatment as determined by mammosphere assay; cells were trypsinized into single cells and 
reformed spheres 7 days later for two passages. Cells were normally maintained in 300 nM 
Dox in untreated group. Data are means ± SEM, n=3. **, P<0.001, compared with untreated 
or Dox-only group.  
Figure 3-9. Combined survivin silencing and Dox treatment reduces the 
percentage of tumourigenic EpCAM+/CD44+/CD24- cells in MCF-7/Adr.
Changes in the abundance of EpCAM+/CD44+/CD24- population in MCF-7/Adr cells after 
illustrated treatments and analyzed by flow cytometry. Data are means ± SEM, n=3. **, 
P<0.001, compared with Dox-only group.  
To further control for the possibility of non-specific RNAi effects, the specificity 
of survivin gene silencing was verified via rescuing the siRNA-induced phenotype 
by expressing an RNAi-resistant version of survivin cDNA, in addition to the 
scrambled siRNA control already employed (Figure 3-7,8,9) (Wang Y. Y. et al. 
2010). Briefly, cells were firstly transfected with survivin siRNA. Twenty-four hours 
later, the cells were transfected with an RNAi-resistant version of the survivin 
expression construct using Lipofectamine 2000 followed by the treatment of 300 nM 
Dox or corresponding controls. As shown in Figure 3-6A, after the introduction of 
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 survivin rescue plasmid, the expression of survivin protein was fully restored. At the 
same time, the increased sensitivity to Dox, reduced mammosphere forming capacity 
and decreased percentage of T-IC marker-positive cells were all reversed (Figure 3-
7, 8, 9), providing reliable functional evidence that the down-regulation of survivin 
gene were responsible for the increased sensitivity of MCF-7/Adr T-ICs to Dox. This 
observation is consistent with previous reports that breast tumours with higher 
chemo-resistance and poor prognosis (a concept relevant to increased 
tumourigenicity) were found to have elevated expression of the survivin gene (Jha et 
al. 2012, Ryan et al. 2006). Of note, this reversal of survivin protein in the cells after 
plasmid rescue was not accompanied by the reversal of the reduction of survivin 
mRNA. This is due to the fact that the forward primer designed for survivin mRNA 
detection is not located in the protein coding sequence (CDS) of the survivin gene 
but rather complementary to the 5’-untranslated region which is absent from the 
RNAi-resistance version of survivin expression construct. Therefore, the primer used 
in qRT-PCR was unable to amplify the transcripts of the rescue plasmid.
Paradoxically, results collected from subsequent studies seemed to run contrary 
with the notion that survivin contributes to drug resistance of breast T-ICs. Firstly, 
down-regulation of survivin using siRNA in wild-type MCF-7 and T47D did not 
affect T-IC frequency (data not shown). Secondly, when the survivin expressing 
plasmid was transfected to several different breast cancer cell lines, no significant 
increase in cell death-resistant phenotype was detected. Probably, the discrepancies 
between these results and those presented in Figure 3-7, 8, 9 were originated from 
the different experiment setup and conditions. Firstly, the over-expression of survivin 
through exogenously introduced expression plasmid differs fundamentally from 
natural induction of survivin expression over a prolonged period of low dose drug 
treatment; and secondly, because of the complexity of the pro-apoptotic and anti-
apoptotic pathways (Liu J et al. 2011), in wild- type breast cancer cell lines, the 
function of the survivin expressed at a relatively low level is probably redundant and 
not as important as that in drug-resistant cells. Considering the heterogeneous 
property of tumours, it is unreasonable to say a certain gene is critical for all kinds of 
T-ICs.  The results presented in Figure 3-7, 8, 9 strongly indicated that at least in this 
Dox-resistant MCF-7/Adr breast cancer model, survivin plays a critical role in the 
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 drug resistance of breast T-ICs. As a result, majority of the work in this project was 
conducted using this experimental breast cancer model. 
3.6 Conclusion
In this chapter, a Dox resistant breast cancer cell line MCF-7/Adr was generated 
using a clinically relevant Dox dose. It was confirmed that these drug-resistant breast 
cancer cells displayed enhanced tumourigenic efficacy with increased expression of 
genes associated with drug efflux, anti-apoptosis, and stemness. More importantly, 
an anti-apoptosis gene, survivin, was confirmed to be a critical gene for the survival 
of T-ICs in MCF-7/Adr. These findings laid the foundation of this whole project, 
allowing the development of a T-IC targeted gene therapy. In addition, the observed 
pivotal role of survivin in the chemo-resistance of breast T-ICs would contribute to 
the better understanding of the role of the anti-apoptosis family in the drug resistance 
of T-ICs.  
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 Chapter 4
Development of an Aptamer-siRNA Chimera for T-IC-targeted 
RNAi
After establishing the drug-resistant MCF-7/Adr cell model and confirming 
survivin as a critical gene for the survival of MCF-7/Adr T-ICs, the next step was to 
design an in vivo siRNA delivery system in order to develop a clinically viable 
therapy. 
Although siRNAs have been routinely used as an experimental tool to suppress 
gene expression in cell culture, in vivo siRNA delivery remains a big challenge 
(Shim and Kwon 2010). However, to realize the full potential of siRNA (i.e. to 
achieve the desired RNAi effect in clinical development), an effective and safe 
siRNA in vivo delivery system is imperative. Among various siRNA in vivo delivery 
systems reported in recent years, the aptamer-siRNA chimera represents a promising 
strategy (McNamara James O. et al. 2006). What distinguishes the aptamer-siRNA 
chimera structure is the promise of having to simply use only nucleotide synthesis to 
generate a pharmacologically viable siRNA therapeutics, obviating the need for 
complicated formulation technologies and reducing costs (Dassie et al. 2009).
Furthermore, when it comes to repeat-administration such a system may cause 
inherently little or no adaptive immunogenicity (Dassie et al. 2009). As a result, 
since it was introduced in 2006 (McNamara James O. et al. 2006), aptamer-siRNA 
chimeras have been comprehensively studied for the treatment of various diseases 
such as cancer and HIV infection (Neff et al. 2011, Thiel et al. 2012, Wheeler et al. 
2011).
Our laboratory was the first to develop an RNA aptamer that could specifically 
target a breast T-IC relevant surface marker - epithelial cell adhesion molecule 
(EpCAM) (Shigdar et al. 2011). Importantly, after specific binding, this EpCAM 
aptamer could undergo receptor-mediated endocytosis, providing a promising tool to 
deliver siRNA specifically to EpCAM-positive breast T-ICs. This EpCAM targeted 
aptamer, along with the newly unravelled critical role of survivin gene in Dox 
resistance of MCF-7/Adr T-ICs, constructs the basis of this study, allowing us to 
develop a T-IC targeted in vivo siRNA therapeutic system. 
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 4.1 The development of an EpCAM aptamer-survivin siRNA chimera 
To develop an aptamer-siRNA chimera structure, apart from the aptamer, a siRNA 
that can effectively silence the targeted gene is required. In this study, a published 
21-mer survivin siRNA was used as the siRNA portion for the generation of the 
chimera (Wang F. W. et al. 2010).  To ascertain this survivin siRNA has robust gene 
silencing efficacy in our hands, various cell lines including MCF-7/Adr, T47D, 
MDA-MB-231, HT-29, HEK293T and U118MG were transfected with 5 nM to 10 
nM of the siRNA using Lipofectamine 2000.  Indeed, more than an 80% survivin 
silencing was achieved at both protein and mRNA levels as determined by 
immunoblotting and qRT-PCR assays (data not shown). Consequently, this 21-mer 
survivin siRNA sequence was used in the subsequent work. On the other front, the 
original 19-nt EpCAM aptamer (Shigdar et al. 2011) was further optimized to an 18-
nt RNA sequence to shorten the length of oligonucleotide and minimize the cost of 
production (Figure 4-1). 
Figure 4-1 Optimization of the 19-nt EpCAM aptamer to 18-nt. The secondary 
structures were predicted using CLC Main Workbench. 
Furthermore, based on recent consensus that a 27-mer siRNA is a better Dicer 
substrate (Dudek et al. 2014, Kim D. H. et al. 2005), the original 21-mer survivin 
siRNA was extended to a 27-mer Dicer substrate duplex (Figure 4-2C) for enhanced 
silencing potency. The design of the aptamer-siRNA chimera entailed the linking of 
the 18-nt EpCAM RNA aptamer to the 27-mer survivin siRNA through annealing a 
longer oligonucleotide strand and a shorter oligonucleotide strand as shown in Figure 
4-2. This chimera consists two portions, one side is the targeting module (aptamer) 
and the other side is the functional siRNA module. These two portions are 
conjugated together with a 2-nt AA linker. According to secondary structure 
analysis, after annealing, the final chimera structure features a single 2-nt overhang 
at the 3’- end of the longer strand and two DNA residues at the 3’- end of the shorter 
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 strand (Figure 4-2 C). As previously reported (Scott D. Rose 2013), such an 
asymmetric duplex structure would facilitate the endogenous Dicer enzyme to cleave 
the substrate (chimera) from the 3’-end overhang of the longer strand and result in 
the tested 21-mer survivin siRNA sequence (Figure 4-2D) (Kim D. H. et al. 2005).
 
Figure 4-2.  Schematic of EpCAM aptamer-survivin siRNA chimera structure
A, secondary structure for the longer strand of chimera in which an 18-nt RNA EpCAM 
aptamer was covalently linked with the guide strand of a 27-mer survivin siRNA through an 
AA bridge.  All pyrimidines were 2’-fluoropyrimidines.  In the negative control version of 
the longer strand, 2 point mutations were introduced as indicated. B, the shorter strand is the 
passenger strand of the 27-mer survivin siRNA with 2-nt DNA at the 3’-end and a 
fluorophore (Dy647) at the 5’-end.  The secondary structural predictions and Gibbs' free 
energy in A and B were generated or calculated using CLC Main Workbench. C, a stable 
aptamer-siRNA chimera with Gibbs' free energy of -42.6 kcal/mol was formed after 
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 annealing the longer and shorter strands. D, the predicted 21-mer survivin siRNA after being 
processed by Dicer.
To better control the potential off-target effects, in addition to a scrambled siRNA 
control, a chimera structure with 2-point mutation in the guide strand to abolish the 
siRNA mediated survivin silencing and retain the identical passenger strand and 
modification pattern was designed to control the potential immune response 
associated gene suppression. In addition, this negative control kept the same 
“miRNA-like seed region” with the chimera, in order to control for the miRNA-like 
off-target.  This design enabled the negative control chimera maximally mimic the 
potential off-target effects mediated by both sequence specific immune response and 
miRNA-like RNAi and therefore provided a reliable control for this study.  To the 
best of our knowledge, this chimera, with a longer strand 47-nt, is the shortest 
aptamer-siRNA chimera molecule ever reported, which makes it amenable to 
chemical synthesis for large-scale production.
4.2 Optimization of EpCAM aptamer-survivin siRNA chimera structure 
In general, clinical translation of siRNA therapeutics require chimeras to meet 
several requirements, (I) potent silencing activity and specificity; (II) enhanced in 
vivo stability and (III) reduced immune induction (Jackson and Linsley 2010, Shim 
and Kwon 2010, Wolfrum et al. 2007).  To these ends, a total of 20 chimera 
structures were engineered and tested during this study. Ten of them are presented in 
Figure 4-3. Finally a chimera (Chimera 10) with an 8.3 h half-life in 50% human 
serum and a dose-dependent survivin gene silencing efficacy (Figure 4-5) was 
selected for further study. The detailed selection procedure is described below. 
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 Figure 4-3. Schematic representatives of serial engineering of the chimera and 
their in vitro stability. For stability assay 5 μL of chimeras (5 μM) were mixed with equal 
volume of 100% human serum and then incubated at 37oC for a series of time points 
including 30 min, 1 h, 2 h, 3 h, 4 h, 6 h, 8 h, 12 h, 14 h, 24 h, 36 h. The incubated samples 
were separated by 4% Metaphor Agarose gel and the quantification was conducted using a 
LAS-4000 Imaging System. The secondary structure of chimeras was predicted by CLD 
MAIN WORKBENCH software 7.0.3 (Qiagen). Black letters, RNA; red letters, 2' O-methyl 
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 RNA; blue letters, 2’-fluoropyrimidine RNA; XX, 18-atom hexaethylenglycol spacer and 
lowercase letters: DNA bases.
Firstly, a chimera structure (Figure 4-3, Chimera 1) consisting of a 23-mer survivin 
siRNA portion was synthesized. In this chimera structure, the longer strand was 
modified with 2’-Fluoro pyrimidine and the shorter strand was left unmodified. As 
shown, although it achieved an in vitro half-life of 9.17 h in 50% human serum, it 
was a poor Dicer substrate (Figure 4-4) with low efficacy in silencing survivin (40% 
knockdown at the dose of 20 nM) (Fig 4-5).  
 
Figure 4-4. Analysis of the Dicer substrate capacity of chimeras.
In vitro Dicer processing was analysed by incubating chimeras with recombinant human 
Dicer enzyme for 12 hours.  The Dicer cleavage or uncleaved (No Dicer) products were 
visualized after electrophoresis through a 4% Metaphor agarose gel. A siRNA was loaded as 
control to indicate the position of 21 bp. 
In order to increase the efficiency of being processed by Dicer, Chimera 1 was 
modified by (I) extending the 23-mer siRNA to a 27-mer survivin siRNA and (II) 
keeping 8-bp unmodified from the 3’-end of the shorter strand (Figure 4-2, Chimera 
2), intending not to interfere with Dicer cleavage at the predicted site of Dicer 
processing (Collingwood et al. 2008). Indeed, the potency for Chimera 2 as a Dicer 
substrate increased significantly (Figure 4-4) and achieved approximately 80% 
knockdown even at the concentration of 5 nM (Figure 4-5).  However, its serum half-
life decreased dramatically to 0.3 h. Since unmodified 21-mer or 27-mer siRNA with 
both strands unmodified (more naked bases than the 8-bp unmodified Chimera 2) 
could achieve greater than one hour half-life in 50% serum (Collingwood et al. 
2008), it was assumed the unmodified 2-nt AA linker contributed to the instability of 
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 Chimera 2. To confirm this hypothesis, the unmodified AA linker was changed to 2’-
O-Me modified AA linker or a hexaethylenglycol (HEGL) linker to derive Chimera 
3 and Chimera 4, respectively.  However, no improvement in serum stability was 
observed for either of them.  Further engineering entailed alternative modification of 
the shorter strand with 2’-O-Me, except the 8 nucleotides from the 3’-end of the short 
strand that gave rise to Chimera 5. Again, no improvement of the serum stability was 
observed.  
 
Figure 4-5. Gene silencing capacity of different chimera structures in MCF-
7/Adr cells.
MCF-7/Adr cells were incubated with various concentrations of different versions of the 
chimera. The knockdown of survivin mRNA was analysed 24 h after the treatment using 
qRT-PCR.  Data are means ± SEM, n=3.  *, P < 0.01, **, P < 0.001 compared with saline
treated.
94 
 
 At this stage, it became apparent that it was the 8 bp unmodified nucleotide at the 
3’-end of the short strand that contributed to the instability of the chimera. Therefore, 
for Chimera 6 and Chimera 7, 2’-O-Me or 2-’F pyrimidine modification was 
introduced to the 8-nt at the 3’ end of short strand, respectively. Disappointedly, 
these modifications not only failed to increase the stability of the chimera but also 
compromised the silencing potency (Figure 4-5). Next, in Chimeras 8 and 9, the 
longer strand was fully modified with 2-’F-pyrimidine and the 8-nt at the 3’-end of 
the shorter strand was modified with either 2’-O-Me or 2-’F pyrimidine, respectively. 
Although these chimeras demonstrated an enhanced stability in 50% serum (t1/2 =11
h), the gene knockdown potency lost completely. Taken together, it seemed that the 
unmodified 8-nt sequence on the 3’-end of the short strand was critical for both the 
potency of gene silencing and the stability of the chimera. 
To achieve a balance between potency and stability, Chimera 10 was engineered in 
such a way that the longer strand was kept fully modified with 2’-F pyrimidine while 
the shorter strand was remained unmodified. As shown, Chimera 10 demonstrated 
prolonged serum stability (t1/2 =8.3 h) and sufficient gene knockdown potency (> 
80% silencing at the concentration of 20 nM). Subsequent work further confirmed 
that Chimera 10 did not cause sequence specific innate immune response (Chapter 9) 
and therefore was likely safe for in vivo application.  Thus, Chimera No. 10 was 
selected for further studies. 
As discussed, it has been shown previously by others that both unmodified 21-mer 
siRNA and 27-mer siRNA could remain stable in 50% serum for more than one hour
(Collingwood et al. 2008). Therefore, it was surprising to note that the unmodified 8-
bp at the 3’-end of the short strand on Chimera 2 contributed to the serum instability. 
This was probably due to the fact that the 47-nt longer strand in the chimera was 
much longer than 21- or 27-mer siRNA and therefore facilitated RNases entry or 
recognition. As a result, this longer chimera structure had to be modified more 
extensively.
Although gene-silencing efficacy of chimeras is sequence specific, considering the 
relatively simple structure of aptamer-siRNA chimera, the experience from this work 
may be generalized to aid the design of chimeras with other aptamers and siRNAs.  
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 Future advances in the understanding of the molecular mechanisms of RNAi, the 
types of chemical modifications that can stable the 8 bp Dicer reorganization region 
and enhancing Dicer processability may represent progresses in the development of 
aptamer-mediated siRNA delivery system.
4.3 Aptamer-siRNA Chimera 10 is able to specifically bind EpCAM positive 
cells
The specific binding property of aptamers is strictly dependent on their three 
dimensional structure (Da Costa and Dieckmann 2013). Therefore, any modification 
to their nucleotide sequence or changes in the external environment such as static 
electricity (in the case of cationic liposomes, peptides or polymers) may potentially 
affect their steric structure and consequently affect or abolish their binding capacity 
(Mahmood et al. 2014). As a result, after the chimera design, the effect of 
conjugation of the survivin siRNA portion on the binding affinity of the EpCAM 
aptamer was investigated. 
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Figure 4-6. Conjugating siRNA does not affect specific binding property of the 
EpCAM aptamer to EpCAM positive cells
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 A, representative confocal graphs show binding of chimera 10 to MCF-7/Adr cells. B, 
representative confocal graphs show binding of chimera 10 to illustrated cells. Cells were 
incubated with 100 nmol/L aptamer-survivin siRNA chimera at 37 qC for 30 min followed y 
washing and fluorescence confocal microscopy. EpCAM negative HEK293T cell line was 
applied as control. Red, Dy647 (chimera), and blue, Hoechst 33342 (nuclei).
As shown in Figure 4-6A, after 30 min incubation, the Chimera 10 could 
specifically target to EpCAM-positive MCF-7/Adr but not the EpCAM-negative 
HEK293T cells. Similar results were also obtained in several other types of EpCAM 
positive cells including MDA-MB-231, T47D, MCF-7 cell lines and primary breast 
cancer biopsies (Figure 4-6B). The specific EpCAM binding property of the Chimera 
10 was further confirmed by flow cytometric assay (Figure 4-7A). As illustrated, The 
Chimera 10 showed specific binding to EpCAM positive cells and the fluorescence 
intensity of the chimera correspond well with the known expression level of EpCAM 
in the cell lines tested (Shigdar et al. 2011). Additionally, flow cytometric analysis 
provided evidence that the Chimera 10 possessed a moderate high binding affinity,
from 12.25 to 53.21 nM in several different breast cancer cell lines (Figure 4-7B), 
which is comparable with the original EpCAM aptamer (from 18.5 to 98.9 nM in the 
same cell lines). Therefore, conjugation with the survivin siRNA did not grossly 
impact the targeting specificity and binding affinity of the EpCAM aptamer.  
Tumour-targeted siRNA treatments require specifically delivering siRNAs to the 
targeted tumour cells. The moderate high binding affinity of the Chimera 10 could 
contribute to this purpose. As reported, for clinical applications, the high affinity of a 
tumour-targeting ligand may not necessarily be advantageous (Schmidt M 2010),
especially when targeting proteins like EpCAM. This is because apart from being 
expressed at high levels in most breast adenocarcinomas, EpCAM is also expressed 
at low levels in a number of normal epithelial cells, including gastrointestinal tract, 
bile ducts, and pancreas (Balzar et al. 1999). Consequently, as revealed in Schmidt’s 
work (Schmidt M 2010), targeting reagents with moderate high binding affinity to 
EpCAM are more likely to bind tumour cells than normal epithelial cells.  
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Figure 4-7. Chimera 10 specifically targets to EpCAM positive cells and shows 
moderate high binding affinity. 
A, quantification of binding of chimera to EpCAM-positive breast cell lines versus that to 
the HEK-293T via flow cytometric analysis. Cells were incubated with fluorescence Dy647 
conjugated 100 nmol/L Chimera 10 for 30 min at 37°C, followed by washing and flow 
cytometric assay. B, determination of the equilibrium dissociation constants (Kd) of chimera 
to illustrated EpCAM positive cell lines using flow cytometry by incubating cells at varying 
concentrations of chimera (1 - 200 nmol/L) using HEK-293T as negative control. Kd was 
derived using GraphPad Prism program 3.03.
4.4 Aptamer-siRNA Chimera 10 is internalized by EpCAM positive cells and 
undergoes endosome escape
Binding to a specific population of cells is only the first step for targeted siRNA 
delivery. To cleave the expected mRNA, a chimera must undergo endocytosis and 
more importantly, escape from the endosome before it is delivered to the lysosome 
and degraded (Gilleron et al. 2013). Next, confocal microscopy was employed to 
study whether Chimera 10 was internalized upon binding to the cell surface EpCAM 
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 protein. Results shown in Figure 4-8 provide evidence that the internalization of 
Chimera 10 was most likely mediated through a receptor-mediated endocytic 
pathway. As illustrated, incubating Chimera 10 with MCF-7/Adr cells in full DMEM 
medium resulted in a particular intracellular pattern of red fluorescence (for Dy467-
labelled aptamer-siRNA chimera) (Figure 4-8A), indicating that the chimera 
underwent endocytosis. In addition, when receptor mediated endocytosis was 
blocked through potassium depletion (Zhang et al. 2013), a method known to be able 
to block receptor-mediated endocytosis, internalization of Chimera 10 was almost 
completely blocked (Figure 4-8B). To further confirm this receptor-mediated 
endocytosis, potassium recovery analysis was performed. Briefly, MCF-7/Adr cells 
were first treated with potassium-depleted medium at 37 ºC for 30 min, followed by 
potassium recovery via replacing the potassium-depleted medium to PBS. The cells 
were then imaged using a confocal microscope at time points of 0 min, 10 min, 15 
min, 25 min and 30 min.  As illustrated in Figure 4-8C, the chimera started to 
internalize 5 min after potassium recovery, and at the time point of 25 min, the 
chimera was detected in all the observed cells. 
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Figure 4-8. Chimera 10 is internalized in EpCAM positive MCF-7/Adr cells 
through receptor-mediated endocytosis
A, representative confocal images, cells were incubated with 100 nmol/L aptamer-survivin 
siRNA chimera at 37 qC for 30 min followed by washing and fluorescence confocal 
microscopy. Red, Dy647 (chimera), and blue, Hoechst 33342 (nuclei). B, chimera 
internalised via receptor-mediated endocytosis as determined by the blockade of chimera 
internalization by potassium depletion. Cells were subjected to potassium depletion followed 
by incubation of chimera and examined by confocal microscopy as in B. Green, LysoTracker
Green. C, Endocytosis was reversed upon replenishing potassium.  MCF-7/Adr cells were 
treated in potassium-depleted medium for 30 min followed by the addition of 100 nmol/L 
chimera for additional 30 min. After removal of the potassium depleted medium, phosphate 
buffered saline was added (0 min), and cells were imaged using confocal microscopy at 
indicated time points.  Arrows, typical MCF-7/Adr cells showing re-entry of chimera after 
the addition of potassium.
Next, the endosome escape capacity of Chimera 10 was studied by analyzing co-
localization of the chimera and the late endosome/lysosome. Briefly, one hour after 
Chimera 10 incubation, MCF-7/Adr cells were washed thoroughly and the surface 
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 chimera fluorescence was quenched with 0.4% Trypan blue (Siemsen et al. 2014).
Cells were then incubated in full DMEM medium for another two hours. Lysotracker 
was added in the last 30 min of this two-hour incubation followed by confocal 
microscopy. Since the transit from early endosomes to late endosomes takes only 5 –
15 min (Bruce et al. 2008), it is reasonable to assume that the chimeras shown in 
Figure 4-9 are either located in the late endosome/lysosome or in the cytoplasm. 
Quantitative analyses showed that 39.83% of the internalized chimeras were not 
detected inside of the late endosome or lysosome. That is to say, around 40% 
delivered chimeras were probably released from the endosome and were capable of 
meeting their targeted mRNAs in the cytoplasm and engaging with the RNAi 
machinery. However, for enhanced endosome escape, the detailed endosome escape 
mechanism need to be studied further. 
         
Figure 4-9. Chimera 10 undergoes endosome escape.
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 Representative confocal images show co-localisation of Chimera 10 with late 
endosome/lysosome. Cells were incubated with 100 nmol/L aptamer-survivin siRNA 
Chimera 10 at 37 qC for 1 hour followed by cell surface fluorescence quench using Trypan 
blue and further incubated for 2 h. Cells were treated with LysoTracker® Green in the last 
30 min of the 2 h incubation followed by confocal microscopy analysis. Arrows depict 
cytoplasmic chimera. Red, Dy647 (chimera), and green, FITC (late endosome/lysosome), 
and orange (co-localization of chimera and late endosome/lysosome). Quantification was 
conducted by Image-Pro software.
4.5 Conclusion
In summary, an aptamer-siRNA chimera structure was developed using a 
previously reported EpCAM aptamer and an effective 27-mer survivin siRNA 
sequence. With optimized structural design and serial chemical modifications, this 
EpCAM aptamer mediated survivin siRNA delivery system demonstrated EpCAM-
dependent targeting, prolonged serum stability and sufficient in vitro gene 
knockdown potency. Considering the comparatively simple structure and short 
length of this chimera, the rational and insight (structural design and modification 
pattern) obtained may be informative to other aptamer mediated RNAi studies. 
Encouragingly, an around 40% intracellular chimera was found to escape the 
endosome/lysosome compartment. Future delineation of mechanisms of endosome 
escape will aid the design of next generation aptamer-siRNA chimeras.
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 Chapter 5
Combined Chimera and Dox Treatment Reduces Tumourigenic 
Capacity of MCF-7/Adr cells in vitro
Theoretically, in in vitro setting where all cells are equally exposed to treatment, 
silencing survivin via transfection reagents plus siRNA (as in Chapter 3) and via 
aptamer-siRNA chimera should show no difference in sensitizing MCF-7/Adr T-ICs
to Dox. However, there are concerns about the off-target effects associated with the 
aptamer-siRNA chimera mediated gene silencing. This is because aptamer-siRNA 
chimera has a similar structure to miRNA precursor, and therefore is likely to trigger 
miRNA-like non-specific gene inhibition (Maida et al. 2013). Taking this factor into 
consideration, during the in vitro work, three strategies were exercised to control the 
potential off-target effects. Firstly, before testing the synergistic effect of combined 
chimera and Dox treatment, the siRNA-mediated sequence specific survivin 
silencing was confirmed by 5’RACE-PCR assay; Secondly, an optimized negative 
control (containing two point mutations) was designed and applied  as discussed in 
Chapter 4; Lastly, a siRNA resistant survivin plasmid control was employed to 
provide functional evidence that the Dox sensitization was resulted from the chimera 
mediated survivin silencing rather than off-target effects. 
5.1 EpCAM-dependent in vitro survivin silencing 
As described in Chapter 4, the dose dependant gene silencing capacity of Chimera 
10 to MCF-7/Adr cells has been determined in vitro via qRT-PCR. Here 
immunoblotting assay was performed to detect survivin gene knockdown capacity of 
chimera at the protein level. In order to assess the EpCAM-dependent survivin 
silencing, EpCAM-positive MCF-7/Adr and EpCAM-negative HEK293T cells were 
incubated with 20 nM chimera without transfection reagents for 48 h. As shown in 
Figure 5-1, the survivin protein level in MCF-7/Adr cells was significantly reduced 
by approximately 82.1%, while no reduction of survivin was observed in HEK293T 
cells, suggesting an EpCAM-dependent survivin knockdown in target cells. To 
further confirm that EpCAM-dependent survivin silencing is not restricted to one 
particular type of tumour cell, the in vitro gene silencing was repeated in a variety of 
EpCAM-positive cells including T47D, MDA-MB-231, KATO III cell lines and 
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 primary breast cancer cells. As shown in Fig 5-1, after 48 h treatment, the expression 
of survivin protein showed around 85%, 81%, 84% and 71% decrease in the above 
tested cells. Similarly, EpCAM-dependent survivin mRNA knockdown was also 
confirmed through qRT-PCR assay. As illustrated in Figure 5-2, after 24 h treatment 
using 20 nM Chimera10, survivin mRNA level was significantly reduced in all the 
tested EpCAM- positive cells but not in EpCAM-negative HEK293T cells, evident 
from the  82.2%, 81.3%, 83.4%, 82.6, 73.6% knockdown in MCF-7/Adr, T47D, 
MDA-MB-231, KATOIII cell lines and primary breast cancer cells, respectively.
 
Figure 5-1.  Chimera10 inhibits survivin expression in EpCAM positive cells  
A, representative immunoblots demonstrating specific knockdown of survivin by chimera 
after 48 h treatment using 20 nmol/L chimera and/or other indicated reagents. siRNA plus 
RNAi-resistant survivin replacement construct (rescue) or mock rescue (vector-only) was 
applied as RNAi rescue. EpCAM-negative and survivin-positive HEK293T cells was used as 
105 
 
 a control for specificity of aptamer targeting. B, quantification of survivin protein 
knockdown. Data are means ± SEM, n=3.  **, P < 0.01 compared with untreated control. 
 
Figure 5-2. Chimera 10 specifically cleaves survivin mRNA in EpCAM positive 
cells.
qRT-PCR assay demonstrates specific cleavage of survivin mRNA by chimera after 24 h 
treatment using 20 nmol/L chimera and/or other indicated reagents with RNAi rescue 
performed as in Figure 5-1. EpCAM-negative and survivin-positive HEK293T cells were 
used as a control for specificity of aptamer targeting. As the forward primer for survivin 
corresponds to the 5’-UTR region, and thus the transcripts from the rescue plasmid were not 
amplified in qRT-PCR. Data are means ± SEM, n=3.  **, P < 0.01 compared with untreated 
control.  
5.2 Silencing of survivin by Chimera is mediated by sequence specific RNAi 
mechanism
Results shown in Figure 5-1 and Figure 5-2 demonstrate the specificity of the 
chimera-mediated survivin knockdown by employing an EpCAM negative 
HEK293T cell line and a negative control chimera. To further verify that the 
cleavage of survivin mRNA is indeed through an Argonaute2 (Ago2) mechanism of 
action, a 5’ rapid amplification of cDNA ends (5’RACE) PCR assay was carried out 
(Figure 5-3). 
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 Figure 5-3 Schematic of the 5’RACE PCR assay
The first step to perform 5’RACE assay was to confirm the integrity of the total 
RNA to be studied. Twenty four hours after chimera treatment, total RNA from 
MCF-7/Adr cells were extracted and quantified. The purity of RNA samples was 
defined by the ratio of optical density (OD) A260/A280. Only samples with a ratio 
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 between 1.80 and 2.0 were selected for further analyses. The integrity of RNA was 
assessed by formaldehyde denaturing agarose gel electrophoresis. After 
electrophoresis, the RNA sample showed two clear 28S and 18S ribosomal RNA 
(rRNA) bands (Figure 5-4A) (Thellin et al. 1999). When the relative light density of 
these two bands was compared, the 28S rRNA band was approximately twice as 
intense as the 18S rRNA band (Figure 5-4B). Since degraded RNA would have a 
smeared appearance or would not show the approximately 2:1 ratio of the intact 
RNA, the high quality of the total RNA sample used in this 5’RACE assay was 
confirmed. 
 
Figure 5-4 The total RNA extracted for 5’RACE assay is integrated. 
A,  The 28S and 18S ribosomal RNA bands were visualized after electrophoresis through a 
1% denaturing agarose gel (formaldehyde) and stained with Gelstar. 400 bp DNA ladder and 
a 2000 nt DNA oligonucleotide were used to indicate the approximate position of rRNA. B, 
Relative quantification of the ratio of 28S and 18S ribosomal RNA. 
Having confirmed the quality of total RNA, a 42-nt RNA adaptor was conjugated 
to the 5’ end of the total RNA and reverse transcribed to cDNA (Figure 5-3). A 
GeneRacer 5’primer for amplifying the adaptor portion and a survivin gene specific 
primer were used to amplify the segment of the cDNA containing the expected 
siRNA cutting site (Figure 5-3). To improve the specificity of PCR, touchdown PCR 
(Korbie and Mattick 2008) was employed and after 30 cycles’ amplification, a band 
with a molecular weight of ~ 800 bp was observed (Figure 5-5A), which was close to 
the expected size of 726 bp (Figure 5-3). Unfortunately, this ~ 800 bp band was not 
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 sharp enough and a series of sized smears were presented on the gel. To solve this 
problem, nested primers were designed and a nested PCR was conducted using the 
amplicon produced from the previous touchdown PCR (Figure 5-3). The nested PCR 
greatly increased PCR efficiency, a clear band with a position similar to the expected 
141 bp (Figure 5-3) was detected (Figure 5-5B). This result suggested there was 
breakage occurring in the survivin mRNA at a position close to the expected survivin 
siRNA cutting site as shown in Figure 5-3. In order to clone this DNA segment of 
~141 bp, the DNA was extracted from the agarose gel (Figure 5-5C).
 
Figure 5-5 5’ RACE-PCR assay suggests specific gene silencing of survivin 
mRNA via RNAi mechanism. 
A, 5’ ligated RNA was reverse transcribed and the resulted cDNA was amplified through 5’ 
adaptor primer and survivin specific primer. PCR products were separated and visualized 
through a 1% agarose gel. B, Nested PCR was conducted using nested primers to amplify 
PCR products from A. The PCR products were then visualized by a 1% low melt agarose gel.  
C, the band corresponds with 141 bp on gel B was collected and recovered by an S.N.A.P 
column. The purified 141 bp DNA product was visualized again through a 1% agarose gel. 
Next, the purified nested PCR product was cloned into a cloning vector (Figure 5-3) 
and propagated in E.coli.  To identify recombinant plasmids, PCR using plasmid 
DNA extracted from five colonies of E.coli was carried out with M13 primers (the 
expected amplicon is 267 bp). As shown in Figure 5-6A, distinct bands were 
observed in all of the five groups, with a size close to the expected 267 bp position. 
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Figure 5-6 Successful transformation of 5’ nested PCR product to E.coli.
A, after 12 hours incubation, E.coli cells were collected and underwent plasmid purification 
using the Qiaprep spin miniprep kit. The purified plasmids were then amplified using M13 
primers and followed by agarose gel separation as shown. B, the PCR products prepared 
with M13 primers were digested with restriction enzyme HhaI and the digestions were 
visualized by 1% agarose gel. 
To further confirm the inserted DNA was originated from the nested PCR product, 
the near 267 bp amplicon amplified by M13 primers were digested with restriction 
enzyme HhaI. According to our sequence analysis, if the near 250 bp M13 primers 
amplicon included the nested PCR product, it would be cut into two shorter 
sequences of 141 bp and 126 bp respectively. As shown in Figure 5-6B, after HhaI
digestion, two bands of approximately 141 bp and 126 bp were obtained. These 
characterized plasmid DNA was used for sequencing analysis.
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Figure 5-7 Chimera cleaves survivin mRNA through Ago2 mediated RNAi 
mechanism
A representative graph of DNA sequencing. The purified plasmids (200 ng – 800 ng) were 
mixed with M13 reverse primer (10 pmol) to 11 μL volume and sent to Australian Genome 
Research Facility (AGRF) for sequencing. Sequencing of the 5’ RACE-PCR products 
generated with 5’ adapter nested primer and survivin specific nested primer demonstrated 
that Ago2-mediated cleavage occurs between bases 10 and 11, relative to the 5’ end of the 
guide survivin siRNA strand.
To pinpoint the cleavage site of the survivin mRNA upon chimera treatment, the 
amplified DNA was sequenced using the M13 reverse primer. As shown in Figure 5-
7, it was revealed that the RNA adaptor was ligated to survivin mRNA from a 
position with sequence of 3’-UGUAGAGAUG-5’ (shown on the amplified DNA 
sequence as 3’-CATCTCTACA-5’ (Figure 5-7, survivin siRNA corresponding 
sequence)), indicating the cleavage site was between base 10 and 11 relative to the 5’ 
end of the guide strand of the previously confirmed 21-mer survivin siRNA (the 
guide strand of survivin siRNA is 5’- UGUAGAGAUG CGGUGGUCCTT-3’). This 
data provided solid evidence that the survivin gene silencing was mediated by 
siRNA/Ago2 mechanism rather than other mechanisms such as miRNA-mediated 
cleavage (Carmell et al. 2002). In addition, since only the previously tested 21-mer
survivin siRNA can cleave survivin mRNA from such a position, this experiment 
also verified that Dicer enters the chimera from the 3’-overhang of the longer strand 
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 of the chimera and results in the expected 21-mer siRNA product as shown in Figure 
4-2.
5.3 Aptamer-guided survivin silencing sensitizes MCF-7/Adr T-ICs to Dox in 
vitro.
Similar with previously observed siRNA-mediated in vitro survivin silencing 
(Chapter 3), following Chimera10 treatment the response of MCF-7/Adr T-ICs to 
Dox was significantly sensitized. As illustrated in Figure 5-8, it was the Chimera 10-
mediated survivin silencing, but not the 2-nt mutation negative control chimera or 
Dox-alone, markedly sensitized the T-ICs of MCF-7/Adr to Dox as evident from a 
3.5-fold and 7-fold reduction in the primary and secondary mammosphere forming 
frequencies, respectively, in MCF-7/Adr cells treated with 20 nmol/L Chimera 10 
and 300 nmol/L Dox (vs Dox-alone).  The ability of targeted survivin silencing in 
combination with low dose (300 nmol/L) of Dox in eliminating breast T-ICs was 
further supported by the approximately 2.4-fold reduction of the tumourigenic 
EpCAM+/CD44+/CD24- population of cells (from around 22% in Dox-alone group to 
9.6%) after the combinatorial treatment (Table 5-1).  
Table 5-1 Percentage of EpCAM+/CD44+/CD24- population in different treated MCF-
7/Adr cells
In in vitro assay, cells were maintained in 300 nM Dox except specifically notified. Data are 
means ± SEM, n=4.  **, P < 0.01 compared with saline treatment. 
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 Figure 5-8. Combined treatment of Chimera 10 and Dox inhibits self-renewal 
capacity of MCF-7/Adr cells. 
A, representative graphs of secondary generation spheres demonstrate knockdown of 
survivin by chimera increase Dox sensitivity of MCF-7/Adr cells and result in reduced 
sphere formation capacity. Cells were trypsinized into single cells and treated with 20 
nmol/L chimera and/or other indicated reagents with RNAi rescue performed as in Figure 5-
1. Spheres were counted 7 days after cell seeding in 6-well ultra-low attachment plates for 
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 two passages. B. quantification of spheres. Data are means ± SEM, n=3.  **, P < 0.01 
compared with cells treated with 300 nM Dox. 
To functionally confirm the Dox sensitizing activity was specifically caused by 
chimera-mediated survivin gene silencing, a control experiment in which over-
expression of the RNAi-resistant version of survivin cDNA after the treatment of 
chimera was conducted. As shown in Figure 5-8 and Table 5-1, after survivin rescue 
(Figure 5-1), the effects of the chimera in targeting T-ICs were all completely 
reversed, suggesting they were indeed resulted from survivin silencing rather than 
off-target effects. Therefore, chimera-mediated survivin silencing restored the 
chemo-sensitivity and inhibited self-renewal of breast T-ICs, at least in vitro.
The gene silencing capacity of the chimera and the critical role of survivin in MCF-
7/Adr T-ICs was further confirmed by ex-vivo limited dilution assay (LDA). Briefly, 
MCF-7/Adr cells were treated with 300 nM Dox, 20 nM negative chimera or 
Chimera 10 plus Dox as shown in Table 5-2. Two days after treatments, a serial 
dilutions of cells as illustrated were injected into mice (n=5). As shown in Table 5-2,
compared with Dox-alone treatment, combinatorial treatment of chimera and Dox 
notably reduced tumour incidence, with the T-IC frequency decreased from 1 in 
1.6×106 cells to 1 in 8.82×106 cells while no difference was observed in cells that 
underwent combined negative chimera and Dox treatment. 
Table 5-2. Tumour incidence and T-IC frequency of MCF-7/Adr cells after 
indicated treatments
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 Taken together, results derived from in vitro and ex-vivo experiments suggested 
this aptamer-siRNA chimera was capable of silencing survivin gene and sensitizing 
MCF-7/Adr T-ICs to Dox in vitro. Moreover, the chimera introduced survivin 
silencing was mediated by a siRNA/ Ago2 mechanism rather than non-specific off-
target effects. 
5.4 Conclusion
In this chapter, the molecular mechanism underlying chimera-mediated survivin 
silence was verified via 5’RACE PCR assay.  Data obtained provided solid evidence 
that (1) the survivin silencing activity of the aptamer-siRNA chimera was mediated 
by Ago2 mediated RNAi mechanism rather than any other off-target effect and (2) 
Dicer entered the chimera from the 3’-overhang of the longer strand of the chimera 
and resulted in the expected 21-mer siRNA product. Importantly, as in the case of 
siRNA-induced survivin silencing, the combined treatment of the aptamer-siRNA 
chimera and Dox successfully impaired the self-renewal efficacy and reduced the T-
IC population in MCF-7/Adr cells in vitro, suggesting chimera-mediated survivin 
silencing improved Dox sensitivity of the breast T-ICs. This in vitro observation was 
further supported by the ex-vivo LDA, in which the combined treatment of chimera 
and Dox notably reduced tumour incidence while no difference was observed in cells 
that underwent other treatments. These results suggested that this aptamer-siRNA 
chimera was promising for further in vivo application. Of note, the translational 
potential of this chimera is underscored by its effective silencing in not only MCF-
7/Adr cells, but also various other EpCAM-positive cancer cells including primary 
breast cancer cells derived from biopsy.
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 Chapter 6
PEGylation Facilitates in vivo Delivery of Chimera
6.1. Chimera 10 is effective in specifically targeting to EpCAM positive MCF-
7/Adr tumours but is inefficient in silencing survivin gene in vivo
Successfully silencing survivin gene in in vitro setting is only the first step toward 
an effective therapy. To fully realize the potential of this aptamer-mediated siRNA 
delivery system, effectively delivering chimera to and silencing survivin gene in 
EpCAM-positive tumours were imperative. For these purposes, the specific targeting 
capacity of Chimera 10 to the EpCAM-positive MCF-7/Adr xenograft tumour was 
tested through in vivo imaging. In short, 2 nmol fluorescence (Dy647) conjugated 
Chimera 10 was delivered to mice bearing MCF-7/Adr (EpCAM positive) or 
U118MG (EpCAM negative) xenograft tumour through tail vein injection. The 
fluorescence signal for Dy647-labelled chimera was monitored in live animals over a 
period of four hours.  According to Figure 6-1, the chimera fluorescence was 
detected only in EpCAM positive MCF-7/Adr tumours but not in EpCAM negative 
U118MG tumours, indicating that the binding of chimera to tumours was EpCAM-
dependent. As shown, the chimera signal appeared on MCF-7/Adr tumours around 
20 min after tail vein injection and lasted approximately three hours.  Four hours 
later, when fluorescence disappeared from the whole mouse imaging, tissues 
including tumour, liver, lungs, kidneys, heart and spleen were dissected and imaged.  
As shown in Figure 6-2, the MCF-7/Adr tumour displayed significantly stronger 
chimera signal than that of the liver, lungs, spleen and heart. Noticeably, the highest 
chimera signal was detected in kidneys.  This is not surprising since small and water-
soluble molecules such as the chimera are eliminated from the body mainly via renal 
filtration (Fox et al. 2009). Therefore, these data suggested that after systemic 
delivery, Chimera 10 was able to specifically target to EpCAM positive tumours. 
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Figure 6-1. Non-PEGylated chimera (Chimera 10) shows specific but faint 
binding to EpCAM positive MCF-7/Adr tumours.
A, a representative live animal imaging of non-PEGylated chimera. NOD-SCID mice 
bearing MCF-7/Adr or EpCAM-negative U118MG tumours implanted at the inguinal 
mammary fat pads with a volume of approximately 60 mm3 received a single intravenous 
injection of 2 nmol of non-PEGylated chimera labelled with Dy647 followed by serial 
fluorescence imaging at the indicated time points. The transplanted U118MG tumour was 
indicated by arrow. Log-scale heat map (middle) of photon flux applies to all panels. 
p/s/cm2/sr: photons per second per cm2 per Ste radian.  B, the fluorescence-time curve of 
non-PEGylated chimera in tumours determined by Living Imaging Software v2.50.  
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Figure 6-2. The relative fluorescence intensity of dissected tissues. 
A representative image of dissected tissues 6 hours after tail vein injection of non-PEGylated 
chimera. NOD-SCID mice bearing MCF-7/Adr tumour received a single intravenous 
injection of 2 nmol of non-PEGylated chimera labelled with Dy647. Six hours after delivery, 
indicated tissues were dissected and fluorescence imaging was conducted. The semi-
quantification of the average fluorescence intensity was performed by Living Image 
Software V2.50 (Xenogen) with the units of photons/s/cm2/sr. Log-scale heat map (middle) 
of photon flux applies to all panels. p/s/cm2/sr: photons per second per cm2 per Ste radian.  
Actually, with an average hydrodynamic diameter of merely 4.4 nm (Figure 6-4B), 
it was unexpected that the Chimera 10 signal could be detected in MCF-7/Adr 
tumours successively for approximately three hours. Theoretically, any particle with 
a size less than 10 nm will be rapidly eliminated from circulation through renal 
filtration (Choi et al. 2007). The 3-hour tumour retention of the chimera might be 
attributed to plasma protein binding (Smith et al. 2010). Plasma protein binding is a 
common phenomenon occurring after the delivery of small molecule drugs such as 
aspirin and diazepam, in which the bound drugs obtain larger particle size and 
achieve prolonged in vivo circulation time (Roberts et al. 2013). However, the 
detailed plasma protein binding mechanism and the corresponding pharmacokinetic 
features of aptamer-siRNA chimera remain unclear and need to be further studied. 
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 Unfortunately, although Chimera 10 displayed specific targeting to xenograft 
MCF-7/Adr (EpCAM positive) tumours, after 3 rounds chimera treatment (2 nmol 
per mouse per time, every other day for 3 rounds), no survivin gene knockdown was 
observed (Figure 6-3). This was likely due to the short blood circulation time leading 
to insufficient tumour accumulation and subsequent internalization (Figure 6-1B).
 
Figure 6-3. The Chimera 10 is inefficient in silencing survivin gene in MCF-
7/Adr tumours. 
NOD/SCID mice bearing orthotopic MCF-7/Adr tumour with a volume of 60 mm3 received 
a bolus intravenous injection of 2 nmol/mouse Chimera 10 every other day over 5 days.  
Two days after the third injection, the tumours were removed and total protein and RNA 
were prepared for gene silencing assay.  A, representative immunoblots for in vivo survivin 
gene silencing and the quantification. B, quantification of survivin mRNA level in treated 
tumours via qRT-PCR. Data are means ± SEM, n=5. **, P < 0.01 compared with saline 
treated group.
6.2. PEGylation does not affect specific binding capacity of chimera 
In order to effectively silence survivin gene in T-ICs in vivo, two chemical 
modifications were added to Chimera 10 to increase serum retention, to facilitate in 
vivo imaging and to allow accurate quantification of chimera without compromising 
Dicer processing efficiency. Firstly, a 20 kDa PEG molecule was added to the 3’ end 
of the shorter strand and secondly, Biotin and FITC molecules were conjugated at the 
two ends of the shorter strand (Figure 6-4A). The purpose of PEGylation was to 
increase particle size (Figure 6-4B) and achieve prolonged circulation time (Jokerst 
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 et al. 2011) while FITC and Biotin conjugation was aimed to enable imaging as well 
as an Enzyme-linked immunosorbent assay (ELISA)-based quantification method 
(Figure 6-10) which will be discussed later. As displayed in Figure 6-4, after 
PEGylation, the hydrodynamic diameter of chimera molecule was greatly increased, 
from around 4.4 nm to 15 nm, well above the pore size of the normal capillary 
endothelium and glomeruli (5 nm and 10 nm respectively). Therefore the PEGylated 
chimera may aid to mitigate the rapid vessel diffusion and renal filtration (Choi et al. 
2007) to achieve prolonged in vivo circulation time. 
 
Figure 6-4. Schematic of PEGylated aptamer-siRNA chimera and the 
comparison of particle size between non-PEGylated and PEGylated chimera. 
A, PEGylated aptamer-siRNA chimera was developed by modifying Chimera 10 by 
attaching a 20 kDa polyethylene glycol - FITC to the 3’-end and a biotin to the 5’- end of the 
shorter strand. In the negative control version of the longer strand, two point mutations were 
introduced as indicated. B, particle size of PEGylated and non-PEGylated version of chimera 
as determined by dynamic light scattering. Data are means ± SEM, n=3.  
As discussed in Chapter 4.3, the specific binding property of aptamer is strictly
dependent on its 3-D structure and any internal or external changes could potentially 
disrupt its specific binding efficacy. As the next step, the potential impact of 
conjugation of PEG, Biotin and FITC on the binding specificity and affinity of the
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 chimera were investigated via flow cytometry. As illustrated in Figure 6-5A, after 30 
min incubation with 100 nmol/L PEGylated chimera, it was confirmed that compared 
with EpCAM negative HEK293T cells, the PEGylated chimera showed specific 
binding to a variety of EpCAM-positive cell lines including MCF-7/Adr, MDA-MB-
231, T47D and MCF-7. Furthermore, the fluorescence intensity of the PEGylated 
chimera corresponded well with the known level of EpCAM in the tested cell lines 
(Shigdar et al. 2011). In addition, flow cytometric analysis provided evidence that 
this chimera possessed a moderate high binding affinity (Kd = 42.19 nM) to MCF-
7/Adr (Figure 6-5B), comparable with the original EpCAM aptamer and the 
previously examined non-PEGylated Chimera 10 (Kd = from 10 nM to 100 nM in 
different EpCAM positive cell lines). Therefore, the conjugation of PEGylation, 
FITC and Biotin did not impose detrimental effects on the targeting specificity and 
binding affinity of the aptamer-siRNA chimera. 
 
Figure 6-5. PEGylated chimera specifically targets to EpCAM positive cells and 
shows moderate high binding affinity
A, quantification of binding of chimera to EpCAM-positive breast cell lines versus that of 
the EpCAM negative HEK-293T cell line via flow cytometric analysis. Cells were incubated 
with PEGylated chimera for 30 min at 37 ºC followed washing and flow cytometric analysis. 
B, determination of the equilibrium dissociation constants (Kd) of chimera to MCF-7/Adr 
cells using flow cytometry by incubating cells at varying concentrations of chimera (1–200
nmol/L) with HEK-293T as negative control. Kd was derived using GraphPad Prism program 
3.03.
Taken together, it seems that the 3-D structure of the EpCAM aptamer used in this 
study is quite stable (reflected by its stable targeting capacity) as evidenced by the
fact that it could resist to different types of chemical modifications. This could be 
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 probably attributed to next three factors. Firstly, the aptamer itself, with a length of 
only 18-nt, is one of the shortest effective aptamers reported. Compared with those 
longer aptamers, this relatively simple structure confers it with a less complicated 
steric structure, which means less interruption to the core-binding site of the aptamer. 
Secondly, different with other materials such as lipids or polymers, conjugating 
double-strand siRNAs to the aptamer is less likely to affect its 3-D structure. As 
shown in Figure 4-2C, the annealed chimera structure showed a very stable 
secondary structure with Gibbs' free energy of -42.6 kcal/mol, compared with the -
4.5 kcal/mol Gibbs’ free energy for the EpCAM aptamer, suggesting that the stable 
structure of the chimera is contributed heavily by the stable double-strand structure 
of the siRNA portion. This means that the conjugation of siRNA is unlikely to affect 
the 3-D structure of aptamer and on the contrary, it probably plays a role to enhance 
the steric stability of the original EpCAM aptamer. Finally, both aptamer and siRNA 
are negatively charged oligonucleotides, they therefore do not incur mutual static 
electrical interruption - a major concern for the application of aptamers (Unal and 
Niazi 2013).      
6.3. PEGylation results in enhanced tumour retention 
Conjugation of a 20 kDa PEG to the chimera increased its particle size to 15 nm. 
As determined by live animal imaging, the PEGylated chimera showed a significant 
increase in the accumulation in the xenograft MCF-7/Adr tumours, evident from a 
9.5-fold larger area under the fluorescence intensity curve (AUC) for the PEGylated 
chimera compared with that of the non-PEGylated Chimera 10 (Figure 6-8). As 
shown in Figure 6-6, the signal of the PEGylated chimera in the MCF-7/Adr tumour 
was detected 10 min after tail vein injection and lasted over the next 24 h. When the 
tissues/organs were dissected and imaged 24 h after chimera delivery, there was 
much stronger chimera signal shown on tumours than on most of other tissues 
including liver, lungs, heart and spleen with the exception of the kidney. As
discussed previously, since the high concentration chimera detected from kidneys 
was most likely caused by the non-specific renal elimination pathway of the chimera, 
it is reasonable to conclude that the PEGylated chimera possessed increased tumour 
targeting capacity and tumour retention.
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Figure 6-6. PEGylated chimera shows enhanced tumour retention and specific 
binding capacity to MCF-7/Adr xenograft tumours. 
A, representative live animal images of PEGylated chimera. NOD-SCID mice bearing MCF-
7/Adr tumour (60 mm3) received a single intravenous injection of 2 nmol of PEGylated 
chimera labelled with Dy647 followed by serial fluorescence imaging at the indicated time 
points. Log-scale heat map (middle) of photon flux applies to all panels.  B, the 
fluorescence-time curve of PEGylated chimera in tumours determined by Living Imaging 
Software v2.50.  C, representative images of dissected tissues 24 h after PEGylated chimera 
injection. NOD-SCID mice bearing MCF-7/Adr tumour received a single intravenous 
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 injection of 2 nmol of non-PEGylated chimera labelled with Dy647. Twenty-four hours after 
delivery, indicated tissues were dissected and fluorescence imaging was conducted. The 
semi-quantification of the average fluorescence intensity was performed by Living Image 
Software V2.50 (Xenogen) with the units of photons/s/cm2/sr. Log-scale heat map (middle) 
of photon flux applies to all panels. p/s/cm2/sr: photons per second per cm2 per Ste radian.  
Interestingly, although the non-PEGylated Chimera 10 was unable to be detected 
on the EpCAM negative U118MG tumour, faint PEGylated chimera signal was 
observed on EpCAM-negative U118MG tumours four hours after tail vein injection
and this signal lasted approximately six hours before it disappeared at the 10-hour 
time point (Figure 6-7). As both the non-PEGylated Chimera 10 and the PEGylated 
chimera appeared on EpCAM-positive MCF-7/Adr tumours only 10 minutes after 
delivery, this delayed signal on EpCAM negative U118MG tumours was most likely 
resulted from an EpCAM-independent mechanism, which will be discussed later. 
The weak accumulation of the PEGylated chimera to EpCAM-negative U118MG 
tumours was further confirmed by imaging assay conducted on the dissected tissues 
(Figure 6-7C). As shown, different with the distribution pattern observed on MCF-
7/Adr tumour-bearing mice (Figure 6-6C), not only kidneys, tissues like lungs and 
liver also showed higher chimera concentration than that of the U118MG tumour. 
However, U118MG tumours did present higher chimera concentration than tissues 
like spleen and heart. Because tumours have much less blood flow than the spleen 
and heart (Raghunand et al. 2003), it is unlikely that the higher chimera 
concentration observed in U118MG tumour than that in spleen and heart was 
resulted from a higher blood flow. Considering the increased particle size of the 
chimera after PEGylation (from 4.4 nm to 15.5 nm), the late-onset and low amplitude 
accumulation of the chimera in EpCAM-negative U118MG tumours and the 
relatively higher concentration of the chimera in the liver and lung were probably 
generated via the enhanced permeability and retention (EPR) effect, which favours 
the accumulation of  nanoparticles to tumours and tissues including lungs and liver 
(Torchilin 2011).
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Figure 6-7. PEGylated chimera shows transient binding to EpCAM negative 
U118MG tumours. 
A, representative live animal images of PEGylated chimera. NOD-SCID mice bearing 
U118MG tumour received a single intravenous injection of 2 nmol of PEGylated chimera 
labelled with Dy647 followed by serial fluorescence imaging at the indicated time points. 
Log-scale heat map (middle) of photon flux applies to all panels. B, the fluorescence-time 
curve of PEGylated chimera in tumours determined by Living Imaging Software v2.50.  C,
representative image of dissected tissues 6 hours after PEGylated chimera injection. NOD-
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 SCID mice bearing U118MG tumour received a single intravenous injection of 2 nmol of 
non-PEGylated chimera labelled with Dy647. Ten hours after delivery, indicated tissues 
were dissected and fluorescence imaging was conducted. The semi-quantification of the 
average fluorescence intensity was performed by Living Image Software V2.50 (Xenogen) 
with the units of photons/s/cm2/sr. Log-scale heat map (middle) of photon flux applies to all 
panels. p/s/cm2/sr: photons per second per cm2 per Ste radian.  
 
The contribution of the EPR effect to the enhanced tumour retention capacity of the 
PEGylated chimera can be inferred from Figure 6-8. When the fluorescence intensity 
- time curves of the illustrated chimeras and tumours were compared, it was apparent 
that the PEGylated chimera had a 9.5-fold increase in AUC in the MCF-7/Adr 
tumours than that of the non-PEGylated Chimera, indicating the contribution of 
PEGylation to the prolonged blood circulation time, a necessary step for enhanced 
tumour accumulation and retention. However, in the EpCAM-negative U118MG 
tumour, this PEGylated chimera-alone displayed a late onset, low concentration and 
short duration of accumulation and consequently, with no survivin gene silencing 
was detected (Figure 6-9). This strongly suggests that the EPR effect alone is 
necessary but not sufficient for delivering an aptamer-siRNA chimera to tumours.  
Only the combined effect of EPR and active targeting via the EpCAM aptamer 
ensures a swift, high level and durable delivery of aptamer-siRNA to the EpCAM-
positive tumour.  
 
Figure 6-8. The fluorescence-time curve of the PEGylated and non-PEGylated 
chimera in EpCAM positive and negative tumours. 
The PEGylated chimera showed enhanced tumour accumulation on the MCF-7/Adr tumour 
than that of the non-PEGylated Chimera and displayed delayed appearance on EpCAM 
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 negative U118MG tumours with low fluorescence intensity and short duration of 
accumulation.
Figure 6-9. PEGylated chimera is inefficient in silencing survivin in the EpCAM 
negative U118MG glioma
NOD/SCID mice bearing xenograft U118MG tumour with a volume of 60 mm3 received a 
bolus intravenous injection of 2 nmol/mouse PEGylated chimera every other day over 5 
days.  Two days after the third injection, the tumours were removed and total protein was 
prepared for immunoblotting analysis. 
6.4. Conjugating FITC and Biotin allows an ELISA-based quantification
Pharmacokinetics assay provides pivotal insight into the behaviour of therapeutic 
or diagnostic agents within the body and is one of the two essential aspects of 
standard pharmacological research (Morgan et al. 2012). For accurate 
pharmacokinetics assay, a reliable absolute rather than semi-quantification method is 
required. As mentioned in Chapter 6.2, during the design of the PEGylated chimera, 
FITC and Biotin molecules were introduced in order to facilitate an indirect ELISA-
based quantification approach (Ferreira et al. 2008) (Figure 6-10). Previous assays 
relied on specific binding of complementary nucleotides (Dassie et al. 2009a, 
McNamara James O. et al. 2006b, Neff et al. 2011a). However, such methods could 
suffer from interference of endogenous nucleotides, leading to lower sensitivity and 
reliability. Instead, in this study, for reliable quantification, the high binding affinity
of antibody to antigen (anti-FITC antibody to FITC) and Biotin to Streptavidin was 
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 harnessed. During the procedure, a fluorogenic peroxidase substrate system was used 
to excite fluorescence rather than optical light for high sensitive quantification. As 
shown in Figure 6-10, the absorbance of fluorescence depended strictly on the 
number of chimera molecules with both FITC and Biotin conjugations. Since FITC 
and Biotin molecules were attached on the two ends of the siRNA portion of the 
chimera, any breakage on the siRNA portion would abrogate the output signals. In 
other words, under this quantification strategy, only chimera with intact siRNA 
portion can be detected, assuring the high specificity. Even so, this quantification 
strategy does not come without problem. Ideally, to quantify the whole chimera 
structure, it is best to add FITC and Biotin molecules on two ends of the chimera 
structure, i.e. one on 3’ end of the longer strand and another one on 5’ end of the 
shorter strand (Figure 6-4A). However, during computational structural analysis, it 
was found that modification on 3’ end of the longer strand (containing the guide 
strand of survivin siRNA) could significantly compromise the gene silencing 
capacity of the chimera. In addition, to label the longer strand of 47-nt will have 
resulted in low yield and high cost. Given that the potential degradation site on the 
whole chimera structure was more likely to be the siRNA portion rather than the
aptamer and linker portions (explained in Chapter 4.2), attaching FITC and Biotin on 
both sides of the shorter strand of the chimera was a most practical option to quantify 
the chimera. 
Figure 6-10. Schematic of RNA ELISA used to quantify aptamer-siRNA 
chimera. 
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 Mouse anti-FITC antibody was added to a 96-well plate that had been pre-coated with goat 
anti-mouse lgG. After 1 h incubation at room temperature, the wells were washed and 
blocked. Samples containing chimera were added to the washed wells and incubated for 1 
hour.  After extensive washing, Streptavidin HRP conjugates were added to each well to 
bind chimera-conjugated biotin. Absolute fluorescence intensities were then measured using 
a plate reader.
The reliability and sensitivity of this ELISA-based quantification method was 
assessed in various measurement conditions including serum and the homogenates of 
skin, brain, heart, eyes, liver, kidneys, lungs, intestine, spleen, excrement, tumour 
and stomach. All of the standard curves were constructed by plotting absorbance of 
fluorescence derived from ELISA vs. chimera concentration (log values were applied 
on both X and Y axis). As illustrated in Figure 6-11, the reliability of this 
quantification method was evidenced by the fact that the standard curves developed 
in all conditions showed acceptable Pearson Coefficient of Determination (R2) (with 
the lowest R2 value of 0.9101 recorded in intestine homogenate). Of note, the 
sensitivity of this quantification was determined to be 5 ng/mL, sufficient for 
subsequent pharmacokinetics (PK) and bio-distribution assays.
As for pharmacokinetics assay, PCR-based methods have been commonly applied 
for aptamer-siRNA chimera quantification. However, PCR based quantification 
requires relatively complicated procedures including RNA extraction, endogenous 
RNA degradation, reverse transcription and PCR amplification (Dassie et al. 2009, 
McNamara James O. et al. 2006), which make it difficult to achieve high accurate
and reliable quantification. Such limitations are further exacerbated by the relatively 
short RNA strand on chimera structure, which makes it difficult to design high 
efficacy primers for PCR. Recently, an in vivo miRNA quantification method 
(suitable for aptamer-siRNA chimera quantification) was developed by Qiagen 
(MiScript II RT Kit). This method applies the similar indirect ELISA principle 
(accompanied by PCR) as used in this RNA-ELISA quantification. However, instead 
of using antibody for detection, fluorescence conjugated nucleic acid probes were 
employed. Theoretically, the specific matching of the complementary nucleic acid is 
exploitable, but, considering the interruption caused by endogenous nucleic acids, a 
high sensitivity might be difficult to achieve. Comparatively, the ELISA based 
method used in this study is not only reliable and sensitive (5 ng/mL) but also, more 
importantly, applicable to other aptamer-siRNA chimera designs.
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Figure 6-11. Standard curves of PEGylated chimera for in vivo pharmaceutical 
analysis.
PEGylated chimera was diluted in serum or illustrated tissue homogenates to make a series 
of concentration (2500 ng/mL, 1250 ng/mL, 625 ng/mL, 300 ng/mL, 150 ng/mL, 75 ng/mL, 
37.5 ng/mL, 18.75 ng/mL, 9.375 ng/mL and 4.6875 ng/mL). The absorbance values of 
different concentrated chimera solution were then measured via ELISA. Calibration curves 
were constructed by plotting OD value vs. chimera concentrations. A linear regression was 
used to determine the reliability of ELISA. The standard formulas were determined by linear 
regression and presented as Y = aX + b, where Y is the OD value of chimera (log) and X is 
the chimera concentration (log).
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 6.5. PEGylation confers favourable pharmaceutical properties to aptamer-
siRNA chimera
For in vivo preclinical study, an optimal treatment schedule including treatment 
doses and treatment intervals is required. This relies on accurate pharmacokinetic 
parameters. Having confirmed the effective targeting of the PEGylated chimera to 
MCF-7/Adr tumours, subsequently, the pharmacokinetics and bio-distribution assays 
were conducted in healthy rats and tumour-bearing mice. 
As acknowledged, one of the key challenges for in vivo siRNA treatment is to 
deliver a sufficient dose of siRNA to the target tissue (Bumcrot et al. 2006).  The 
efficacy of the PEGylated chimera in delivering siRNA to the EpCAM-positive 
MCF-7/Adr tumour was assessed through a bio-distribution study. This was 
conducted by injecting mice bearing MCF-7/Adr xenograft tumour of ~150 mm3 
with 2 nmol/mouse of chimera followed by quantification of the aptamer-siRNA
chimera using the ELISA approach (Figure 6-10). As illustrated in Figure 6-12, the 
PEGylated chimera accumulated rapidly in the highly perfused organs including 
heart, liver, kidneys, spleen and lungs, and reach the peak concentration 30 min after 
delivery, followed by a swift decline and remained at between 0.76~4.8 % of the 
respective peak concentrations from 6 h onwards. In contrast, the delivery of chimera 
to the xenograft tumours displayed a very different time course, with the chimera 
reached one third of its peak concentration in 30 min, persisted in the tumour over 
the next few hours and reached the peak concentration at the 6-hour time point.  
Between the 6-hour and 10-hour time points after administration, the xenograft 
tumour kept the highest chimera concentration among the organs/tissues examined.  
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 Figure 6-12. Bio-distribution property of PEGylated chimera in MCF-7/Adr 
tumour-bearing mice. 
NOD-SCID mice bearing MCF-7/Adr tumour (150 mm3) received a single intravenous 
injection of 2 nmol of PEGylated chimera labelled with Dy647. Indicated tissues were 
dissected at time points of 0.5 h, 3 h, 6 h and 10 h and the concentration of chimera in 
various tissues were determined using ELISA. The chimera concentration was then 
normalized to ng chimera per gram tissue and plotted. 
To delineate further pharmacokinetic parameters to guide in vivo treatment, the 
time-related variations of chimera in serum was studied in healthy SD rats. As shown 
in Figure 6-13A and B, the drug-time curve follows a two-compartment distribution 
model and the pharmacokinetic parameters of the PEGylated chimera is akin to 
previous reported aptamers with comparable molecular weight (Healy et al. 2004, 
Talbot et al. 2011). As illustrated, consistent with the data collected from bio-
distribution study, the examination of pharmacokinetic profile of chimera revealed 
that the PEGylated chimera exhibited a short initial redistribution half-life (t1/2 Į 
0.14 h) and was reasonably long-lasting, with an elimination half-life (t1/2 ȕRIQHDUO\
5 h and a mean residence time of more than 6 h. Taken together, the PEGylated 
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 chimera possessed favourable pharmaceutical attributes and was capable of robust 
delivery of siRNA to MCF-7/Adr tumours.
 
Figure 6-13. Drug-blood curve and main pharmacokinetic parameters of 
PEGylated chimera in Rats. 
A, drug-blood curve of PEGylated chimera in Sprague Dawley rats. A single dose of 100 
nmol/kg of PEGylated chimera was injected intravenously and blood samples were collected 
at the indicated time points. The concentration of chimera in the blood was determined using 
ELISA. B, pharmacokinetic parameters of PEGylated chimera in rats. AUC,  area under the 
curve; CmaxPD[LPXPFRQFHQWUDWLRQREVHUYHGWĮKDOI-life for rapid/initial 
UHGLVWULEXWLRQWȕHOLPLQDWLRQKDOI-life; CL, clearance; MRT, mean residence time; Vss, 
steady state volume of distribution.
As shown in the time-dependent bio-distribution study, after a single systemic 
delivery (2 nmol/mouse), between time points of 0.5-hour and 10-hour, the chimera 
concentration of tumour maintained continually between approximately 800 ng/g 
tumour (10-hour time point) and 2800 ng/g tumour (6-hour time point), equivalent to 
~22.5 nM to ~65 nM chimera in tumours for 9.5 hours (assuming the tumour density 
being 1 g/mL). Such a concentration and duration of siRNA in the tumour would 
seem sufficient to silence most target genes (Kim Sun Hwa et al. 2008, Park T. G. 
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 2008). Furthermore, during our in vitro work, it was found that around 80% survivin 
gene silencing (mRNA level) could be achieved in MCF-7/Adr cells after 20 nM 
PEGylated chimera treatment for only 6 hours (data not shown). These data indicate 
that a single dose treatment of chimera with 2 nmol/mouse has potential to achieve 
effective gene-silencing in MCF-7/Adr xenograft tumours. However, considering the 
fact that the complicated microenvironment of tumours would probably compromise
the permeability of chimera (Tailor et al. 2010), in the subsequent in vivo gene-
silencing assay, a 7-day and 3-injection regimen was used. Specifically, a dose of 2 
nmol chimera/ mouse was injected to mice on day 1, 3, 5 and total protein or total 
RNA were extracted on day 7 for survivin silencing assay using immunoblotting or 
qRT-PCR assays.
Unexpectedly, after chimera delivery, the intestine shared a similar chimera 
distribution pattern with tumour, with the highest concentration of chimera appeared 
at the time point of 6-hour. Since mouse intestine is reported to be EpCAM positive, 
the possibility of the EpCAM aptamer (developed using human EpCAM protein) 
binding to mouse EpCAM was investigated. Two mouse EpCAM-positive cell lines,
LA-4 and IMGE5, were tested and no specific binding of the chimera to mouse 
EpCAM protein was observed (Figure 6-14). Given similar intestine distribution 
pattern has been reported in previously studies using other types of aptamer (Healy et 
al. 2004), it is likely that the accumulation of aptamer to intestine is managed by a 
kind of non-specific approach. As survivin gene is undetectable or detected with low 
level in intestine (Bao et al. 2002, Deveraux and Reed 1999, Montorsi et al. 2007, 
Sah et al. 2006), the potential side effect in intestine caused by the non-specific 
accumulation of the chimera, if any, might likely be restricted to the chimera 
materials, i.e. oligonucleotides and the chemical modifications. The possibility of
chimera resulted intestine toxicity was studied subsequently, with no noticeable 
pathological abnormalities observed (see Chapter 9).  
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 Figure 6-14. PEGylated chimera is unable to specifically target to mouse 
originated EpCAM protein. 
Representative confocal images, illustrated cells were incubated with 100 nmol/L PEGylated 
chimera at 37 qC for 30 min followed by washing and fluorescence confocal microscopy. 
U118MG cells were used as EpCAM negative control. Red, Dy647 (chimera), and blue, 
Hoechst 33342 (nuclei).
6.6 Conclusion
In this chapter, conjugation of a 20 kDa PEG conferred the chimera with prolonged 
circulation time and enhanced tumour accumulation. With a size of 15 nm, this 
PEGylated chimera harnessed the EPR effect and increased in vivo half-life to 5
hours, paving the way for its in vivo application. Unlike most published tumour-
targeted siRNA delivery systems which have a size between 60 nm and 150 nm, this 
PEGylated chimera had a size of only 15 nm, well-below the 30 nm threshold for 
effective tumour penetration (Cabral et al. 2011, Tang et al. 2013), was expected to 
display more efficient tumour penetration upon specific binding. Compared with 
other methods developed for siRNA quantification, the ELISA- based quantification 
strategy employed here showed great sensitivity, reproducibility, in addition being 
economic. More importantly, its application could be generalized to not only 
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 quantifying other aptamer-siRNA chimeras but also any oligonucleotide-based study.
In summary, results presented in this chapter laid solid foundation for the subsequent 
in vivo experimentations. 
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 Chapter 7
PEGylated chimera reverses chemo-resistance of T-ICs in MCF-
7/Adr xenograft tumours
7.1 Aptamer-guided RNAi efficiently silences survivin gene in MCF-7/Adr 
tumours 
After establishing both active and passive targeting underlie the specific delivery of 
PEGylated chimera to EpCAM-positive MCF-7/Adr tumours, the EpCAM-
dependent in vivo gene silencing capacity of PEGylated chimera was studied using 
MCF-7/Adr tumour-bearing mice with mice bearing U118MG tumour (EpCAM-
negative and surviving-positive) served as negative control. Briefly, tumour cells 
were implanted to the 4th mammary fat-pad (in the case of MCF-7/Adr) or 
subcutaneously (in the case of U118MG) in NOD/SCID mice, eight mice per group.
Based on the knowledge obtained from the pharmacokinetics assay, a 7-day 
treatment protocol was performed. In short, mice bearing MCF-7/Adr or U118MG 
tumours were treated with PBS, negative chimera or chimera three times, at an 
interval of two days with a dose of 2 nmol/mouse/time. Two days after the last 
treatment, total RNA and protein were extracted from tumours for gene expression
analysis. As expected, no difference in survivin mRNA or protein levels was
observed between U118MG tumours that underwent chimera or negative control 
chimera treatment as determined by immunoblotting and qRT-PCR assays (Figure 7-
1A, B, C). In contrast, after three round chimera treatments, pronounced suppression 
of the survivin gene ensured in MCF-7/Adr tumours as evident from the 74.2% and 
80.6% knockdown of survivin protein and mRNA, respectively, indicating that the 
chimera demonstrated EpCAM-dependent survivin silencing.
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Figure 7-1. EpCAM aptamer-survivin siRNA chimera is capable of specifically 
silencing survivin gene in MCF-7/Adr tumours. 
NOD/SCID mice bearing orthotopic MCF-7/Adr tumour with a volume of 60 mm3 or similar 
size of EpCAM-negative U118MG glioma received a bolus intravenous injection of 2 
nmol/mouse PEGylated chimera every other day over 5 days.  Two days after the third 
injection, the tumours were removed and total protein and RNA were prepared for 
immunoblotting or qRT-PCR assays.  A, representative immunoblots for in vivo survivin 
gene silencing. B, quantification of survivin protein expression in treated tumours via 
immunoblotting.  C, quantification of survivin mRNA level in treated tumours via qRT-
PCR. Data are means ± SEM, n=8. **, P < 0.01 compared with saline treated group.
As has long been noticed, after siRNA delivery, the observed gene silencing effect 
can be induced by not only siRNA, but also “miRNA-like RNA interference” 
(Davidson and McCray 2011) and sequence-specific innate immune response which
results in a universal gene inhibition (Jackson and Linsley 2010). As a result, apart 
from employing EpCAM negative U118MG tumours to show the EpCAM dependent 
gene silencing, next strategies were employed to further confirm the siRNA-induced 
specific RNAi. Firstly, applying a 2-point mutation negative control that would have 
very similar off-target potential with that of the PEGylated chimera (discussed in
Chapter 4.2). Secondly, during this study, the potential immunogenicity of the 
chimera was tested both in vitro using human peripheral blood mononuclear cells 
and in vivo using immunocompetent mice, with no detectable innate immune 
response was observed (detailed in Chapter 9). These results not only demonstrated
the safety of this chimera structure in in vivo application but also illustrated that the 
in vivo survivin gene silencing was unlikely caused by innate immune response 
mediated off-targeting. Lastly, 5’RACE-PCR assay was conducted to verify the 
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 siRNA/Ago2 mechanism mediated sequence specific survivin silencing. As shown in 
Figure 7-2, sequencing of the 5’RACE-PCR products demonstrated that an Ago2-
mediated cleavage occurred between bases 10 and 11 relative to the 5’end of the 
guide strand of survivin siRNA, consistent with that observed in in vitro studies 
(Figure 5-7). 
Collectively, it was confirmed that the PEGylated chimera introduced in vivo
survivin gene silencing was resulted directly from siRNA-mediated sequence 
specific RNAi rather than off-target effects.
Figure 7-2 Chimera cleaves survivin mRNA in MCF-7/Adr tumours through 
Ago2 mediated RNAi mechanism. 
A, After 5’RACE PCR assay using 5’ nested primer and survivin gene specific nested 
primer, the products were separated on 1% agarose gel and chimera treated group showed a 
sharp band at the expected near 141bp position. B, the 141 bp nested PCR product was 
purified and transformed to E.coli cells through a pCR 4-TOPO vector. Plasmids harvested 
from E.coli cells (200ng - 800ng) were then mixed with M13 reverse primer (10 pmol) and 
sent to Australian Genome Research Facility (AGRF) for sequencing. Sequencing of the 
5’RACE-PCR products generated by 5’ adapter nested primer and surviving nested primer 
demonstrated that Ago2-mediated cleavage occurs between bases 10 and 11, relative to the 
5’end of the guide strand of survivin siRNA.
7.2 Aptamer-guided RNAi sensitizes MCF-7/Adr tumours to Dox
Having established the capacity of the chimera to effectively silence survivin in 
tumours, the effects of chimera mediated in vivo survivin silencing on the Dox 
response of MCF-7/Adr tumours was examined. Mice bearing orthotopic MCF-
7/Adr xenograft tumour were treated with three intravenous injection of chimera or 
control chimera with or without 5 mg/kg Dox.  As illustrated in Figure 7-3, 
compared with saline treated group, the combinatorial treatment of the chimera and 
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 Dox resulted in significant decrease in tumour weight (9.3-fold). More importantly, 
pronounced reduction in tumour weight was also observed in combinatorial 
treatment group compared with chimera-alone or Dox-alone treatments (6.5-fold and
3.3-fold decrease in tumour weight, respectively).  These data suggest a synergistic 
anti-tumour effect of the chimera and Dox in the xenograft MCF-7/Adr tumour 
model.  
 
Figure 7-3. PEGylated chimera and Dox show synergistic anti-tumour effect in 
MCF-7/Adr tumour model.  
A, image of MCF-7/Adr xenograft tumours after illustrated treatments. NOD/SCID mice 
bearing orthotopic MCF-7/Adr tumour with a volume of 60 mm3 were injected i.v. of 2 
nmol/mouse PEGylated chimera or indicated controls with or without 5 mg/kg Dox every 
other day over 5 days.  Two days after the third injection, the tumours were removed and 
measured. B, Quantification of tumour weight in illustrated groups. Data are means ± SEM, 
n=8. **, P < 0.01 compared with saline treated group unless specifically noted. 
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 Since survivin is a key member of the anti-apoptotic gene family, the effects of 
combinatorial chimera and Dox treatment on apoptosis of MCF-7/Adr tumour cells
was examined via TUNEL assay using formalin-fixed, paraffin-embedded tissue 
sections prepared from treated tumours. Consistent with results of tumour weight 
reduction, the combinatorial treatment by chimera and Dox greatly enhanced the 
drug sensitivity of MCF-7/Adr tumours to Dox. As shown in Figure 7-4, while single 
treatment with Dox-alone or chimera-alone induced limited apoptosis in tumours 
(8.2% and 12.3% respectively), the combinatorial Dox and chimera treatment elicited 
apoptosis in 57.3% of the treated tumour cells.
The process of apoptosis has been proved to be an important factor for not only 
normal mammary gland development but also the progress of breast cancer (Motyl et 
al. 2006, VanHouten et al. 2010).  Previously, the role of survivin gene over-
expression in the chemo-resistance of breast cancer cells has been observed in vitro 
(Bao et al. 2002, Deng X. H. et al. 2013). This work provided further evidence that 
survivin played a pivotal role in the drug resistance of breast cancer in in vivo setting.
This observation is consistent with the reported close relationship between survivin 
over-expression and poor breast cancer prognosis in patients (Jha K et al. 2012).
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 Figure 7-4. Combined chimera and Dox treatment induces enhanced apoptosis 
on MCF-7/Adr tumour cells. 
A, representative images of apoptosis assay on MCF-7/Adr xenograft tumour sections with 
illustrated treatments. NOD/SCID mice bearing orthotopic MCF-7/Adr tumour with a 
volume of 100 mm3 were injected i.v. of 2 nmol/mouse PEGylated chimera or indicated 
controls with or without 5 mg/kg Dox every other day over 5 days.  Two days after the third 
injection, the tumours were dissected and tumour sections were prepared and apoptotic rate 
was measured via TUNEL assay. B, percentage of apoptotic cells in treated tumours as 
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 determined by TUNEL. Data are means ± SEM, n=8. *, P<0.05; **, P < 0.01 compared with 
saline treated group unless specifically noted.
The development of cancer is controlled by a balance between cell proliferation 
and apoptosis (Han Y. et al. 2013). Thus, tumour growth is not simply a result of 
reduced apoptosis but also of enhanced proliferation. Consequently, the effect of 
combined chimera and Dox treatment on the proliferation of MCF-7/Adr tumour 
cells was analysed via the determination of the Ki-67 index (Figure 7-5). Also known 
as MKI67, human Ki-67 protein is found exclusively in growing, dividing cells but 
not in the resting phase of cell growth. As a cell proliferation-associated antigen, Ki-
67 staining has been used to determine the extent of cell proliferation in various 
types of cancer including breast cancer, colon cancer and liver cancer (Fisher et al. 
2013, Jakobsen and Sorensen 2013, Miller et al. 2014, Tamaki et al. 2014). In fact,
Ki-67 index has now been routinely used for pathological diagnosis of breast cancer 
(Matsubara et al. 2013). Generally, a breast tumour that shows higher Ki-67 score 
indicates there are more cells undergoing rapid division and growth. As illustrated in 
Figure 7-5, although Ki-67 expression showed positive in all tested tumour groups 
(defined as higher than 15% of the cells are positive for Ki67) (Inwald et al. 2013), in 
comparison to saline treated group, the expression of Ki-67 protein was significantly 
lower in Dox treated group and combined chimera and Dox treated group. More 
importantly, while approximately 36% MCF-7/Adr tumour cells were Ki-67 positive 
after Dox treatment, there were only 19% of Ki-67 positive cells in tumours 
underwent combinatorial chimera and Dox treatment. Given the chimera-only 
treatment did not affect tumour proliferation (compared to saline treatment), it is 
apparent that survivin gene silencing mediated by the chimera enhanced the anti-
tumour activity of Dox and the significant reduction of tumour proliferation after the 
combined treatment was resulted from a synergistic effect between chimera and Dox. 
Thus, this study confirmed the critical role of survivin over-expression in the drug 
resistance of MCF-7/Adr tumours. In addition, these results showed that the 
combined chimera and Dox treatment not only inhibited the proliferation of MCF-
7/Adr tumour cells but also greatly promoted apoptosis – two of the crucial factors in 
determining the overall growth and regression of tumour in response to 
chemotherapy, radiotherapy and more recently, hormonal treatment (Brisken 2013, 
Felice et al. 2013).
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 Figure 7-5. Combined chimera and Dox treatment inhibits proliferation of 
MCF-7/Adr xenograft tumour cells.
A, representative images of Ki-67 stain on MCF-7/Adr xenograft tumour sections with 
illustrated treatments. NOD/SCID mice bearing orthotopic MCF-7/Adr tumour with a 
volume of 60 mm3 were injected, i.v. of 2 nmol/mouse PEGylated chimera or indicated 
controls with or without 5 mg/kg Dox every other day over 5 days.  Two days after the third 
145 
 
 injection, the tumours were dissected and tumour sections were prepared and the 
proliferation rate was measured via Ki-67 stain. B, Percentage of Ki-67 positive cells in 
treated tumours as determined by Ki-67 stain. Data are means ± SEM, n=8. **, P < 0.01 
compared with saline treated group unless specifically noted. 
7.3 Aptamer-guided RNAi increases Dox sensitivity of T-ICs in MCF-7/Adr 
xenograft tumours
Conventional chemotherapy drugs, such as Dox, are largely ineffective in 
eliminating T-ICs (Maugeri-Sacca et al. 2011).  However, according to the T-IC 
theory, these cells are responsible for the deterioration and drug resistance of 
tumours. To cure cancer, T-ICs must be exterminated (Medema 2013). The markedly 
increased apoptosis and reduced proliferation in the MCF-7/Adr tumours treated by 
chimera and Dox combination, but not in those treated with Dox-only or other 
controls (Figure 7-4 and Figure 7-5), along with the previously observed Dox 
sensitization of T-ICs of MCF-7/Adr cells after chimera treatment in in vitro and ex-
vivo experiments, led to a key  hypothesis of this study – aptamer-guided in vivo
survivin silencing should be able to convey Dox sufficient anti-cancer power to 
inhibit breast T-ICs in vivo.
Next, a number of experiments were designed to test this hypothesis,
Firstly, a mammosphere assay using single cells dissociated from in vivo treated 
MCF-7/Adr tumours was conducted. Following treatments using Dox, chimera, 
combined chimera and Dox, and corresponding negative controls, tumours were 
dissociated by Collagenase digestion and single cells were prepared and seeded in 
serum-free stem cell medium in ultra-low attachment 6-well plates for observation 
(Shaw et al. 2012). Encouragingly, the chimera induced survivin silencing greatly 
enhanced Dox sensitivity of T-ICs in MCF-7/Adr tumours and the combined chimera 
and Dox treatment resulted in reduced T-IC frequency in treated tumours. As 
illustrated in Figure 7-6, cells prepared from tumours underwent combinatorial 
chimera and Dox treatment showed reduced sphere forming efficacy in both primary 
and secondary sphere analyses (2.5-fold and 4.6-fold reduction compared with Dox-
alone treatment), while no significant difference in sphere forming efficacy was 
observed in cells underwent Dox-alone or chimera-alone or other types of treatments. 
These results suggest that although either Dox or chimera was inefficient in 
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 suppressing the self-renewal capacity of T-ICs in MCF-7/Adr tumours, the combined 
treatment was able to sensitize T-ICs to Dox, leading to the killing of T-ICs and 
reduced tumourigenic capacity. To further confirm this conclusion, direct analyses of 
the change in the population of T-IC surface marker positive cells were carried out. 
As illustrated in Figure 7-7, after combined chimera and Dox treatment, the 
abundance of the tumourigenic EpCAM+/CD44+/CD24- cell population in MCF-
7/Adr tumours was markedly reduced  from 11.82% pre-treatment to 1.87%. Of note, 
the 1.87% EpCAM+/CD44+/CD24- cell population was comparable with that of 
observed in the parental MCF-7 cells (Figure 3-3A).
Figure 7-6. Combined treatment of PEGylated chimera and Dox inhibits self-
renewal capacity of MCF-7/Adr xenograft tumour cells. 
NOD/SCID mice bearing orthotopic MCF-7/Adr tumour with a volume of 60 mm3 were 
injected i.v. of 2 nmol/mouse PEGylated chimera or indicated controls with or without 5 
mg/kg Dox every other day over 5 days.  Two days after the third injection, the tumour 
tissues were dissociated to single cells via Collagenase digestion. 2000 viable single cells 
from different treatment groups were cultured in DMEM/F-12 media supplemented with 1x 
B27, 20 ng/mL EGF, 10 ng/mL FGF and 4 ng/mL insulin in ultralow attachment surface 6-
well plates at 5% CO2 and 37 ºC. Spheres were counted 7 days after cell seeding in 6-well 
ultra-low attachment plates for two passages. Data are means ± SEM, n=3. **, P < 0.01 
compared with saline treated group.
Consistent with the diminished tumourigenic population, the expression of several 
stemness and drug resistance related genes including Notch1 (Tosello and Ferrando 
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 2013), Nestin (Park D. et al. 2010), ABCG2 (Natarajan et al. 2012), BMI1 (Siddique 
and Saleem 2012) and Bcl-2 (Souers et al. 2013) were found to have decreased in 
tumours that underwent combined chimera and Dox treatment, while no significant 
reduction of these proteins was observed in tumours underwent other treatments 
(Figure 7-8). 
The implications of all the above data are that the chimera-mediated in vivo
survivin silencing not only sensitized MCF-7/Adr tumours to Dox as a whole, but 
also significantly reversed the chemo-resistance in T-ICs. 
Figure 7-7. Combined PEGylated chimera and Dox treatment inhibit tumour 
initiating EpCAM+/CD44+/CD24- cells in MCF-7/Adr xenograft tumours. 
Representative graphs of flow cytometric assay. NOD/SCID mice bearing orthotopic MCF-
7/Adr tumour with a volume of 60 mm3 were injected i.v. of 2 nmol/mouse PEGylated 
chimera or indicated controls with or without 5 mg/kg Dox every other day over 5 days.  
Two days after the third injection, the tumours were dissociated to single cells via 
Collagenase digestion. The abundance of EpCAM+/CD44+/CD24- population was analysed 
by flow cytometry. Data are means ± SEM, n=3. **, P<0.01, compared with saline treated 
group.  
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 Figure 7-8. In vivo treatment by combined PEGylated chimera and Dox 
suppressed the expression of stemness and drug resistance related proteins.
Representative Immunoblots of stemness and drug resistance related proteins in tumours 
treated by chimera or indicated controls. Figures under each band indicated the fold of 
change of each protein level compared to the saline treated sample. NOD/SCID mice bearing 
orthotopic MCF-7/Adr tumour with a volume of 60 mm3 were injected i.v. of 2 nmol/mouse 
PEGylated chimera or indicated controls with or without 5 mg/kg Dox every other day over 
5 days.  Two days after the third injection, the different treated tumours were homogenized 
and total protein was prepared followed Western blot assay using illustrated antibodies.
As realized, although sphere formation assay and surface marker analysis can 
provide valuable supportive information for the assessment of self-renewal and 
changes in the abundance of T-ICs, they are after all imperfect surrogates for the 
gold standard in vivo LDA (Mo et al. 2013). To provide concrete evidence that the 
combined chimera and Dox treatment eliminated T-ICs in MCF-7/Adr tumours, T-
ICs in various groups receiving different treatment were directly enumerated using in 
vivo LDA. According to Table 7-1, although Dox-alone group showed significantly 
longer tumour latency in mice injected with 1 × 106 and 2 × 106 tumour cells
(compared to saline treatment), the observed T-IC frequency of 1 in 2.5 × 106 and 1 
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 in 3.3 × 106 cells, respectively, was essentially the same as that for saline treated 
control group. This result agrees with the known inability of Dox to eliminate T-ICs 
in both clinical and preclinical settings (Angeloni V et al. 2014, Ke XY et al. 2014).
In contrast, following combined treatment of Dox and chimera, substantial increase 
in tumour latency and decrease in T-IC frequency were observed (1 in 2.5 × 106 cells 
and 1 in 17 × 106 cells for saline treatment and combined treatment, respectively). 
Moreover, over a six-month observation period, no tumour was detected in mice 
injected with 1 × 106 or 2 × 106 tumour cells and underwent combined treatment. 
Table 7-1. Combined treatment of PEGylated chimera and Dox shows increased 
tumour latency and reduced T-IC frequency in MCF-7/Adr xenograft tumours.
Admittedly, in vivo LDA usually includes a wide range of cell dilutions (with 10 × 
dilution between two groups for instance) in the experiment (Lu et al. 2013). In this 
study, only a 2 × cell dilution was designed between the treatment groups. This is 
because that unlike some other types of cancer cells such as HT-29 (Sadanandam et 
al. 2013), larger number of MCF-7/Adr cells (around 4 × 106 cells) was required to 
generate a tumour in mice (without estragon supplement). 
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 Taken together, the reduced T-IC frequency in in vivo LDA, along with the 
previous in vitro and ex-vivo results, suggested that the combined treatment of Dox 
and chimera had reversed the chemo-resistance of MCF-7/Adr T-ICs both in vitro
and in vivo. And, therefore, such novel therapy may be valuable in treating chemo-
resistant breast cancers that over-express survivin.
7.4 Aptamer-guided RNAi extends survival of MCF-7/Adr tumour bearing mice
The overall survival of tumour-bearing patients represents a key indication of 
efficacy in elimination of T-ICs in oncologic clinics (Huff et al. 2006).  Therefore, 
after the establishment that the aptamer-guided survivin silencing in breast T-ICs 
sensitized these cells to Dox, the efficacy of the combined chimera and Dox 
treatment in extending the overall survival of MCF-7/Adr tumour-bearing mice was 
assessed. Briefly, once the orthotopic MCF-7/Adr tumours were detected (~30 
mm3), the tumour-bearing mice were randomly divided into six groups and treated 
with three cycles of alternating aptamer-siRNA chimera and Dox, with a 2-day 
interval in between to allow the knockdown of survivin before the administration of 
the apoptosis-inducing Dox. Consistent with the in vitro results (Figure 5-8), the 
negative-control chimera-alone had no effect on either tumour growth or survival 
rate (Figure 7-9).  Knockdown of survivin by chimera-alone elicited a moderate 
response. Treatment by Dox-alone or combined with the negative control chimera 
merely retarded tumour growth initially, but the tumour-bearing mice eventually 
reached the designated animal ethics end points by Day 80 (Figure 7-9A).  In 
contrast, in mice that received combinatorial chimera and Dox treatment, the rate of 
tumour growth was markedly retarded (p=0.0007, compared with Dox-alone
treatment), indicating a sustained reduction in tumour growth.  Importantly, seven 
out of eight mice receiving the combinatorial treatment survived at Day 80, with an 
average tumour burden 2.7-fold lower than that reached in other treatment groups. 
Therefore, targeting breast T-ICs in vivo using aptamer-guided survivin silencing and 
Dox resulted in significantly extended overall survival of the tumour-bearing mice. 
In actuality, this is exactly the aim of T-IC targeted anti-cancer therapy - through 
eliminating tumourigenic cells, to not only inhibit tumour growth temporarily but 
also extend survival period of tumour bearing patients in the long run (Williams et al. 
2013).
151 
 
 Figure 7-9. Chimera-mediated survivin silencing extended survival period of 
MCF-7/Adr tumour bearing mice. 
NOD/SCID mice bearing MCF-7/Adr orthotopic tumour with a tumour volume of ~30 mm3
were randomised into 6 groups and received an i.v. injection of 2 nmol of aptamer-siRNA or 
controls indicated on day 1, 3 and 5 with or without 5 mg/kg doxorubicin or vehicle control 
at day 3, 5 and 7.  A, tumour volume was measured. Values represent the means ± SEM, 
(n=8). B, Kaplan-Meier survival curves of mice (n=8 per arm) bearing MCF-7/Adr tumour 
treated as in A. Log rank (Mantel-Cox) p value is shown for aptamer-siRNA chimera + Dox 
treatment versus Dox-alone.
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 7.5 Conclusion
In summary, data from all these experiments, including the gold standard for T-IC 
assessment (in vivo LDA), suggested that the PEGylated chimera mediated survivin 
silencing not only sensitized MCF-7/Adr tumours to Dox as a whole, but also 
significantly sensitized T-ICs to Dox. More importantly, the combined chimera and 
Dox treatment significantly extended the overall survival of MCF-7/Adr tumour-
bearing mice. Since survival assay has been regarded as a key indication of efficacy 
in elimination of T-ICs in oncologic clinics, this combined treatment holds potential 
in the treatment of chemo-resistant breast cancers. Of note, the combinatorial 
treatment also resulted in the reduction in the expression of the proteins known to be 
involved in stemness and chemo-resistance, including Notch1, Nestin, ABCG2, 
BMI1 and Bcl-2. Since these proteins are involved in different signalling and 
survival pathways, the interrelationship between these proteins and survivin in the 
development of chemo-resistance and tumourigenicity need to be explored in future. 
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 Chapter 8
PEGylated Chimera Directly Acts on and Reverses Chemo-
resistance of Breast Tumourigenic EpCAM+/CD44+/CD24- Cells
Results from previous chapters provided strong functional evidence that EpCAM 
aptamer-guided in vivo siRNA delivery system was able to target T-ICs in xenograft 
MCF-7/Adr tumours.  To further confirm this observation, in this chapter, direct and 
physical evidence was sought via experiments conducted directly on the 
tumourigenic EpCAM+/CD44+/CD24- cells purified from both in vitro cell cultures 
and in vivo treated MCF-7/Adr tumours.
8.1 PEGylated chimera targets and penetrates into tumourigenic 
EpCAM+/CD44+/CD24- cells both in vitro and in vivo
Firstly, the specific targeting and internalization of the chimera into tumourigenic 
T-ICs were studied. Briefly, cultured MCF-7/Adr cells were incubated with 100 
nmol/L chimera, while mice bearing MCF-7/Adr tumours received a single 2 
nmol/mouse tail vein injection of the chimera or indicated controls. Single cell 
suspensions were prepared from treated tumours or cell cultures 6 h or 30 min after
treatments, respectively. Tumourigenic and non-tumourigenic breast cancer cells 
were then purified via FACS based on cell surface marker combination 
EpCAM+/CD44+/CD24- and EpCAM-/CD44-/CD24- respectively. After cell sorting, 
the binding and internalization of the chimera to these two FACS-sorted populations 
of cells were examined using confocal microscopy. As shown in Figure 8-1A, the 
Dy647 labelled chimera was indeed internalized into EpCAM+/CD44+/CD24- cells 
sorted from both in vitro cell culture and xenograft tumours. Quantitative analyses 
revealed that 89% and 100% of tumourigenic EpCAM+/CD44+/CD24- cells
dissociated from tumours or in vitro cell cultures contained internalized chimera 
(Figure 8-1C). Furthermore, both the in vitro and in vivo T-IC targeting was 
EpCAM-dependent as no Dy647-labelled chimera was found in EpCAM-/CD44-
/CD24- cells (Figure 8-1A). This experiment indicates that the EpCAM aptamer-
guided siRNA delivery can indeed effectively target T-ICs in MCF-7/Adr breast 
cancer both in vitro and in vivo.
154 
 
  
155 
 
            
Figure 8-1.  PEGylated chimera specifically targets and penetrates into 
tumourigenic EpCAM+/CD44+/CD24- cells.
NOD/SCID mice bearing orthotopic MCF-7/Adr tumour with a tumour volume of ~50 mm3
received an i.v. injection of 2 nmol/mouse of aptamer-siRNA chimera and the treated 
tumours were dissected 6 hours later. After 3 hours dissociation with 100 U collagenase II, 
single cells were prepared from tumours. EpCAM+/CD44+/CD24- as well as EpCAM-/CD44-
/CD24- cells were then sorted by FACS using corresponding antibodies.  For in vitro cell 
culture, MCF-7/Adr cells were incubated with 100 nmol/L chimera for 0.5 hour before 
conducting single cell preparation and cell sorting via FACS. A, representative confocal 
micrographs (low magnification) showing the presence or absence of chimera in FACS-
sorted cells. B, representative enlarged micrographs from A depicting internalisation of 
chimera in EpCAM+/CD44+/CD24- cells. C, quantification of percentage of chimera-positive 
cells as shown in A with 100 cells counted in triplicate. Data are means ± SEM, n=3. **, P <
0.001.
During this study, it was noticed that the sorted EpCAM-positive cells often 
displayed low EpCAM signal in confocal microscopy. This could be attributed to the 
photochemical properties of the fluorophore employed. In this study, Dy647, FITC, 
V450 and PE were conjugated to chimera, anti-human EpCAM antibody, anti-human 
CD44 antibody and anti-human CD24 antibody, respectively. Compared with 
Dy647, V450 and PE, FITC is unstable and prone to quenching (LE Dong 2014).
Since confocal microscopy was conducted approximately 2 hours after cell sorting,
the quenching of FITC during FACS sorting procedure resulted in only part of the 
sorted EpCAM- positive cells being detected with clear FITC fluorescence in 
confocal imaging work. As a result, the green FITC fluorescence was only presented 
in the enlarged images as shown in Figure 8-1B. 
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 Although systemic bio-distribution and intracellular trafficking are of primary 
interests to siRNA in vivo delivery, intra-tumoural distribution is another critical 
factor to consider in order to develop clinically viable siRNA delivery systems 
(Bae,You Han and Park 2011). In order to effectively silence targeted genes in the 
individual tumour cells, a drug carrier has to penetrate into and distribute within the
tumour tissue after extravasating through the leaky openings in the tumour blood 
vessels via the ERP effect (Chauhan et al. 2012). Given siRNAs and their delivery 
systems move into tumour tissue compartments mainly by random Brownian motion 
and convection, the rate of diffusional extravasation at a certain concentration 
gradient across tumour vascular fenestrae would be affected mainly by the particle 
size (Bae, You Han and Park 2011).  For example, when tumour penetration capacity 
was tested using two particles with a size of 25 nm and 60 nm, respectively, although 
the 25 nm particle was found to clear faster from the plasma compared to the 60 nm 
particle, its tumoural clearance was delayed and the subsequent study revealed that 
the 25 nm particle diffused further away from the blood vessels following 
extravasation, compared to that of the 60 nm particle which mainly remained in the 
perivascular regions (Lee H. et al. 2010). In another study, although a 90 nm stealth 
liposome achieved a relatively higher concentration in tumours, it did not seem to 
penetrate deeply into tumour tissue even two days after delivery (Yuan et al. 1994). 
Apparently, poor tumour penetration predicts a low probability for a therapeutic 
agent to reach the majority of the target cells within a tumour and thus leading to 
poor therapeutic response and tumour relapse (Imai K et al. 2006). In recent years, it
has been suggested that the size of 30 nm represents a threshold for effective tumour 
penetration (Cabral et al. 2011, Tang et al. 2013). The aptamer-guided siRNA 
delivery system developed in this study has an average size of 15 nm, which would 
confer superior efficacy for tumour penetration.  Indeed, the PEGylated chimera of 
EpCAM aptamer and survivin siRNA developed in this study demonstrated 
detectable EPR effect (Chapter 6) and superior tumour penetration, as evident from 
the fact that about 89% T-ICs dissociated from the treated xenograft tumours 
contained intracellular chimera (Figure 8-1C).
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 8.2 Chimera is able to silence survivin gene in the tumourigenic 
EpCAM+/CD44+/CD24- cells
After confirming the specific targeting and internalization of the PEGylated 
chimera to the FACS sorted breast T-ICs both in vitro and in vivo, qRT-PCR assay 
was performed to verify the T-IC targeted survivin silencing capacity of the 
PEGylated chimera. Consistent with the demonstrated specific cellular uptake, the 
PEGylated chimera resulted in EpCAM-dependent gene silencing in both in vitro and 
in vivo experimental settings. As presented in Figure 8-2, different with EpCAM-
/CD44-/CD24- cells in which no survivin silencing was observed, the tumourigenic 
EpCAM+/CD44+/CD24- cell population showed a reduced survivin level after 
chimera treatment, with approximately 78% and 83% survivin mRNA reduction 
being recorded in T-ICs purified from in vivo and in vitro, respectively. Therefore, 
siRNA delivered by an RNA aptamer to T-IC surface marker can effectively target 
T-ICs and silence critical gene related to chemo-resistance and tumourigenicity in 
vivo.
 
Figure 8-2. PEGylated chimera specifically reduces survivin mRNA level in 
tumourigenic EpCAM+/CD44+/CD24- cells in xenograft tumours after systemic
delivery. 
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 NOD/SCID mice bearing orthotopic MCF-7/Adr tumour with a tumour volume of ~50 mm3
received an i.v. injection of 2 nmol/mouse of aptamer-siRNA chimera or negative control on 
Day 1, 3 and 5.  Tumours were removed on Day 7 and EpCAM+/CD44+/CD24- as well as 
EpCAM-/CD44-/CD24- cells were sorted by FACS via corresponding antibodies. For in vitro
test, MCF-7/Adr cells treated with 20 nmol/L chimera for 2 days were also dissociated and 
sorted by FACS. A, levels of survivin mRNA (via qRT-PCR assay) prepared from FACS-
sorted tumour cells or cultured MCF-7/Adr cells that had been treated as described above. 
Data are means ± SEM, n=3. **, P < 0.01; compared with saline-treated group. 
8.3 Aptamer-guided survivin silencing is able to reverse the chemo-resistance of 
breast tumourigenic EpCAM+/CD44+/CD24- cells.
Lastly, to test the effects of the survivin silencing on the Dox response of T-ICs in 
in vivo environment, TUNEL assay was employed on the T-ICs and non-T-ICs 
sorted from xenograft tumours underwent various treatments. As shown in Figure 8-
3, combined chimera and Dox treatment resulted in 75.4% apoptosis in 
EpCAM+/CD44+/CD24- cells dissociated from treated xenograft tumours, compared 
with almost 6-fold (13.5%) less apoptosis in Dox-alone group. Of note, although 
Dox-alone treatment showed merely 13.5% apoptosis in T-ICs, a near 30% apoptosis 
was observed in non-T-ICs in Dox-alone group, illustrating Dox was capable of
inhibiting non-tumourigenic bulk tumour cells. These data provided direct evidence 
that (I) the chimera-mediated survivin depletion in MCF-7/Adr T-ICs sensitized 
them to the toxicity of Dox and (II) Dox was capable of inhibiting bulk tumour cells 
and therefore the combined chimera and Dox treatment was able to exterminate not 
only the non-tumourigenic bulk tumour cells but also the drug-resistant T-ICs. Since 
T-ICs and non-T-ICs may interconvert (Chaffer et al. 2011, Iliopoulos et al. 2011),
the bimodal treatment strategy presented here to target T-ICs and their progenies 
simultaneously appears advantageous, and indeed imperative.  
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 Figure 8-3. Combined chimera and Dox treatment caused increases apoptosis in 
tumourigenic EpCAM+/CD44+/CD24- cells in MCF-7/Adr tumour
NOD/SCID mice bearing orthotopic MCF-7/Adr tumour with a tumour volume of ~50 mm3
received an i.v. injection of 2 nmol/mouse of aptamer-siRNA chimera on Day 1, 3 and 5 with 
or without 5 mg/kg doxorubicin at Day 3, 5 and 7.  Tumours were removed on Day 9 and 
EpCAM+/CD44+/CD24- as well as EpCAM-/CD44-/CD24- cells were sorted by FACS.  A,
representative of confocal micrographs of TUNAL assay of cells with illustrated treatment. 
B, percentage of apoptotic cells in FACS-sorted cells dissociated from MCF-7/Adr tumours 
after indicated treatment. The extent of apoptosis is determined by TUNEL assay. Data are 
means ± SEM, n=3. **, P < 0.01; compared with saline-treated group, unless specifically 
denoted.
The notion that aptamer-guided survivin silencing was able to directly reverse 
chemo-resistance in breast T-ICs was further addressed by the subsequent 
mammosphere assay. This assay was conducted with EpCAM+/CD44+/CD24- cells 
sorted from the cell cultures or xenograft tumours treated by different regimens. As 
shown in Table 8-1, while Dox-alone or chimera itself did not show inhibitory effect 
on mammosphere formation efficacy of T-ICs, the combined chimera and Dox 
treatment resulted in prominent decrease of self-renewal capacity of T-ICs as evident 
from the reduction in mammosphere number in both in vitro and in vivo
mammosphere assays.
Table 8-1. Mammosphere formation capacity of sorted EpCAM+/CD44+/CD24-
cells (%)
 
Data are means ± SEM, n=3. **, P < 0.01; compared with saline treatment (in vivo) or Dox-
alone treatment (in vitro).
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 8.4 Conclusion
In this chapter, through the studies conducted on purified breast T-ICs from both in 
vitro cell cultures and xenograft tumours, direct and physical T-IC targeting data 
were obtained.  The results provided strong evidence that the PEGylated chimera was 
able to effectively penetrate xenograft tumours, bind to and internalize breast T-ICs 
and consequently silence survivin gene in them. All in all, this was the first 
demonstration of the feasibility and efficacy of effective delivery of siRNA to target 
T-ICs. The aptamer-guided T-IC-targeted gene silencing combined with rationally 
selected chemotherapeutic agent(s) may open up new and practical avenues to 
combat chemo-resistance and treatment relapse.
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 Chapter 9
PEGylated Chimera Does Not Show Detectable Side Effects
9.1 Chimera treatment does not affect the overall health state of mice 
To evaluate the potential acute side effects of the chimera on the overall health 
state, a complete blood count (CBC) assay was performed on immunocompetent 
Balb/c mice. Briefly, 24 h after chimera treatment (2 nmol/mouse), 100 μL blood 
was collected from each mouse. In addition to the whole blood cell profiling using an 
automated blood cell analyser, blood smear was also prepared and the subtypes of 
white blood cells were counted under a microscopy. As shown in Table 9-1, in saline 
treated group, no abnormality in blood cells was detected, suggesting the mice used 
in these experiments were generally healthy. Similar with saline treated mice, 
treatments by both the chimera and the negative control chimeras did not show 
significant abnormality in all the parameters examined. The results of this broad 
screening test suggested that the chimera did not have gross and acute negative 
impact on the general health of the animals. 
Table 9-1. PEGylated chimera does not induce abnormal hemogram on mice
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 GB: haemoglobin; MCV: mean corpuscular volume; MCH: mean corpuscular haemoglobin; 
MCHC: Mean Cell Haemoglobin Concentration; WBC: white blood cell; RBC: red blood 
cell; HCT: haematocrit.
9.2 PEGylated Chimera Does Not Trigger Innate Immune Response
As activation of innate immune response by oligonucleotides can lead to cellular 
toxicity and thus confound their in vivo therapeutic effects (Palm-Apergi and Dowdy 
2013), the immune stimulatory potential of the chimera was assessed. To study the 
activation of Toll-like receptor (TLR) 7 and 8 by synthetic RNAs, an in vitro assay 
using human peripheral blood mononuclear cells (PMBCs) and their ability to secrete 
interferon (IFN)-ĮDQGWXPRXUQHFURVLVIDFWRU71)-ĮZDVFRQGXFWHG*DQWLHUDQG
Williams 2010). High dose of chimeras (750 nmol/L), either chimera-alone or 
duplexed with the cationic liposome N-[1-(2,3-Dioleoyloxy)propyl]-N,N,N-
trimethylammonium methyl-sulfate (DOTAP) targeting endosomal TLR7/8, failed to 
induce significant levels of IFN-ĮDQG71)-ĮLQ3%0&VXQOLNHWKHNQRZQ7/5
single strand RNA ligand (ssRNA control) (Figure 9-1A) (Gantier et al. 2010). This 
suggested a lack of immunostimulatory activity of the chimera in in vitro
environment. Next, the in vivo innate immune response was investigated following 
i.v. injection of 2 nmol/mouse of the chimera or the RIG-I and TLR3 ligand 
polyinosinic:polycytidylic acid (poly I:C) in the immunocompetent Balb/c mice 
(Gantier and Williams 2007). Unlike poly I:C which instigated a rapid and sustained 
induction of IFN- ĮDQG71)- ĮWKHUHZDVQRGHWHFWDEOHF\WRNLQHSURGXFtion after 
chimera treatment (Figure 9-1B).  
Finally, to address the potential activation of intracellular RIG-I like pathways 
which may not necessarily lead to detectable circulating cytokines, the induction of 
the RIG-I target, interferon-induced protein with tetratricopeptide repeats 1 (IFIT1) 
(Marques et al. 2006), in the liver and lung of Balb/c mice treated with 2 nmol 
chimera was also tested. While poly I:C led to a 100-fold increase in IFIT1 
expression in both organs, there was no detectable induction following the 
administration of chimera (Figure 9-1C). Collectively, these data establish that the 
chimera does not activate the immune system (a major concern for oligonucleotide 
associated treatments), indicating that the suppression of tumour growth by the 
Dox/chimera co-treatment is not immune mediated.  
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 Figure 9-1.  PEGylated Chimera Does Not Trigger Innate Immune Response
A, chimera did not stimulate human peripheral blood mononuclear cells (PBMCs) in vitro.
Human PBMCs were incubated with 750 nmol/L chimera, negative control chimera or 
indicated controls overnight. The IFN-ĮDQG71)-ĮLQWKHFXOWXUHPHGLDZDVGHWHUPLQHGE\
ELISA. B, chimera did not elicit inflammatory responses in mice. Balb/c mice were treated 
with a single intravenous injection of 2 nmol/mouse chimera or 200 ng/mouse Poly I:C and 
blood was collected 4 h or 24 h post-treatment.  Levels of IFN-ĮDQG71)-ĮLQWKHVHUXP
was determined using ELISA.  E, treatment of chimera in Balb/c mice for 24 h as in D did 
not cause the elevation of IFIT1 mRNA in the liver and lungs as determined by qRT-PCR.  
Data in C-E are means ± SEM, n=6. **, P < 0.001; compared with saline-treated group.
9.3 Chimera does not cause pathological abnormality on intestines. 
As discussed in Chapter 6, during bio-distribution assay, the intestine shared a 
similar chimera distribution pattern to tumours, with a persistently higher chimera 
concentration from the 6-hour time point onwards. The potential side effects of this 
unexpected accumulation of chimera on intestines were tested by pathological 
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 examination. According to Figure 9-2, compared with saline treated control, no 
morphological/pathological abnormality was discernible on intestines in both acute 
and chronic toxicity experiments. 
 
Figure 9-2. Chimera treatment does not show pathological abnormality on 
intestine.  
Representative images of mice intestine following chimera treatment. Balb/c mice were 
intravenously injected 2 nmol/mouse of aptamer-siRNA on Day 1, 3 and 5. Then intestines 
were dissected on day 7 (for acute toxicity) or 3 months after the treatment (for chronic 
toxicity). HE stain was then conducted and pathological examination was conducted by a 
qualified pathologist under microscopy. 
Theoretically, the potential side effects of chimera to intestines may originate from 
two factors. The firstly factor is silencing survivin gene on intestines, which may 
result in survivin gene related functional abnormality; and the second factor is the 
toxicity caused by the materials of chimera (nucleotides and the chemical 
modifications presenting on the chimera). Given survivin gene is undetectable or 
detected with very low levels in both human and mouse normal intestine (Bao et al. 
2002, Sah et al. 2006), and more importantly, given the observation that the survivin 
addiction mechanism specifically shown on tumours while not on normal tissues 
(O'Connor et al. 2002), it is likely that the potential side effect of chimera to intestine 
would be restricted to chimera itself (the materials and modifications). As for the 
chimera materials, i.e. oligonucleotide, FITC, PEG and biotin, they are generally 
biocompatible and safe except the possibility of triggering sequence-dependent 
innate immune response by oligonucleotide (Palm-Apergi and Dowdy 2013). Since 
no gross morphological abnormality and immunogenicity were detected in the 
studies as displayed in Table 9-1 and Figure 9-1, this chimera seems to be safe for 
future clinical application.
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 9.4 Conclusion
Collectively, a major advantage of the aptamer-mediated in vivo siRNA delivery -
lack of immunogenicity was confirmed here by both in vitro and in vivo experiments. 
This has in turn confirmed that the chimera mediated gene silencing was not a result 
of immune associated off-target. Moreover, the overall safety of the chimera was 
supported by a complete blood count (CBC) assay and a histo-pathological 
examination on intestines, in addition to the cytokine studies. The simple structure 
and biocompatible nature of the chimera laid solid foundation for the observed lack 
of detrimental effects in a series of preclinical safety studies. Future test of the safety 
of the chimera in non-humane primates will pave the way to clinical trials.
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 Chapter 10
Summary and Perspectives
10.1 Summary
RNA interference (RNAi) is heralded as “a major scientific breakthrough that 
happens once every decade or so” and its importance was recognized by the award of 
the 2006 Nobel Prize for Physiology or Medicine (LaMattina 2014). Theoretically, 
RNAi can be applied to knock down any gene. Since virtually almost all diseases 
involve some forms of genetic abnormality, this technology holds great potential in 
treatment of many traditionally incurable diseases such as cancer, HIV infection and 
various metabolic disorders (Xia et al. 2002). As a result, in the last 10 years, 
dramatic progress has been made to translate RNAi from basic scientific research to 
drug development. Among RNAi family, both siRNA and short hairpin RNA 
(shRNA) have been intensively researched. However, it seems siRNA attracted more 
attention in recent years, this is because although shRNA can take advantage of the 
endogenous RNAi machinery and obtain high potency and sustainable gene silencing 
effect, the simplicity of manufacturing and easy to control nature (transient gene 
silencing) of siRNA make it more pharmaceutically attractive (Burnett et al. 2011).
Currently, there are at least 35 siRNA-associated clinical trials registered in the 
world, with several haYLQJPDGHWKHLUZD\WRWKHSKDVHɒVWDJH(ClinicalTrials.gov 
2014).  Under this circumstance, it is reasonable to assume that the first clinically 
viable siRNA drug may soon become available. 
Specifically for cancer treatment, current technology, at least in laboratory, allows 
us to not only deliver siRNAs to cancer cells in vitro but also effectively to tumours 
(Merkel et al. 2014). However, despite the wide appreciation of the critical role T-
ICs play in treatment failure/relapse (Schmidt and Abken 2011), to the best of our 
knowledge, no T-IC targeted siRNA delivery has been reported. Admittedly, T-IC 
theory is still under debate, especially regarding their origin and frequency in 
tumours (Clevers 2011). However, the consensus is that T-ICs stand for the most 
invasive and refractory cells in tumours. The lack of a specific targeting strategy 
against such population of cells in current cancer treatment is at least partly 
responsible for the short survival period experienced by many cancer patients 
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 (Clevers 2011). It is in this context, a novel T-IC-targeted in vivo siRNA delivery 
system was developed.
When it comes to T-IC targeted siRNA delivery, two factors are required to be 
taken into account. The first is that the targeted gene has to be critical for the survival 
of T-ICs, and the second is that the siRNA has to be delivered to T-ICs in vivo with 
sufficient amount and long enough duration for effective gene silencing. In this 
project, firstly, we endeavoured to find a critical gene for T-ICs. Since tumours are 
highly heterogeneous, noticeable phenotype differences are often detected in even 
the same type of tumour (Croteau et al. 2013), it is unreasonable to claim a certain 
gene is critical for all kinds of T-ICs. To facilitate the study of the drug-resistance-
related genes of T-ICs, a Dox-resistant breast cancer cell line MCF-7/Adr was 
developed via chronically exposure of MCF-7 cells to a clinically relevant Dox dose 
(300 nM). It was found that this cell line enriched with breast T-ICs, and the survival 
of which was again affected greatly by an anti-apoptotic gene – survivin (Martin D. 
T. et al. 2014). Once survivin gene was silenced, the Dox resistance of T-ICs in this 
model was reduced. Since T-ICs are best characterized by enhanced drug resistance, 
reversing of drug resistance of T-ICs means they could be got rid of from tumours 
(Chapter 3). Therefore, at least in this model, the over-expressed survivin gene is 
critical to T-ICs. Accordingly, majority of the work of this project was conducted 
using this drug-resistant breast cancer model. 
Next, how to effectively deliver siRNA to T-ICs in in vivo setting. In this study, T-
ICs were targeted by means of aptamer. Aptamer is another hot point in current
biomedical research. Basically, aptamers are kind of antibodies. But different from 
traditional protein-based antibodies, they are much smaller and after proper chemical 
modification, could be very stable in serum. Previously, an RNA aptamer which can 
specifically target to the epithelial cell adhesion molecule (EpCAM) was developed 
in our laboratory (Shigdar et al. 2011). Since EpCAM has been accepted as one of 
the breast T-IC surface markers, this aptamer allows us to deliver siRNA to T-ICs in 
the drug-resistant breast cancer model (MCF-7/Adr).
After meeting two of the essential prerequisites for T-IC targeted siRNA delivery 
(A survivin siRNA to silence a T-IC critical gene and an aptamer which can deliver 
siRNA to T-ICs in the drug-resistant breast cancer model), an aptamer-mediated 
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 siRNA delivery system, in the form of the aptamer-siRNA chimera, was designed 
and tested (Chapter 4). This chimera was created by conjugating the EpCAM 
aptamer and a 27-mer siRNA portions via a nucleotide linker (AA), with an 
asymmetric secondary structure to facilitate Dicer recognition from an expected 
position (the creation of the expected siRNA sequence was confirmed in Chapter 
5 by 5’RACE PCR assay). Since the rules of siRNA specificity are not yet fully 
defined (He C. et al. 2013), to better control for  potential off-target effects, a 
negative control chimera with 2-point mutation in the guide strand of the siRNA 
portion was used rather than relying on commonly employed scrambled siRNA 
control.
Although the structure of the aptamer-siRNA chimera seemed simple, it actually 
took significant effort and protracted time to engineer a structure that possessed both 
good serum stability and Dicer substrate property. During this study, totally 20 
different structures with different chemical modifications were designed and tested.  
The finally selected Chimera 10 structure featured a full 2’-fluoropyrimidine 
modification on the longer strand and a 2-nt DNA modification on the 3’end of the 
short strand. According to our analysis, this structure showed prolonged in vitro
stability yet kept a sufficient gene knockdown potency (Chapter 4).
However, although the selected Chimera 10 performed well in in vitro setting 
(Chapter 5), achieving around 80% gene silencing rate in various types of breast 
cancer cells and successfully inhibiting T-IC populations in the MCF-7/Adr model, it 
was not a robust construct for in vivo gene silencing. As illustrated in the imaging 
analysis (Chapter 6), although Chimera 10 could target to xenograft MCF-7/Adr 
tumours, the accumulation of the chimera in the xenograft tumour was not sufficient 
and did not last long enough for effective gene silencing. To solve this problem, two 
modifications were made on Chimera 10. Firstly, conjugating a 20 kDa PEG and 
secondly, attaching FITC and Biotin molecules on both ends of the short strand of 
the chimera. The aim of PEGylation was to increase its size, from 4.4 nm to 15 nm, 
and achieve prolonged in vivo circulation time (taking advantage of the EPR effect). 
Attaching FITC and Biotin allowed an ELISA-based quantification method with a 
sensitivity of 5 ng/mL, sufficient for the pharmacokinetics and bio-distribution 
studies. As expected, after systemic administration, the PEGylated chimera showed 
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 prolonged in vivo circulation time, even 24 hours after delivery, signal still could be 
detected from the xenograft MCF-7/Adr tumours. This phenomenon was further 
confirmed by the bio-distribution assay, 6 hours after i.v. administration, there were 
more chimeras in MCF-7/Adr tumours than in other tissues (Chapter 6). 
Subsequently, in vivo gene silencing assay was conducted in the xenograft MCF-
7/Adr tumour. Following a 7-day treatment protocol, an approximately 75% in vivo
survivin gene silencing was achieved in the treated xenograft tumours at both protein 
and mRNA levels. Furthermore, the siRNA-mediated sequence specific gene 
silencing was confirmed by 5’RACE PCR assay (Chapter 7).  More importantly, 
after survivin gene silencing, the chemo-resistance of MCF-7/Adr tumours was 
reversed (Chapter 7). This activity was firstly confirmed by the fact that compared 
with single Dox treatment, combined chimera and Dox treatment resulted in an 
approximately 3.3-fold more decrease in tumour weight.  The great reduction of 
tumour weight was corroborated by a 4.5-fold more apoptosis (combinatorial 
treatment vs Dox-alone) as assayed by TUNEL assay, suggesting the promotion of 
Dox sensitivity of the MCF-7/Adr tumour cells through chimera mediated in vivo
survivin silencing. Again, this conclusion was confirmed by the subsequently 
conducted Ki-67 assay from the perspective of proliferation – another key factor of 
the tumour progress regulation. Compared with single Dox, the proliferation rate in 
the combined treatment group showed an around 2-fold decrease (Chapter 7).
After confirming the Dox sensitizing capacity of the chimera treatment in MCF-
7/Adr tumours, a series of experiments, including the gold standard of T-IC 
assessment – in vivo limited dilution assay (LDA) (Lathia 2013), were performed to
ascertain the capacity of the chimera mediated survivin silencing in sensitizing Dox 
response of T-ICs in vivo (Chapter 7). Firstly, the expression of genes involved in 
stemness, tumourigenicity and drug efflux was studied. Encouragingly, the 
expression of tested genes related to stemness and survival, e.g. Bcl-2, Nestin, 
ABCG2 and BMI1, showed a universal decrease after the combinatorial treatment, 
suggesting the disruption of key signalling pathways responsible for stemness and 
tumourigenicity. Subsequently, the mammosphere formation capacity and the change 
of the T-IC marker-positive population were investigated using cells dissociated 
from treated MCF-7/Adr tumours (Chapter 7). Similar with that observed in in vitro
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 assay, the combined chimera and Dox treatment resulted in significant decrease in 
self-renewal efficacy and T-IC marker-positive population of cells derived from 
xenograft tumours. Finally, targeting of the T-IC was further confirmed by directly 
measuring T-IC frequency using the gold standard in vivo LDA, in which the 
combined chimera and Dox treatment led to a more than 5-fold decline in the T-ICs 
frequency in MCF-7/Adr tumours compared with those treated with Dox-alone.
Having established the concept that aptamer-guided in vivo survivin silencing
could increase chemo-sensitivity of MCF-7/Adr T-ICs, the efficacy of EpCAM-
targeted survivin RNAi combined with Dox in extending the overall survival of 
MCF-7/Adr tumour-bearing mice was assessed (Chapter 7). Indeed, the 
combinatorial treatment resulted in significantly increased survival rate of MCF-
7/Adr tumour-bearing mice (p=0.0007, vs Dox-alone treatment).
To provide direct evidence that chimera was able to target MCF-7/Adr T-ICs, 
FACS sorted tumourigenic EpCAM+/CD44+/CD24- or non-tumourigenic EpCAM-
/CD44-/CD24- cells were subjected to analysis using confocal microscopy (Chapter 
8). Encouragingly, the Dy647-labelled PEGylated chimera was detected in around 
89% single cell preparation dissociated from tumours treated with chimera,
accompanied by a 78% survivin silencing, suggesting an excellent tumour 
penetration efficacy and a potent T-IC targeted gene silencing potency of the 
chimera. When Dox sensitizing capacity of the chimera to purified T-ICs was tested, 
the self-renewal efficacy (via mammosphere assay) of the T-ICs purified from 
combined chimera and Dox treated tumours showed significant decrease, from 
19.21% in the Dox-only group to 3.09% in the combined treatment group. 
Additionally, a 5.6-fold increase in apoptosis rate was detected in T-ICs sorted from 
tumours underwent combined chimera and Dox treatment compared with those 
treated with Dox-alone. The implications of all these are that EpCAM aptamer-
guided in vivo survivin gene silencing markedly sensitized the breast T-ICs to Dox, 
impaired the self-renewal capacity of breast T-ICs and thereby prohibited tumour 
initiation.
At the end of this project, the potential toxicity and immunogenicity of the chimera 
was investigated (Chapter 9). This is a pivotal step for the development of a 
clinically viable siRNA drug. The complete blood count analysis did not uncover any 
172 
 
 detrimental effect of chimera on the overall health of the hematologic system of the
tested animals. Since the activation of innate immune response is one of the major 
concerns for nucleic acids-based therapies, the potential immunogenicity of chimera 
was studied both on human peripheral blood mononuclear cells (PMBCs) and on 
healthy immunocompetent mice, with no detectable cytokine production or induction 
of IFIT1 was observed. These data provide comprehensive evidence that the chimera 
elicited in vivo survivin gene silencing does not result from nonspecific immune 
toxicity. As unexpected high concentration of chimera was observed in intestines in 
the bio-distribution assay, the potential side effects of chimera in intestines were 
investigated and no detectable pathological abnormality in both acute and chronic
experiments was detected. Taken together, these results suggest that the chimera is 
probably safe for clinical application.  
In conclusion, in this work, firstly, the critical role of survivin in the chemo-
resistance of T-ICs in a drug-resistant breast cancer model was confirmed; secondly, 
we developed a T-IC targeted siRNA in vivo delivery system with built-in 
quantification mechanism and excellent pharmaceutical attributes. Lastly, for the first 
time since the discovery of RNAi, a proof-of-principle for the feasibility of T-IC-
targeted in vivo siRNA delivery was demonstrated. Theoretically, this approach can 
be applied to target T-ICs in any type of cancer as long as a critical gene and a 
reliable surface marker are identified.   
10.2 Perspective
In this study, an aptamer-siRNA chimera that showed favourable pharmaceutical 
attributes including specific targeting efficacy, potent gene silencing capacity and 
safety has been developed. However, there are still several challenges to be 
overcome before this strategy can be translated into clinics. In this section, the 
challenges facing clinical translation of the aptamer-siRNA chimera and the possible 
solutions are discussed. 
10.2.1 How to increase gene silencing efficacy of the chimera
Firstly, how to reduce the dose of chimera used in in vivo treatment. Admittedly, 
compared with some other published in vivo siRNA delivery systems, the chimera 
dose (2 nmol/mouse) used in this project is not the lowest. However, this is a very 
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 important factor in terms of industrial production and clinical application. Obviously, 
even only decreasing the dose slightly, one third for example, it could bring out 
significant decrease in the cost in in vivo application. Two strategies could be applied
to address this issue. The first is to research for new chemical modifications that can 
increase both stability and Dicer substrate property of the chimera structure. As 
shown in Chapter 4, although the complete 2’-fluoro pyrimidine modification on 
longer strand (Chimera 10) showed acceptable serum stability and gene silencing 
capacity, an around 4-fold increase in in vitro gene silencing capacity was achieved 
in chimeras with the 8 bp Dicer recognition portion unmodified (Chimera 2,3,4). 
Unfortunately, this modification pattern was not practical for in vivo work because of 
its high sensitivity to serum nucleases. Due to the limitation of time and funding, no 
exhaustive search and testing were able to proceed to find a chimera construct that is 
more potent yet still stable in vivo. With the advancement in chemical modification
and improved understanding of the RNAi mechanism, a fine balance between Dicer 
substrate property, serum stability and silence efficacy might be found in the near 
future. 
Another potential approach to reduce the therapeutic dose is to promote the 
endosome escape efficiency of the chimera. As only after being released from 
endosomes to cytoplasm, siRNAs can meet their corresponding mRNA and engage 
the RNAi machinery (Endoh and Ohtsuki 2009). Therefore, with a given dose, the 
gene-silencing efficacy of chimeras can be affected significantly by endosome 
escape. Nowadays, although it has become clear that at least part of the delivered 
chimeras were able to escape from the acidic endosome and thus avoiding being 
digested in lysosome (Liu H. Y. and Gao 2013), the precise mechanism underlying 
endosome escape remains a mystery. Thus, the lack of knowledge of how chimera 
escape endosomes hampers the efforts in improving the endosome escape efficiency 
of aptamer-siRNA chimeras. Recently, this problem was exploited by Liu’s group 
via adding a 20 kDa pH-dependent polyhistidine to siRNA portion of the chimera 
structure (Liu H. Y. and Gao 2013) (Figure 10-1). In this study, the small protein tag 
not only facilitated in vivo treatment by increasing the particle size and achieving 
prolonged circulation time but also promoted endosome escape through disrupting 
the endosomal membrane in acidic environment. The significance of this study is that 
through engaging a traditional strategy of using pH-sensitive material, the authors 
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 bypassed the need to explore the detailed escape mechanism of chimera structures 
and achieved enhanced endosome escape. However, although this study presented an 
alternative approach to improve gene silencing capacity of the chimera structure, 
ultimately, the real improvement of endosome escape efficiency can only be 
achieved until the molecular and cellular mechanisms and pathways by which the 
chimera reaches the cytoplasm are unravelled.
 
 
Figure 10-1. Schematic of protein tag conjugated aptamer-siRNA chimera
10.2.2 How to extend the application of the chimera 
The second issue is how to extend the applications of this delivery system. Three 
items should be considered. Firstly, whether this aptamer-mediated siRNA delivery 
system (including the chemical modification pattern) can be used to delivery other 
types of siRNAs or other RNAi related oligonucleotides such as anti-miRNAs. It has 
been established that the gene silencing capacity of aptamer-siRNA chimeras is 
sequence-dependent (Dassie et al. 2009, Neff et al. 2011), which means even using 
the same aptamer and chemical modification pattern, it is necessary to test 
empirically when other siRNA sequences were conjugated. However, as discussed in 
Chapter 4, the chimera developed in this study enjoys a less complicated structure 
and a short overall length. The insight and experience on chemical modification 
pattern and structural design achieved in this project may be generalized, at least in 
part, in the delivery of other siRNAs. Secondly, whether the success in reversal of
chemo-resistance and extension of overall survival achieved in this study can be 
translated to breast cancer treatment. Of note, although this chimera performed well 
in the tested Dox-resistant MCF-7/Adr model and achieved near 70% survivin
silence in the primary breast cancer cells (Chapter 4), no sensitization of T-ICs to 
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 Dox was observed in the tested clinical samples (data not shown). This result, though 
frustrating, is understandable given the highly heterogeneous feature of tumours. In 
addition, the breast cancer samples collected in this study were all biopsies from 
patients bearing naive (untreated) tumours. The sensitization of the primary cancer 
cells to chemotherapy agents is likely to be achieved in drug-resistant breast tumours 
with elevated survivin levels. Lastly, since both EpCAM and survivin also highly 
expressed in many other types of cancers, the anticancer effect of this chimera may 
be applicable to other types of cancers. Recently, the targeting effect of this chimera 
in a HT29 colon cancer model was studied in our laboratory. Encouragingly, it was 
observed in the pilot study that the chimera sensitized T-ICs of HT-29 cells to 5-
fluorouracil. Indeed, it is unreasonable to expect this chimera could show T-IC 
inhibition effects on all types of cancers. However, even its application can be 
extended to only another kind of tumour or even only extended partly (only 
promoting chemo-sensitivity of the bulk tumour cells for example), it is still 
promising. 
10.2.3 Potential toxicity of the chimera structure
The last question is about the potential toxicity of the chimera structure. In this 
study, apart from testing the acute immunogenicity of the chimera both in vitro and 
in vivo, the potential intestine toxicity was also ruled out through pathological 
analysis. Admittedly, the acute immune response is a major concern for any 
oligonucleotide-related therapies (Judge et al. 2005). However, considering it is 
usually required to deliver treatment reagents repeatedly over a long period of time in 
order to cure cancer, it is necessary to conduct chronic toxicity assay to test the 
potential side effect of the chimera on vital organs and the possibility of 
carcinogenicity and reproductive toxicity in large animals or non-human primates.
This is necessary given the unexpected immune response was detected even with 
PEG (after repeated administration), a material previously regarded as highly 
biocompatible (Ichihara et al. 2013). 
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